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Protein S-palmitoylation plays a crucial role in many biological systems. S-palmitoylation
involves the post-translational attachment of palmitate to a cysteine residue through a
reversible thioester linkage. S-Palmitoylation is used to modify both integral and membrane
proteins, many of which are involved in intracellular trafficking, membrane localization, and
signal transduction pathways. Intracellular palmitoylation is mediated by a family of protein
acyltransferases (PATs). PAT mutations are associated with neurological diseases and cancer
progression. Proteins in the PAT family are defined by the presence of a 51-amino acid cysteinerich domain (CRD), which contains a highly conserved aspartate-histidine-histidine-cysteine
(DHHC) motif. The structure and function of DHHC proteins are still under investigation due to
the difficulty in purifying eukaryotic multi-pass transmembrane proteins.
In the model eukaryotic organism Dictyostelium discoideum, fourteen DHHC proteins
have been discovered, labeled PAZ1-14. Previous work has investigated the localization of these
proteins during growth and differentiation, with attention paid towards their effect on
palmitoylation of the Gα2 subunit of the G protein. The PAZ5 protein was chosen for further

investigation as cells transformed with a knockout PAZ5 presented a unique malformed
phenotype in the fruiting body stage of the D. discoideum lifecycle. The fruiting body would
collapse as fewer cells differentiated into stalk cells; the cell lines would return to normal
functioning after rescue with the wildtype. It was also previously shown that mutations to the
DHHC motif of PAZ5 induced the same malformed phenotype as the knockout, indicating a
crucial role for PAZ5 in D. discoideum development.
Using site-directed mutagenesis, seventeen independent mutations to PAZ5 were
created, both in the DHHC-CRD and other conserved motifs. These were ligated into a
fluorescent-tagged extrachromosomal expression plasmid (pTX-GFP) and transformed into D.
discoideum. They were analyzed for fluorescent localization and the previously seen fruiting
body malformations. Unforeseen low transformation efficiency prevented the full use of all
seventeen mutants. The mutants that were able to be analyzed produced a phenotype
dissimilar to both the wildtype and knockout strains; moreover, fluorescent localization of PAZ5
was unable to be discerned. It was determined that the plasmid experienced a loss of function,
though this was not apparent until after the results were collected. Consequently, it is unknown
to what extent the observations are experimentally valid. The work can be salvaged by religating the mutant PAZ5 proteins into a new fluorescent expression plasmid. Further
investigation into the DHHC-CRD of PAZ5 would provide an important eukaryotic analog for PAT
research.
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CHAPTER 1
INTRODUCTION

Eukaryotic organisms utilize a vast array of chemical signals to modulate their behavior
and the behavior of cells around them; this system of cell stimulus-response is known as signal
transduction. A common method of cellular signal transduction involves the binding of
chemicals to receptor proteins that exist as part of the plasma membrane of the cell. Once a
ligand binds to one of these integral membrane receptors, a signal is sent into the cytoplasm to
bring about a response from the appropriate effector protein. These signal transduction
pathways are responsible for coordinating various cellular responses, including changes in
metabolism, gene expression, cell division, and apoptosis. Studying these cellular signal
transduction pathways can be performed in several ways.
The Gundersen lab focuses on the model eukaryotic organism Dictyostelium discoideum,
a social amoeba that is often used in developmental studies (Annesley & Fisher, 2009; Consalvo
et al., 2019; Van Haastert & Devreotes, 2004). D. discoideum is a model organism because it
undergoes a lifecycle that shares many similar genetic, cellular, and biochemical processes of
more complex organisms, such as mammals. The lifecycle and reproduction of D. discoideum
involve two significant phases: a trophic phase, where individual cells consume bacteria and
divide mitotically, and a starvation phase, characterized by multicellular aggregation and
differentiation (Kessin & Van Lookeren Campagne, 1992). The starvation phase is of great
interest because it involves hundreds of thousands of cells cooperating to produce a fruiting
body, an arrangement of various differentiated cells (Kessin, 2001).
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A standard signal transduction pathway, shared by all eukaryotic organisms and used for
a wide variety of functions, is the G protein-mediated pathway (Lochrie & Simon, 1988). G
proteins are a family of proteins that act as molecular switches. They are peripheral plasma
membrane proteins that mediate signals from integral membrane receptor proteins to the cell
interior. When a ligand signal binds to a G protein complex outside, an inner G protein is
released to allow effector activation.
G proteins, along with a wide range of other membrane-bound proteins, use lipid
modifications to modulate their interactions with other proteins. Lipid modifications involve the
covalent attachment of a lipid group to a protein, which changes its hydrophobicity and thus its
affinity for the cellular membranes of protein domains. Different lipid modifications, such as
palmitoylation or myristoylation, provide different affinities, and multiple lipid modifications
can modify a single protein. Lipid modifications are ubiquitous in eukaryotes and occur on
almost a thousand different proteins (Resh, 2013).
S-Palmitoylation, a widespread lipid modification, is known to regulate G protein
function (Linder et al., 1993). A family of proteins containing DHHC cysteine-rich-domains has
been associated with palmitoylation mediation (Greaves & Chamberlain, 2011). The Gundersen
lab has previously shown that the Gα2 subunit of the G protein controls entry into the
developmental stage of the D. discoideum life cycle (R. E. Gundersen et al., 2005). The
Gundersen lab has also shown that the Gα2 subunit localizes through the action of
palmitoylation (S. Alamer et al., 2018). In D. discoideum, fourteen genes have been identified
containing DHHC-CRD regions, known as Putative Acyltransferases with Zinc Fingers (gene
name: pazA-N, protein name: PAZ1-14) (Bodwell, 2007). The characterization of these PAZ
2

genes may lead to a better understanding of how palmitoylation is performed and how it
affects cellular signal transduction.

1.1. Dictyostelium discoideum
The social amoeba Dictyostelium discoideum is a powerful eukaryotic model organism
used for developmental studies (Annesley & Fisher, 2009). For over 90 years, D. discoideum has
been the subject of serious study; in fact, it is the most studied of all the social amoebae, also
known as cellular slime molds (Kessin, 2001). Despite its relatively simple appearance, it has
many developmental features in common with more complex eukaryotes. D. discoideum are
initially found as single vegetative cells living in soil, dividing mitotically, and consuming
bacteria through phagocytosis. Upon exhausting their local food supply, the cells enter a
starvation phase, which forces the amoeba to undergo significant developmental changes. The
cells have two distinct responses to this newfound pressure; they can form either macrocysts or
fruiting bodies. The fruiting body (sorocarp) process is easily the most studied because it
manifests features common to all developing organisms (Kessin, 2001). Namely multicellular
cooperativity, cell specialization and differentiation, and complex intracellular signal
transduction.
The cells respond to starvation by sending out chemotactic signals to attract nearby cells
to aggregate and transform into a multicellular organism capable of undergoing cell
differentiation and morphogenesis (Kessin, 2001). Through signaling, the cells regulate and
differentiate themselves into set proportions and patterns, allowing for the creation of a
complex multicellular structure. The end result is a fruiting body, a comparatively large
3

structure with a ball of resistant spores at its peak suspended by a stalk comprised of dead
cellulose-producing cells. A useful consequence of these two developmental stages,
consumption and starvation, is that genes induced during development are not typically
needed during mitotic growth. Moreover, if cells undergoing starvation are exposed to food,
they rapidly revert to the amoeboid stage of growth, in a process known as erasure (Finney et
al., 1979). These genes can be mutated without affecting the viability of the growing organism
(Kessin, 2001).

Figure 1.1. Starvation Phase of D. discoideum Life Cycle. Upon starvation, individual D.
discoideum cells undergo aggregation into a multicellular mound; this mound then transforms
into a motile slug. The cells then differentiate into spore and stalk cells, after which they
culminate into a fruiting body. The fruiting body eventually releases its spore cells, which
germinate into individual cells once again.

4

Starvation also induces a slew of new genes that are necessary for the chemotactic aggregation
response. As a result, the mitotic growth stage provides many advantages in maintenance and
experimental ease associated with microorganism research. Simultaneously, the starvation
phase allows for a multicellular perspective comparable to more complex organismal growth.
Besides its lifecycle, D. discoideum possesses many other useful aspects conducive to
research. These include its small (3.4 x 107 bp) genome that has been completely sequenced
(Eichinger et al., 2005) in addition to possessing mitochondria and plasmids, with the
mitochondria also having been sequenced (Ogawa et al., 2000). By comparison, E. coli and S.
cerevisiae respectively have a genome size of 4.6 x 106 and 1.2 x 107 bp. The genome covers a
haploid set of six chromosomes and has 90% efficient transcription into about 12,500 genes. In
comparison, the diploid human genome (109 bp) has an efficiency of 10% transcribed with only
around twice the number of genes, several of which are analogous across both organisms
(Tatischeff, 2019). In 1999 the National Institute of Health (NIH) chose D. discoideum as one of
eight non-mammalian model organisms for biomedical research (Koller et al., 2016; Tatischeff,
2019).

1.1.1. History of Research into D. discoideum
The genus Dictyostelium was first identified 130 years ago by the mycologist Oskar
Brefeld. It was so named because Dicty means net-like and stelium means tower, so-called due
to the aggregation territories resembling nets and the fruiting bodies like towers. Brefeld
realized that the trophic and fruiting body stages belonged to the same organism. Researchers
at the time had trouble cultivating the amoeba because they used cultures composed of dung
5

and sometimes enriched with agar; however, they were always contaminated with bacteria
that the amoeba fed off. It was not until 1903 that the scientist Jean-Paul Vuillemin realized
that amoeba engulfed the bacteria and that the digestion was intracellular rather than the
extracellular digestion that fungi were known to use (Kessin, 2001).
Dictyostelium, as a developmental model, did not see widespread adoption until 1935,
thanks to the works of Kenneth Raper (Kenneth B Raper, 1935). Raper was the first to isolate D.
discoideum in soil samples from the hardwood forest of Little Butt’s Gap in Ashville, North
Carolina; these became the type strain and were labeled NC4. Raper was also the first to begin
using an agar-based bacterial lawn of Klebsiella aerogenes to grow the amoeba and began a
sweeping examination of many stages of the D. discoideum lifecycle (Kenneth B Raper, 1940).
For example, they noted that cells maintained a 20%: 80% proportion of stalk to spore cells
regardless of aggregate size. They also determined that they would segregate and form
separate fruiting bodies when mixing different species of amoeba (Kenneth B Raper, 1940). In
1944 John Tyler Bonner discovered that the aggregation of cells was driven by chemotactic
molecules (J. T. Bonner, 1944). However, it was not until 1969 that the molecule was
determined to be cyclic adenosine monophosphate (cAMP). Bonner also determined that the
chemotactic agent was emitted in a pulsatile manner, such that every 6 minutes, a pulse of the
signal was released in a steadily increasing gradient to attract the cells (J. Bonner et al., 1969).
Other significant contributions to D. discoideum becoming recognized as a model
organism for developmental studies came about in the late 1960s with the independent work
of Maurice Sussman and Günter Gerisch. Both scientists led the way for molecular biology and
biochemistry techniques in an organism that had primarily been the focus of biological
6

methods. Sussman used a biochemical approach to determine that gene activation led to
increases in enzymes for polysaccharide biosynthesis, spearheading the notion that gene
induction led to enzyme activity changes (R. Sussman & Rayner, 1971). Gerisch pioneered the
immunological approach in discovering cell adhesion systems in aggregating cells using
antibodies to block adhesion (Gerisch, 1968). These same approaches were later adapted for
use in mammalian cells (Kessin, 2001).

1.1.2. Phylogeny and Genomics of D. discoideum
D. discoideum lies in the Eukaryota superkingdom, Amoebozoa clade, Evosea phylum,
Eumycetozoa class, Dictyostelia clade, Dictyosteliales order, and Dictyosteliaceae family
(Schoch et al., 2020). However, the evolutionary biology of D. discoideum is still a source of
confusion. There is no fossil record for amoeba; instead, molecular phylogenetic techniques
must be relied upon, such as comparisons of conserved proteins or ribosomal RNAs. There are
several difficulties with this method. Firstly, phylogenetic inference relies on the assumption
that there is no lateral gene transfer. When a species has diverged, it no longer exchanges
genetic material with other divergent species. Unfortunately, this is not the case with D.
discoideum; for example, it possesses a cyclic nucleotide phosphodiesterase used to control
cAMP in aggregation with no known homologs in plants or animals but does share homology
with enzymes from S. cerevisiae. Other domains likely accumulated from lateral gene transfer
include its ability to degrade bacterial walls using dipeptidase and to survive the effects of
tellurite in its soil environment (terD) (Eichinger et al., 2005). A second problem with
phylogenetic inference lies with the appearance of paralogs, gene copies created by a
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duplication event within the same genome. It then leads to difficulty separating the
evolutionary history of species from the evolutionary history of individual genes, though, in
recent years, this problem has been somewhat ameliorated (Hellmuth et al., 2015). However, it
is known that the Amoebozoa clade diverged from the animal-fungal lineage after splitting from
the plant-animal lineage (Eichinger et al., 2005). Suffice to say, D. discoideum diverged a very
long time ago, though precisely when is still up for debate depending on preferences toward
either protein or ribosomal sequence analysis (Romeralo et al., 2011; Schilde et al., 2019).
The genome of D. discoideum is relatively small but is extremely rich in A-T nucleobases,
especially in intergenic regions and introns (Kessin, 2001). The introns are around 100 bp and
are found in many genes. The genome covers a haploid set of six chromosomes and has 90%
efficient transcription into about 12,500 genes. Despite having a compact genome of only
12,500 transcribed genes, D. discoideum can operate one of two developmental cycles,
macrocysts or fruiting body formation. D. discoideum is also able to produce all it needs, save
for a carbon source, eight amino acids, and a few vitamins (Franke & Kessin, 1977). The base
composition is 77% AT, while in coding sequences A and T make up around 65% (Kessin, 2001).
Coding sequences also have an AT bias, such that if the third position of a codon can be an A or
T, it typically is. Moreover, coding sequences often have long repeats of the AAC triplet in all
reading frames, producing extensive lengths of Asparagine (AAC), Glutamine (CAA), and
Threonine (CAA), though their function is as yet unknown (Erber et al., 2020; Shaw et al., 1989).
An important issue with the genome of D. discoideum results from its ability to
accumulate random chromosomal changes, such as duplications, during its serial passage.
Duplications of 15 kb and larger are common, so common in fact that the same stocks obtained
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from different laboratories can have different duplications (Bloomfield et al., 2008). These
variations, especially when unknown, may result in phenotypic differences across strains. It may
also make genetic manipulation, especially knockouts, more problematic as two loci could
target instead of one.
There are two major axenic strains used in laboratories today, AX2 and AX3/4; both
were created independently in the 1970s through repeated sub-culturing of the original 1933
NC4 D. discoideum type strain that grew well in complex media (HL-5) (Franke & Kessin, 1977;
Schwalb & Roth, 1970). In comparison to NC4, the axenic strains grow slower on bacteria and
produce smaller fruiting bodies (Bloomfield et al., 2008). The AX1 line was generated from the
original NC4 type strain. The AX2 line was generated from AX1, though AX1 was lost soon after
the generation of the AX2 line. The AX3 line, independently created from NC4, was re-labeled
AX4 in the 1980s. As a result, AX2 and AX3/4 are the two significant strains (DictyBase, 2000).
The AX4 strain was eventually sequenced in 2002, mainly because most of the genome had
previously been transcribed into a yeast artificial chromosome (YAC) map for AX4. The YAC map
consisted of approximately 1,000 YACs, each containing 200 kb of sequence with 5-fold
redundancy. The resulting YACs could be overlaid and aligned with one another to produce a
larger contig (contiguous set of overlapping DNA); these were then used to compare and
correlate genomic sequencing data with a solid footing (Kuspa et al., 1992; Loomis et al., 1995).
At the time of sequencing the AX4 genome, it was known that there were duplications
on the chromosomes of both major strains, duplications that went unnoticed until the
compiling of the YACs in the 1990s. For example, the published genome of AX4 has a large 750
kb inverted segmental duplication on chromosome 2 (Kuspa et al., 1992), which is absent in the
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NC4 type strain. AX2 also has a 26 kb duplication on chromosome 1. The original NC4 lines also
contain duplications as the oldest original stocks were only lyophilized in 1969, 30 years after
first being isolated. Fortunately, it is still possible to go to the original forest in Ashville, North
Carolina, and isolate ‘true’ wild-type strains without apparent duplications. It is thereby
suggested that the duplications may arise from problems inherent to laboratory sub-culture
technique and growth practices associated with the instability of the AT-rich D. discoideum
genome (Kessin, 2001).

1.1.3. Developmental Lifecycle of D. discoideum
The developmental lifecycle of D. discoideum is known almost exclusively from
laboratory observations (Kenneth Bryan Raper, 1984). In a scientific setting, amoebae are
grown either on sterile agar plates, sterile agar plates with bacterial lawns, or in a sterile liquid
medium. When analyzing the lifecycle, amoebae are typically grown on sterile agarose plates
composed of minimal media. Rarely, the amoebae are grown on sterile soil to mimic starvation
in its natural environment better, although this method makes it hard to compare samples.
During the trophic stage of growth, individual amoebae use a chemotactic mechanism
to interpret their surroundings. The chemotactic capacity of these cells has been compared to
leukocytes as they both share similar chemotactic detection, signal transduction pathways,
cytoskeleton mobilization, and macrophagy (Devreotes & Zigmond, 1988; Jin et al., 2009). In
leukocytes, such as neutrophils, the chemotactic receptors are evenly distributed around the
cell; they also do not concentrate at one spot during chemotaxis. The primary focus of which
are the binding of chemotactic molecules to G protein-coupled receptors (GPCRs) on the
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plasma membrane. The amoebae move rapidly without forming focal adhesions to the
substratum (Tarantola et al., 2014).
When the cells of D. discoideum are confronted with imminent starvation, they take
immediate action. Processes associated with growth come to a halt, the cell cycle stops, and
transcripts used for growth disappear. Regarding the cell cycle, D. discoideum lacks a G1 phase;
instead, cells go through mitosis and immediately enter the S phase before spending a long
period in G2. During starvation, chromosomal DNA synthesis stops, such that cells undergoing
the G2 phase stop regardless of their proximity to the G2-M boundary. These cells are more
likely to differentiate into pre-spore cells (Shaulsky & Loomis, 1995). The organism switches to
metabolic reserves stockpiled during the trophic phase in anticipation of new protein synthesis.
Within hours, D. discoideum will begin producing proteins used for chemotaxis, both in
signaling and response, and for aggregation (Kessin, 2001).
The primary molecule used for chemotaxis in D. discoideum is cyclic adenosine
monophosphate (cAMP). The cAMP is produced from ATP by adenylyl cyclase. The ability to
produce, release, detect, and degrade cAMP is imperative for aggregation, and the entire
chemotactic process only occurs during the starvation phase (Kessin, 2001). At around 6 hours,
a few sporadic amoeba cells will begin releasing cAMP into the nearby population; as the cAMP
is detected by nearby cells, they move closer to the source and release their own pulse of
cAMP. This subsequent pulse is stronger than the initially received pulse and encourages more
outward cells to move inward; the pulses continue to re-occur every 6 minutes. Cells only move
for about 60 seconds and only when the gradient is positive, discouraging movement in the
opposite direction. The result is an outwardly propagating wave that draws cells inward in a
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stepwise fashion. This wave manifests as circular or spiral patterns that eventually form into
streams of cells; as these cells aggregate, they become adhesive, forming a loose aggregate
(Figure 1.2); they eventually move from this loose aggregate and form a three-dimensional
mound structure. If the cells are disaggregated, they will rapidly reaggregate in one-tenth of the
original aggregation time (Finney et al., 1979). The process from single cells entering starvation
to forming the mound takes 8 hours; the resulting mound comprises between 105-106 cells
(Kessin & Van Lookeren Campagne, 1992).

Figure 1.2. D. discoideum cells undergoing aggregation. D. discoideum cells are seen
aggregating and forming streams on DB agar at 5.5 hours post-starvation (hps). Pictured using a
4X objective on a light microscope.
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The genome of D. discoideum contains 55 genes that code for GPCRs, belonging to four
of the six mammalian GPCR families (Prabhu & Eichinger, 2006). There are 12 genes encoding
for Gα subunits, but only single genes encoding for Gβ and Gγ (Pergolizzi et al., 2017). The
primary GPCR receptors that bind cAMP in D. discoideum are in the cAR family, a group of
seven-transmembrane domain (7-TMD) receptors that activate an associated heterotrimeric Gprotein (Consalvo et al., 2019). Four different cAMP receptors, cAR1-4, are expressed
sequentially during development (Kim et al., 1998). These chemotactic cAR receptors are evenly
distributed on the cell plasma membrane. cAR1 was the first to be identified and is the primary
receptor involved in cAMP chemotaxis (Consalvo et al., 2019, 2019). cAR1 and cAR3 have higher
affinities for cAMP than cAR2 and cAR4 (Ginsburg & Kimmel, 1997). Of the 12 Gα subunits in D.
discoideum, the Gα2 subunit controls many genes known to be necessary to aggregation; car1
signaling itself is mediated by the Gα2βγ subunit (Pergolizzi et al., 2017). Gα2 is highly
developmentally regulated, directly bound to the cAMP receptor, and is maximally expressed
during aggregation (Kumagai et al., 1989). An immediate response made by cAR1 binding to
cAMP is the activation of Ras. Activated Ras then triggers adenylyl cyclase to create more cAMP
from metabolic energy reserves of ATP. Most of the cAMP is then released into the local
environment around the cell; this cAMP is then used to signal more cells via the same
chemotactic mechanism, known as the cAMP relay (Kortholt et al., 2011).
The gradient response for cAMP movement and direction is very fine. D. discoideum, if
placed in a gradient, will extend pseudopods towards the area with the highest concentration
of cAMP (Kessin, 2001); moreover, these differentials in cAMP concentration can be as small as
2% (Caterina & Devreotes, 1991). When moving, cells will always face the direction with the
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most occupied cAMP receptors, subtracting one side versus another; the cell focuses on the
absolute difference in receptor activation, in a process known as adaptation (Theibert &
Devreotes, 1986). This difference has been theorized to be as small as 250 receptors out of
40,000 to 200,000 (Mato et al., 1975). The speed of cells moving up a gradient is about 10
μm/min, or one cell diameter per minute (Kessin, 2001). Despite the even distribution of
chemotactic receptors on the cell surface, the ability to move is confined to specific areas of the
cytoskeleton. This directional sensing is mediated by a G-protein linked pathway that uses a
pleckstrin homology (PH) domain to bind the Gβγ subunit. These PH domains are induced on the
side of the cell that faces the higher concentration of cAMP, eventually leading to the extension
of the pseudopod and movement of the cell in that direction (Parent & Devreotes, 1999; N.
Zhang et al., 2001). Subsequently, the uropod at the back of the cell is retracted by the
movement of the PH domain away from that side (Van Haastert & Devreotes, 2004).
Following chemotactic aggregation, the cells in the mound form a sheath layer
composed of mucopolysaccharide and cellulose. However, not all cells will aggregate during
starvation. Up to 15% of cells will not aggregate into the mound stage, which is significant at a
population level. It has been hypothesized that these third-fate cells have an advantage in
resuming growth if exposed to new nutrients (Dubravcic et al., 2014). The mound then forms an
anterior tip, which organizes the cells behind it and controls further development. The tip
triggers the aggregate to elongate, forming a standing slug. From here, the standing slug can
either migrate as a pseudoplasmodium (also known as a slug or a grex) or directly begin the
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process of fruiting body formation, known as culmination. The slug movement is controlled by
the anterior tip, which is both photo- and thermo-tactic.

Figure 1.3. The Motile Slug of D. discoideum. The motile slug is composed of pre-stalk and prespore cells in a 20:80 ratio.

At this stage, cells differentiate into either pre-stalk or pre-spore, based on their stage in
the mitotic division cycle (M-S-G2). The pre-stalk proportion to pre-spore cells is typically 20%:
80% (Kessin, 2001). However, neither differentiation is necessarily permanent, as cells can
convert between precursor populations or even revert to individual amoeba again. Precursor
transmutation is typically due to a change in proportion between the two populations, and
reversion occurs if food is given, ending the starvation phase. The different precursor cell
populations then move to the top or bottom of the aggregate, such that pre-stalk cells move to
the top and pre-stalk cells to the bottom.
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Figure 1.4. The Fruiting Body of D. discoideum. The fruiting body represents the final stage of
the starvation lifecycle. The pre-stalk cells have died to form the stalk, and the pre-spore cells
have sporulated, then moved to the bulb at the tip.

The multicellularity of the aggregated body, arising from a collection of single cells,
raises the question of how precursor selection operates with a population of genetically distinct
cells. The mound could be recognized as a chimeric rather than a homogenous or clonal
assortment of cells. It is known that different species of Dictyostelium, when placed together,
will re-segregate and form separate fruiting bodies (J. E. Strassmann et al., 2000). Yet it is still
unknown how the cells determine degrees of relatedness; or how such a clonal organism deals

16

with individual cells that stray farther from the clonal norm, especially considering how
development relies on intracellular cooperation (Joan E. Strassmann & Queller, 2011). This
intracellular cooperation also leads to the question of the aggregate avoids internal parasitism,
exemplified by the notion of cheater cells. Cheater cells are cells that may avoid the stalk cell
fate because of a mutation or defect (Matapurkar & Watve, 1997). These cells would likely have
a strong evolutionary advantage and lead to a more heterogeneous population; hence it has
been hypothesized that D. discoideum may have some mechanism for policing itself (Khare &
Shaulsky, 2010).
The stalk is formed when pre-stalk cells release and deposit cellulose as they die, then
they are moved through a narrow collar at the tip of the aggregate to form a stalk tube (Blanton
et al., 2000). The pre-spore cells then encapsulate themselves in a layered wall of
mucopolysaccharide and cellulose to form the spore. The pre-spore cells are then moved
upwards as the stalk is being created around them (Jermyn & Williams, n.d.). The process lasts
between 8-10 hours, and the resulting fruiting body typically reaches a height of 1-2 mm tall.
The spores can then be released either into the air or onto the body of a passing animal, such as
a predatory nematode. These spores then become myxamoebae, ready to begin the lifecycle all
over again.

1.2. G Protein Signaling
G proteins, or guanine nucleotide-binding proteins, are members of a larger group of
enzymes called GTPases. GTPases are a large family of enzymes that bind to guanosine
triphosphate (GTP) and hydrolyze it to guanosine diphosphate (GDP) (Trzaskowski et al., 2012).
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The G protein commonly refers to two different families of protein. G proteins can either exist
as a heterotrimeric G protein complex, made up of alpha (Gα), beta (Gβ) and gamma (Gγ)
subunits; or as small monomeric GTPases, which are akin to the individual Gα subunit but
function as independent monomers. G-protein-linked receptors (GPCR) constitute a significant
class of transmembrane proteins involved in signal transduction. All eukaryotes use G proteins
for signaling. GPCRs all display a seven-transmembrane domain topology, with an extracellular
N-terminus, three intracellular and three extracellular loops, and a final intracellular C-terminus
(Rosenbaum et al., 2009). A GPCR is activated when a specific ligand binds and induces a
conformational change in the receptor. Ligands can bind to either an extracellular N-terminal
loop or a binding site within the transmembrane domain (Trzaskowski et al., 2012). Ligands can
range in size from small peptides to large proteins, as GPCRs are responsible for regulating
various processes.
Heterotrimeric G proteins, also known as ‘large’ G proteins, are G proteins associated
with GPCRs on the cell plasma membrane, forming a heterotrimeric complex (Rosenbaum et al.,
2009). When a ligand binds to a membrane-bound GPCR attached to a heterotrimeric G
protein, it induces a conformational change in the receptor. This change allows for the
guanosine diphosphate (GDP) molecule linked to the G protein to be replaced with guanosine
triphosphate (GTP). The Gα subunit, which binds the GDP, then detaches from the Gβ and Gγ
subunits upon GTP binding; both separated subunits can trigger an associated response within
the cell (Grisshammer et al., 2005). Subsequent hydrolysis of the GTP to GDP then ends this
signal. This hydrolysis effectively makes the GTP/GDP an ‘on/off’ switch for the G protein. The
activation and regulation of receptors rely upon a few crucial concepts. Firstly, desensitization is
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the lessening of a response after persistent stimulation. If desensitization occurs without loss of
plasma membrane receptors, this is called adaptation. If receptor molecules are destroyed, the
process is known as down-regulation. Finally, if receptors are removed but not destroyed, this
is known as sequestration.
Small monomeric GTPases, also known as ‘small’ G proteins or Ras GTPases, are a family
of related enzymes that can bind and hydrolyze GTP. Small GTPases are responsible for
regulating several critical cellular processes, including cytoskeletal control, cell proliferation,
membrane trafficking, and cell division, among others. All small GTPases belong to the Ras
superfamily, so-named because the superfamily founding members are encoded by human Ras
genes that were homologous to the viral ras oncogene (Yang, 2002). Homologous to the Gα
subunit, small GTPases can function independently of the Gβ and Gγ subunits, able to hydrolyze
GTP to GDP (Paduch et al., 2001). Unlike the heterotrimeric G proteins bound to GPCRs on the
plasma membrane, small GTPases are soluble. Like Gα proteins, small GTPases alternate
between an ‘on' state (bound to GTP) and an 'off' state (bound to GDP) (Hepler & Gilman,
1992). All small GTPases contain four conserved domains for guanine nucleotide-binding and an
effector domain (Yang, 2002). The Ras superfamily of small GTPases is composed of five main
families that are generally responsible for different signal pathways: Ras for cell proliferation,
Rho for cytoskeletal dynamics and cell morphology, Rab for membrane trafficking, Rap for
cellular adhesion, and Arf for vesicular transport (Goitre et al., 2014). Due to the wide variety of
important roles that small GTPases are involved with, insight into their functional mechanisms
is of great interest (Song et al., 2019)
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The G protein subunits Gα and Gγ can undergo lipid modifications, wherein a lipid moiety
is attached to the protein, altering their hydrophobicity and allowing the modified protein to
localize to different cellular compartments depending on their role. Such as the endoplasmic
reticulum, Golgi apparatus, and plasma membrane (Sobocińska et al., 2018). An essential lipid
modification in G protein function is palmitoylation, the lipid modification involving the
attachment of a palmitic acid moiety to cysteines of substrate proteins. The linkage is a
thioester bond and is reversible (De & Sadhukhan, 2018). Palmitoylation is often used to
enhance protein-membrane localization in conjunction with other, non-reversible, lipid
modifications.
G-proteins are essential to many cellular processes, and their malfunction is associated
with a swathe of diseases. There are several different subtypes of G protein subunits; in
humans, there are 18 Gα, 5 Gβ, 12 Gγ subunits, and numerous small GTPases (Heng et al., 2013).
GPCRs are also an important drug target, with almost 50% of drugs on the market targeting
GPCRs (Trzaskowski et al., 2012). Consequently, a significant amount of research has and
continues to be performed in understanding the mechanisms and function of G-proteins and
their involvement in signal transduction.

1.3. Lipid Modifications
G-protein membrane localization, function, and targeting are dependent on several
specific lipid covalent modifications. Attachment of lipid groups occurs on almost a thousand
different proteins (Resh, 2013). Proteins are typically much larger than lipids, so while the
modification results in small change in the local properties of the protein, it provides a
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substantial change to the localization and subsequent fate of the protein. Lipid modifications
are classed based on the type of attached lipid, including prenylation, myristoylation, GPIanchored proteins, and palmitoylation (Casey, 1995). The type of lipid modification used
produces a specific property. It provides a vital role for a diverse array of processes for
substrate proteins, such as membrane trafficking. Proteins can also contain more than one type
of lipid attachment allowing for different levels of hydrophobicity, and therefore membrane
specificity.
Prenylation involves the post-translational covalent attachment of either a farnesyl (15carbon) or a geranylgeranyl (20-carbon) isoprenoid moiety to a conserved C-terminal (COOH)
cysteine residue of the target protein (F. L. Zhang & Casey, 1996). Prenylation takes place in the
cytoplasm of the cell and is commonly used in the process of attaching to the plasma
membrane. These two similar lipids are attached via one of three different enzymes:
farnesyltransferase, geranylgeranyltransferase I, or CaaX protease. These enzymes are chosen
based on their presentation with the CaaX box, where ‘C’ is the cysteine to be prenylated, ‘a’ is
an amino acid containing an aliphatic side chain, and X is the type of amino acid that
determines which moiety will be used. Such a farnesyl will modify x = A, C, M, Q or S, the C; on
the other hand, if X = E or L, a geranylgeranyl will be attached. The process results in a stable
modified protein. Prenylation also occurs in small G-proteins that lack the CaaX motif; instead,
they have two C-terminal cysteine residues that undergo prenylation by the addition of
geranylgeranyl. After prenylation, most proteins are further processed by cleaving the aaX
residues from the newly created prenyl-cysteine. This prenyl-cysteine can then be further
methylated to allow for more specific localizations, such as via a palmitoyl linkage; moreover,
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the attachment of a second signal allows for the possibility of reversible association (Casey,
1995; Clarke, 1992).
Glycosylphosphatidylinositols (GPI)-anchored proteins are a variety of cell surface
proteins that do not cross the plasma membrane into the cytoplasm yet are still a kind of signal
transduction molecule. It is estimated that 1% of eukaryotic proteins are modified by GPIanchored proteins (Resh, 2013). GPI anchored proteins involve the post-translational
attachment of a phosphoglyceride to the C-terminal amino acid of a protein. Unlike more
straightforward lipid modifications, the GPI anchor has a much more complex structure. The
GPI contains a phosphatidylinositol composed of mannose and glucosamine glycosidically
attached to an inositol residue; the attachment to the C-terminus is made through an
ethanolamine phosphate bridge (Paulick & Bertozzi, 2008). The GPI linkage is also reversible
and can be broken down by phospholipases. It has also been shown that the GPI anchor can
jump from one cell to another via intermembrane transfer (Resh, 2013).
Myristoylation is generally a co-translational process, which takes place at the ER. It is
estimated that 0.5-0.8% of eukaryotic proteins are myristoylated (Resh, 2013; Wolven et al.,
1997). Myristoylation involves the covalent attachment of a myristoyl (14-carbon) group in an
amide bond to an N-terminal (NH2) glycine residue (Boutin, 1997). Typically, proteins to be
myristoylated contain the sequence MGxxxS/T. The addition of the myristoyl group is catalyzed
via the N-myristoyltransferase enzyme, after which it also results in a stably modified protein.
However, in rare situations, the myristoyl moiety can be cleaved from the myristoyl-glycine
(Manenti et al., 1994). Myristoylation provides for weak protein-protein and protein-lipid
interactions due to its small hydrophobic character, vital for membrane targeting and several
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signal transduction pathways. Myristoylated protein often undergoes other lipid modifications,
such as palmitoylation, to enhance their hydrophobicity and increase affinity for other specific
localizations (Farazi et al., 2001).
Palmitoylation is the post-translational covalent attachment of a palmitic acid (16carbon) residue to either a cysteine via a thioester bond (S-palmitoylation) or a serine and
threonine (O-palmitoylation), via an ester bond (Greaves & Chamberlain, 2011). Palmitoylation
typically involves membrane or transmembrane proteins and is used to enhance their
hydrophobicity for various processes, such as protein trafficking, plasma membrane
localization, protein assembly, and as a stability factor (Linder & Deschenes, 2007). Unlike
prenylation and myristoylation, palmitoylation is reversible due to its thioester linkage and can
be broken down through the actions of palmitoyl protein thioesterases (PTEs). On the other
hand, while prenylation and myristoylation linkages cannot be physically removed, they can be
sequestered via a hydrophobic cleft (Resh, 2013). The thioester linkage's ability to be reversed
allows for dynamic cycles of palmitoylation and depalmitoylation to occur; many of these
enzyme cycles have been characterized, such as H-Ras, the β2-adrenergic receptor, the Gprotein Gα subunit, and endothelial nitric oxide synthase (Lynch et al., 2015). An especially
prominent usage of palmitoylation cycling is in PSD-95, a postsynaptic density protein, which is
dynamically regulated in synaptic activity, suggesting that palmitoylation has a role in regulating
neurotransmitter release (Fukata et al., 2004).
N-palmitoylation is a comparatively rare form of palmitoylation that occurs in hedgehog
(Hh) protein. Unlike S-palmitoylation, N-palmitoylation involves an amide bond between the
palmitate and the N-terminal cysteine residue, added during an autoprocessing stage. Also,
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unlike S-palmitoylation, N-palmitoylation is an irreversible modification. N-palmitoylation is
uniquely catalyzed by the multipass hedgehog acyltransferase (Hhat). Uniquely, it is also
modified via the covalent attachment of cholesterol to its C-terminus using an ester bond. Hh
proteins specifically localize to the lumen of the ER.

1.4. S-Palmitoylation and the DHHC Domain
The vast majority of palmitoylated proteins are modified via S-palmitoylation; in fact, up
to 3500 human proteins are known to be S-palmitoylated (Blanc et al., 2015); S-palmitoylation
is also the focus of this study. The enzymes that perform S-palmitoylation are the posttranslational covalent attachment of a palmitic acid (16-carbon) residue, to cysteine via a
thioester bond. These palmitoyl thioester linkages have been known to occur spontaneously in
vitro in the presence of palmitoyl-CoA at neutral pH (Bharadwaj & Bizzozero, 1995). However,
S-Palmitoylation is primarily catalyzed by a family of cysteine-rich domain, thiol-directed,
protein acyltransferases (PATs, or DHHC-PATs). These PATs contain a highly conserved 50amino acid sequence known as the DHHC domain due to its Asp-His-His-Cys tetrapeptide motif
in the active site. While S-palmitoylation was discovered almost 50 years ago, identification of
the enzymes responsible and the associated DHHC domain was only confirmed in 2002 (Lobo et
al., 2002; Roth et al., 2002). Examples of PATs that include this DHHC domain include the yeast
PATs Erf2/Erf4 that palmitoylate prenylated Ras, Pfa4, the PAT that regulates the transit of
yeast chitin synthase Chs3, and the PAT for yeast casein kinase II, Akr1 (Lam et al., 2006;
Mitchell et al., 2012).
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Recent studies in yeast and mammalian cell lines suggest that DHHC proteins use a twostep, or ping-pong, catalytic process; this process is generally accepted to apply to most DHHC
proteins, albeit not in Swf1 and Pfa4 (Gottlieb & Linder, 2017). During the first step, DHHC autoacylates via a palmitoyl-CoA donor to form an acyl-enzyme intermediate. In the second step,
palmitate is transferred to the substrate protein. Thanks to mutational analysis of the DHHC
motif, it was determined that the first histidine in DHHC is used to transfer palmitate to a
protein, whereas the cysteine is catalytic and used for autoacylation (Jennings & Linder, 2012;
Mitchell et al., 2010).
The DHHC-PATs are responsible for S-palmitoylation in a variety of organisms ranging
from yeast (7 DHHC family members in Saccharomyces cerevisiae) to D. discoideum (14 DHHC
family members) to humans (23 DHHC family members) (Lemonidis, Werno, et al., 2015). Genes
encoding DHHC proteins have been found in all eukaryotic genome databases (Mitchell et al.,
2006). However, no prokaryotes or archaea have been discovered with DHHC-PATs, though
certain bacteria can co-opt the hosts DHHC-PATs to palmitoylate their proteins. DHHC proteins
are expressed in various tissues and even different subcellular locations (Linder & Deschenes,
2004). The DHHC PATs are multi-pass polytopic membrane proteins with 4-6 transmembrane
domains; they localize to the ER, Golgi, and plasma membrane. The palmitate is transferred
from palmitoyl CoA to the protein of interest via an acyl-enzyme intermediate. Some proteins
are modified by a single DHHC, whereas multiple DHHC PATs may modify others at different
times (De & Sadhukhan, 2018).
Protein palmitoyltransferases were initially isolated in S. cerevisiae in the search to
determine the enzyme that palmitoylated palmitoylation-dependent Ras proteins. Like other
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Ras proteins, yeast Ras required several lipid modifications to localize properly as a signal
transducer. It had previously been shown that a farnesyl moiety was added to the Ras, but this
would not have provided the necessary hydrophobicity for localization to the plasma
membrane; instead, a second signal in the form of a palmitoyl group enhanced the protein
(Boyartchuk et al., 1997; Hrycyna & Clarke, 1990). Initially, a non-enzymatic reaction was
suggested as isolating the PAT proved unsuccessful, especially as palmitoyl CoA had been
shown to react to proteins on its own given the required conditions. The key to elucidating the
identity of the palmitoyltransferases came with studies of the Ras2 allele and the discovery of
the ERF (Effectors of Ras Function) mutations (Bartels et al., 1999; Jung et al., 1995).
Ras2 had been isolated because of its propensity to localize after palmitoylation but
without the need to be prenylated beforehand via a C-terminal amino acid residue (Kataoka et
al., 1984). Subsequently, PAT contenders were isolated from yeast mutations that were
screened in the presence of Ras2, that mutations that proved fatal were isolated. Ras2 was
solely dependent on palmitoylation, so mutants that died were those that effectively reduced
or blocked palmitoylation; these mutants were labeled ERF mutations, ERF1, ERF2, and ERF4
(Bartels et al., 1999). Further studies on these mutations discovered that Erf2 and Erf4 co-purify
as a complex and that to provide Ras PAT activity, both had to be present as a heterodimer
(Zhao et al., 2002). Such that Erf2 possesses the four transmembrane domains, and Erf4 is
attached to TM4 but sits exclusively in the cytoplasm. An immediately characterized aspect of
Erf2 was the DHHC domain located between the second (TM2) and third (TM3) transmembrane
domains; when the yeast genome was searched for this domain, it showed up in seven other
genes. Since then, a number of these have been shown to catalyze S-palmitoylation reactions,
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such as Akr1 and Pfa3 (Roth et al., 2002, 2006). Of interesting note is the DHYC domain in Akr1,
which replaces the second histidine in DHHC with a tyrosine; its ability to autoacylate and
palmitoylate does not seem to be affected as it is missing the two zinc-finger motifs common in
other DHHC domains (Figure 1.5). The high degree of sequence homology across DHHC
domains makes it possible to test and study, possibly even determining similar palmitoylation
pathways across various eukaryotes. Despite knowledge of the DHHC-PATs, high-resolution
structures have only recently been three-dimensionally mapped; Primarily due to the difficulty
in purifying a eukaryotic multi-pass transmembrane protein to determine its structure (Rana et
al., 2018).
The 51-amino acid domain surrounding the DHHC tetrapeptide motif is so-named the
Cysteine Rich Domain (CRD) due to the high number of conserved cysteine residues flanking the
motif. The DHHC-CRD is typically found between TM2 and TM3, which puts it on the cytosolic
side of the plasma membrane; the N-terminus before the TM1 and the C-terminus after TM4
are also in the cytosol (Mitchell et al., 2006). The original DHHC-CRD consensus sequence was
obtained from a Drosophila melanogaster open reading frame called DNZ1 (Mesilaty-Gross et
al., 1999; Putilina et al., 1999): C-x2-C-x9-H-C-x2-C-x4-D-H-H-C-x5-C-x4-N-x3-F. However, upon
further cluster alignments across yeast, humans, and a host of other organisms, a revised
consensus sequence was determined:
C-x2-C-x3R/K-P-x-R-x2-HC-x2-C-x2-C-x4-DHHC-x-W-V/I-x-N-C-I/V-G-x2-N-x3-F
One clear revelation was that more residues than just the cysteines were conserved in
the domain. These include, in order, the positively charged arginine or lysine (R/K) at position 8,
the proline (P) at 9, the arginine (R) at 11, the histidine-cysteine (HC) at 14/15, the tryptophan
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(W) at 31, the hydrophobic valine or isoleucine (V/I) at 32 and 36, the asparagine (N) at 34, the
glycine (G) at 37, and the phenylalanine (F) at 44. Despite these conserved residues, there is still
quite a bit of variability in the N- and C-terminals around the DHHC-CRD; this is especially
apparent with the large size differences between different DHHC genes. This may suggest a
selective pressure to maintain these conserved residues, especially the cysteines seen across
practically all organisms. The consensus sequence for the DHHC-CRDs in D. discoideum is
presented in Figure 1.5. In addition to the conserved residues in the DHHC-CRD, a few other

Figure 1.5. Consensus Sequence of D. discoideum DHHC-CRDs to Several Orthologous
Domains. PAZ1-14 are shown with their corresponding DHHC-CRDs, also shown are orthologs in
yeast, zebrafish, mice, fruit fly, roundworm, and humans. The two CCHC zinc-finger motifs are
labeled in purple and blue; other conserved amino acids are labeled in red; the DHHC domain is
black, except for the second histidine, which is part of the second CCHC zinc-finger motif. The
yeast Akr1 DHHC lacks both zinc-fingers seen in other organisms.
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conserved motifs also appear. A DPG (Asp-Pro-Gly) tripeptide motif is often found near TM2, a
TTxE (Thr-Thr-x-Glu) tetrapeptide motif near TM4, and palmitoyltransferase conserved C
terminus (PaCCT) a 16-amino acid motif found at the cytosolic C-terminus that is found in 70%
of eukaryotic PATs (González Montoro et al., 2009; Stix et al., 2020). The precise chemical role
for these motifs still has not been elucidated, but there have been a few insights into their
structure. For example, the second threonine in the TTxE complex has been shown to interact
with the aspartic acid of the DHHC motif, though the significance is presently unknown.
The conserved cysteine residues in the DHHC-CRD have been shown to coordinate zinc
to maintain the structural integrity of the DHHC protein rather than act in a catalytic function
(Gottlieb et al., 2015). This lack of catalytic function finds support from the fact that DHHC PATs
do not need zinc to be as active in their role as PATs, such as in yeast Akr1, which lacks 5 of the
cysteines seen in other DHHC orthologs (Roth et al., 2002). The DHHC-CRD contains two CCHC
zinc-finger motifs (Figure 1.5), and previous studies have shown a loss of function when the
conserved cysteines and histidines are mutated (Hou et al., 2009; Young et al., 2014). A zinc
finger is a protein structural motif common in all plants and animals. Zinc fingers are a metalbinding domain that allows for the coordination of one or more zinc ions to stabilize protein
folding (Laity et al., 2001). There are several types of zinc fingers; in general, they coordinate
zinc using a combination of cysteine and histidine residues (Laity et al., 2001). There are six
cysteines and two histidines involved in the two zinc fingers. The conserved cysteines and
histidines engaged in zinc-coordination are separate from the first histidine and cysteine of the
DHHC motif itself; however, the second histidine is involved. The presence of zinc bound to the
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zinc-binding sites has also been confirmed and quantified from an active DHHC protein via the
mag-fura-2 fluorescent indicator (Gottlieb et al., 2015).
A subset of DHHC proteins also has ankyrin repeats in the N-terminal region from the
DHHC motif. A consensus sequence (VIAP-VIT-xxQP) has been identified in the unstructured
regions of some DHHC proteins. This region allows binding some ankyrin repeats, perhaps
helping the DHHC access the appropriate cysteine in a substrate protein (Lemonidis, SanchezPerez, et al., 2015). However, it is unknown whether the ankyrin repeats are required for PAT
activity (Hemsley & Grierson, 2011). Ankyrin repeats are a common structural motif that are
typically used to mediate protein-protein interactions (Mosavi et al., 2004). Most proteins that
contain the motif have four to six repeats. The ankyrin fold itself is more recognized for its
structure than its function, as no specific sequence or structure binds to it in all cases (Mosavi
et al., 2004).
S-palmitoylation affects various targets, including small GTPases, receptors, ion
channels, cell-adhesion proteins, transporters, scaffold proteins, and more. S-palmitoylation is
consequently crucial for cellular signaling, metabolism, meiosis, and endocytosis. Humanspecific parasites encode DHHC enzymes that are critical to their survival (Jones et al., 2012).
Pathogenic bacteria can co-opt a host cell’s DHHC enzymes to modify their effector proteins
before re-injecting them back into the host to proliferate, as bacteria lack their own DHHC-PATs
(Hicks et al., 2011; Lin et al., 2015). The DHHC-PATs have been linked to various diseases in
humans ranging from cancer to neuropsychiatric disease (De & Sadhukhan, 2018). Spalmitoylation is essential for the function of certain oncogenes and tumor suppressors (Ko &
Dixon, 2018). S-palmitoylation is also known to be involved with neuronal protein trafficking,
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for example in Alzheimer’s disease (Andrew et al., 2017; Cho & Park, 2016). Two DHHC-PATs
have recently been suggested as oncogenic targets (Runkle et al., 2016; Sharma et al., 2017).
Research into S-palmitoylation, PATs, and the associated DHHC domain has a bright future.

1.5. The PAZ5 Protein/pazE Gene
BLAST analysis was performed on the D. discoideum genome using the DHHC motif
(Figure 1.6). Fourteen D. discoideum proteins and associated transcribed genes were
discovered, each containing a DHHC-CRD (Bodwell, 2007). These were designated Protein
Acyltransferase with a Zinc finger-like domain (Bodwell, 2007). The proteins were labeled PAZ114, and the reflective genes were labeled pazA-N (S. Alamer et al., 2018).

Figure 1.6. BLAST Analysis of PAZ5 Protein. BLAST analysis shows the Ankyrin and DHHC
superfamilies on the 751 aa PAZ5 protein.
BLAST analysis of PAZ5 is seen in Figure 1.6, showing the DHHC-CRD and the presence of
6 ankyrin repeats. PAZ5 contains two conserved CCHC zinc-finger residues, a conserved DPG
motif, and a conserved TTYE motif. PAZ5 has a predicted total of 6 transmembrane domains. It
has also been predicted to localize to the Golgi membrane. The DHHC motif of PAZ5 has
previously been mutated; the resulting mutations caused slowed growth and malformations in
the fruiting body stage of the D. discoideum lifecycle (Amburg, 2010). Two PAZ5 knockouts
were created, which mutated the first histidine and the cysteine in the DHHC domain. The
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resulting phenotypes had cell sorting issues, such that fewer than normal cells differentiated
into cellulose-producing stalk cells. The resulting fruiting bodies collapsed under their own
weight and continued to grow along the agar surface. Upon rescue with the wildtype, stalk
malformations ceased, and cells grew normally (Amburg, 2010). The pazE gene (PAZ5 protein)
was initially chosen for further study as it possessed no introns in its domain. Previous work has
discovered that mutations in the DHHC motif of the pazE gene cause a characteristic deformity
in the fruiting body formation of D. discoideum (Amburg, 2010). This deformity manifests as
slowed growth and an inability for the stalk to stand on its own. It appears the stalk, which is
usually composed of dead stalk cells 3-5 cells thick, is instead only 1-2 cells thick and collapses
under its own weight. PAZ5 is 2256 bp and is located on the second chromosome, from
coordinates 5060014 to 5062269. PAZ5 is 751 amino acids in length and has a molecular weight
of 85,828 Da. The Dictybase accession number for PAZ5 is DDB_G0275097, and the UniProt
accession number is Q554E7 (ZDHC5_DICDI).

1.6. Rationale
The Gundersen lab’s focus has primarily been to study the signal transduction pathways
associated with the heterotrimeric G protein using the model organism D. discoideum,
specifically the effect and mediation of palmitoylation of the Gα2 subunit. The Gundersen lab
has previously found evidence that the Gα2 subunit of the G protein is essential to the
developmental lifecycle of D. discoideum, as loss of function of the Gα2 subunit leads to cells
failing to enter the developmental phase (R. E. Gundersen et al., 2005). The Gα2 subunit
regulates three major response pathways: cAMP signaling, chemotaxis, and differentiation (R.
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E. Gundersen, 2001). The Gα2 subunit has been implicated as the major transducer between cell
surface cAMP receptors and the associated intracellular responses within the cell (R. Gundersen
& Devreotes, 1990). G protein-membrane localization, including the Gα2 subunit, is dependent
on lipid modifications such as myristoylation and palmitoylation. Myristoylation, the irreversible
attachment of a myristic acid, is vital to membrane localization of the Gα2 subunit, and its
dysfunction can lead to inadequate cAMP response (Root et al., 1999). Palmitoylation allows for
a reversible attachment of palmitate to a cysteine via thioester linkage, allowing for enhanced
hydrophobicity of a substrate protein to localize to the plasma membrane. Palmitoylation is
also vital to proper localization and function of the Gα2 subunit (S. Alamer et al., 2018).
Intracellular S-palmitoylation reactions are catalyzed by a family of DHHC protein
acyltransferases (PATs) (Greaves & Chamberlain, 2011). DHHC proteins transfer palmitate in a
two-step process; the enzyme first uses autoacylation to modify itself with palmitate, then it
transfers the palmitate to the substrate protein (Bahl, 2006; Wells, 2003).. These DHHC PATs all
contain the DHHC-CRD (Cysteine Rich Domain), a highly conserved 51-amino acid catalytic
domain. Within the DHHC-CRD, there are typically two CCHC zinc fingers; these have previously
been demonstrated to bind and coordinate zinc ions for the structural integrity of the DHHC
protein (Gottlieb et al., 2015). It has also been shown that some of the cysteines in the DHHCCRD act as the site of autoacylation during the first step of DHHC mediated palmitoylation.
Specifically, cysteines involved in the second CCHC zinc finger have been observed to bind
palmitate (Gottlieb et al., 2015). It has also been shown that mutations of these conserved
cysteines can introduce issues with palmitoylation activity, likely by disruption of the tertiary
structure of the DHHC protein (Gottlieb et al., 2015). The DHHC PATs also contain two other
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highly conserved motifs, the DPG and TTxE (TTYE) regions, though their function is still
unknown (Stix et al., 2020). Most research into the DHHC-CRD proteins has centered on
enzymatic models, as it is challenging to purify these transmembrane proteins. In this regard,
the unique developmental lifecycle of the model organism D. discoideum provides a fascinating
in vivo model.
In D. discoideum, 14 genes that contain the DHHC-CRD have been characterized and
labeled Putative Acyltransferases with Zinc Fingers (gene name: pazA-N, protein name: PAZ114) (Bodwell, 2007). These 14 genes have been analyzed for expression during the D.
discoideum lifecycle (Bodwell, 2007). The large number of DHHC proteins that exist in D.
discoideum makes for a challenge in determining which are of the greatest significance. Of
these 14 PAZ proteins, the PAZ5 protein (pazE gene) is the first to be characterized in greater
detail. Unlike other PAZ proteins, the PAZ5 protein contained no introns, providing a tantalizing
opportunity for mutagenic phenotype analyses. Initial work characterizing the PAZ5 protein
used qRTPCR and phenotypic analysis to determine that it had a high expression level during
the trophic and culmination stages of development, especially in the formation of stalks
(Bodwell, 2007).
Further investigations into PAZ5 determined a significant difference in stalk formation
when one of two mutations were made to the tetrapeptide DHHC motif itself. Specifically, one
mutation replaced the first histidine with alanine, and the other mutation involved replacing
the cysteine with a serine (Amburg, 2010). These mutations disrupted the DHHC region and
produced a very odd malformation in the fruiting body formation of D. discoideum. This
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phenotype was identical to cells with the knockout of the PAZ5 protein, suggesting that the
DHHC motif was essential to the protein's function (Amburg, 2010).
The phenotype consisted of the fruiting body growing to a third its standard height, then
collapsing under its own weight, before continuing to grow along the surface of the agar,
suggesting the stalk had weakened in strength (Amburg, 2010). Calcofluor staining of cellulose
deposited by the cells revealed deficits in the stalk's structural organization, namely a
disruption in the cell organization. The lower stalk is typically composed of multiple layers of
cells for support; in the malformed phenotype, the lower stalk was composed of a single cell
stack, a feature usually seen only in the upper parts of the stalk (Amburg, 2010). The stalk
collapses when a larger than normal ball of pre-spore cells travels up the narrow stalk, bending
it over and causing the spore head to burst upon contact with the agar surface. Though not
proven, it was hypothesized that this change in cellular structure was due to a change in prestalk ratio to pre-spore cells during the tight aggregate stage of development.
The occurrence of a clear phenotypic change for the PAZ5-KO line suggests that
mutation rescue is a viable option to test the significance of the DHHC-CRD conserved sequence
(Amburg, 2010). To that end, single-base substitutions of conserved residues in the DHHC-CRD,
DPG, and TTxE residues of the pazE gene will be created. These mutant PAZ5 proteins will then
be moved into a green fluorescent protein (GFP) fusion/expression vector and transformed into
D. discoideum with a PAZ5 knockout (Amburg, 2010). The PAZ5 knockout was earlier created in
the Gundersen lab, but we will remake it and confirm its function too. The resulting
transformants will then be investigated for their intracellular localization via confocal
fluorescence imaging. They will also be examined for phenotypic changes in their lifecycle,
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primarily in fruiting body formation. These observations can be grouped with the kind of
mutation introduced and the effect of the mutation on the phenotype of the organism. The aim
is to determine the functional importance of the conserved residues in the PAZ5 protein/pazE
gene using an in vivo model and use this information to determine how the DHHC-CRD family
coordinates palmitoylation in the Gα2 subunit of the G protein.
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CHAPTER 2
MATERIALS AND METHODS

2.1. Cell Culture
In this study, an axenically grown AX-2 stock strain of D. discoideum was used as the
wild-type cell line. The cells were grown under axenic conditions using HL-5 media (1%
dextrose, 1% neutralized proteose peptone, 0.5% yeast extract, 3.6 mM Na2HPO4, 3.6 mM
KH2PO4, and 41 μM dihydrostreptomycin; autoclaved then filter sterilized using Nalgene RapidFlow Vacuum Filters) at 22 oC (Watts & Ashworth, 1970). The cells were grown on cell culture
plates or in a shaking culture.
A knockout strain of PAZ5 (PAZ5-KO) was also grown from D. discoideum stock. The
PAZ5-KO strain was previously created by inserting a 1.4 kb Blasticidin S (BLS) resistance
cassette into the ClaI site (ATCGAT) of PAZ5, located at 1040 bp (Amburg, 2010). The PAZ5-KO
strain was also remade recently and re-analyzed for the phenotype observed in the original
PAZ5-KO strain. The cells were grown on HL-5 cell culture plates with BLS (20 μg/mL, 13 μL BLS
in 13 mL HL-5) instead of G418 (20 μg/mL, 13 μL BLS in 13 mL HL-5) as the antibiotic selection
media.

2.2. Polymerase Chain Reactions
PCR was used for three kinds of reactions. Firstly, a mutation was made to the
PAZ5/pGEM (5.5 kb) plasmid was to remove the already-present KpnI site by substituting the
GTA codon for valine to GTT such that the KpnI site was GGTTCC rather than GGTACC. PAZ5
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cDNA had earlier been inserted into a pGEM plasmid (Promega). Secondly, PCR was used to
generate single base substitutions in the PAZ5 gene to change single highly conserved amino
acids of the DHHC-CRD in the PAZ5/pGEM-KpnImut plasmid via site-directed mutagenesis
(Reikofski & Tao, 1992). Lastly, after cloning and recovering the mutant PAZ5/pGEM-KpnImut
DNA, PCR was used to add a KpnI linker cassette to the ends of the PAZ5 gene in the
PAZ5/pGEM plasmid for ligation into the pTX-GFP expression vector (Levi et al., 2000).
For site-directed mutagenesis, complementary primers were designed with a mismatch
a minimum of 20 bp from the end of the respective primer sequence. As the primers were
extended, the mutation was created in the resulting amplicon (Kunkel, 1985; Zoller, 1991).
Seventeen different mutant varieties were created in this manner, each with their specific
annealing temperatures calculated via the Tm calculator from NEB (NEB Tm Calculator, n.d.).
They were also checked for hairpin formation via OligoCalc (OligoCalc: Oligonucleotide
Properties Calculator, n.d.). A total of 17 such mutations were made, labeled 1-17 based on the
date the original mutant primer was created. The number and corresponding label are shown
below.
Originally the Phusion High-Fidelity DNA Polymerase (NEB) was used. However, during
the research, the switch was made to the Q5 Ultra-High-Fidelity DNA Polymerase (NEB) due to
its higher fidelity and because it similarly produced blunt ends (Menin, n.d.).

PAZ5 KpnI Mutant Primers
PAZ5KpnIMUT-s TAAATTATTGGGTTCCAGAGAGAAACAATTGGTTATTAC
PAZ5KpnIMUT-a TTGTTTCTCTCTGGaACCCAATAATTTAAGTGTAAATAATTC
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PAZ5 Sequence and Mutations
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKL
PPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQN
KDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDIQNLE
EGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQC
KDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGCIKGHKQVVSMLCSFEGQD
SIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLFGGNERLYHRFWTVMGVLTVLVPTW
ILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMA
INIFPNLIINATSWYFFYFFIRLTKEDPGTISKHISKEKSNENFMNALSSGRQIPLICPTCLIN
RPIRSKHCPSCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSN
APILSESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFE
SRQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKK
DSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVD475A (4)
G477Y (1)
C506A (2)
C509G (3)
P514A (8)
R516P (9)
H519L (15)
C523G (6)
F530S (16)
W536L (10)
N538I (11)
G542S (12)
Q546L (17)
F549S (14)
F549V (13)
T628A (5)
E631A (7)
Red indicates a mutation to a conserved amino acid; green are members of the DPG motif;
purple are members of the first CCHC zinc-finger; blue corresponds to the second CCHC zinc
finger; teal are members of the TTYE motif; black are members of the DHHC motif.
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Complete Primer Sequences
ID
G477Ys (1)
G477Ya
C506As (2)
C506Aa
C509Gs (3)
C509Ga
D475As (4)
D475Aa
T628As (5)
T628Aa
C523Gs (6)
C523Ga
E631As (7)
E631Aa
P514As (8)
P514Aa
R516Ps (9)
R516Pa
W536Ls (10)
W536La
N538Is (11)
N538Ia
G542Ss (12)
G542Sa
F549Vs (13)
F549Va
F549Ss (14)
F549Sa
H519Ls (15)
H519La
F530Ss (16)
F530Sa
Q546Ls (17)
Q546La

Sequence
AAGGAAGATCCATACACAATTTCTAAACATATCTC
TGTTTAGAAATTGTGTATGGATCTTCCTTTGTTAAACGAATG
ATCCCTTTGATTGCTCCAACCTGTTTAATTAATCG
TTAAACAGGTTGGACGAATCAAAGGGATTTGACGACCAC
ATTTGTCCAACCGGTTTAATTAATCGTCCAATTCGTTC
TGGACGATTAATTAAACCGGTTGGACAAATCAAAGGG
TTAACAAAGGAAGCTCCAGGCACAATTTCTAAAC
AGAAATTGTGCCTGGAGCTTCCTTTGTTAAACGAATG
TTATTCAATAAAGCTACTTATGAACAAATTCAAC
TGTTCATAAGTAGCTTTATTGAATAAAATTGTTAAAACTTGTG
CATTGTCCATCTGGTAAAGGTTGTTTTGCACG
TGCAAAACAACCTTTACCAGATGGACAATGTTTTGAACG
AAACTACTTATGCACAAATTCAACAAATTAGAG
ATTTGTTGAATTTGTGCATAAGTAGTTTTATTGAAT
TGTTTAATTAATCGTGCAATTCGTTCAAAACATTGTCC
TGTTTTGAACGAATTGCACGATTAATTAAACAGGTTGG
TTAATCGTCCAATTCCTTCAAAACATTGTCCATCCTG
GGACAATGTTTTGAAGGAATTGGACGATTAATTAAAC
TCATCATTGTGTTTTGATTAATAAATGTATTGGTATC
ATACATTTATTAATCAAAACACAATGATGATCAAAACG
ATTGTGTTTGGATTATTAAATGTATTGGTATCAATAAC
TACCAATACATTTAATAATCCAAACACAATGATGATC
TTAATAAATGTATTAGTATCAATAACCAAGCTTTATTC
GCTTGGTTATTGATACTAATACATTTATTAATCCAAAC
ATAACCAAGCTTTAGTCATCACTGTACTCTTCTCATATG
GAGTACAGTGATGACTAAAGCTTGGTTATTGATACC
TAACCAAGCTTTATCCATCACTGTACTCTTCTCATATG
AAGAGTACAGTGATGGATAAAGCTTGGTTATTGATACC
CAATTCGTTCAAAACTTTGTCCATCTTGTAAAGGTT
TACAAGATGGACAAAGTTTTGAACGAATTGGACGAT
GTTGTTTTGCACGTTCTGATCATCATTGTGTTTGG
ACACAATGATGATCAGAACGTGCAAAACAACCTTTAC
TTGGTATCAATAACCTAGCTTTATTCATCACTGTAC
TGATGAATAAAGCTAGGTTATTGATACCAATAC
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Tm
65
69
70
75
71
72
70
73
62
65
71
73
63
63
69
70
71
67
63
64
63
65
61
64
69
69
69
69
68
70
71
71
67
64

Ta
66
66
71
71
72
72
71
71
63
63
72
72
64
64
70
70
68
68
64
64
64
64
62
62
70
70
70
70
69
69
72
72
65
65

Notes
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK

Partial Primer Sequence
ID
G477Ys (1)
G477Ya
C506As (2)
C506Aa
C509Gs (3)
C509Ga
D475As (4)
D475Aa
T628As (5)
T628Aa
C523Gs (6)
C523Ga
E631As (7)
E631Aa
P514As (8)
P514Aa
R516Ps (9)
R516Pa
W536Ls (10)
W536La
N538Is (11)
N538Ia
G542Ss (12)
G542Sa
F549Vs (13)
F549Va
F549Ss (14)
F549Sa
H519Ls (15)
H519La
F530Ss (16)
F530Sa
Q546Ls (17)
Q546La

Sequence
TACACAATTTCTAAACATATCTC
TATGGATCTTCCTTTGTTAAACGAATG
GCTCCAACCTGTTTAATTAATCG
CGAATCAAAGGGATTTGACGACCAC
GGTTTAATTAATCGTCCAATTCGTTC
CGGTTGGACAAATCAAAGGG
CTCCAGGCACAATTTCTAAAC
GCTTCCTTTGTTAAACGAATG
GCTACTTATGAACAAATTCAAC
CTTTATTGAATAAAATTGTTAAAACTTGTG
GGTAAAGGTTGTTTTGCACG
CAGATGGACAATGTTTTGAACG
CACAAATTCAACAAATTAGAG
GCATAAGTAGTTTTATTGAAT
GCAATTCGTTCAAAACATTGTCC
CACGATTAATTAAACAGGTTGG
CTTCAAAACATTGTCCATCCTG
GGAATTGGACGATTAATTAAAC
TGATTAATAAATGTATTGGTATC
AAAACACAATGATGATCAAAACG
TTAAATGTATTGGTATCAATAAC
ATAATCCAAACACAATGATGATC
AGTATCAATAACCAAGCTTTATTC
TAATACATTTATTAATCCAAAC
GTCATCACTGTACTCTTCTCATATG
CTAAAGCTTGGTTATTGATACC
CCATCACTGTACTCTTCTCATATG
GATAAAGCTTGGTTATTGATACC
TTTGTCCATCTTGTAAAGGTT
AGTTTTGAACGAATTGGACG
CTGATCATCATTGTGTTTGG
GAACGTGCAAAACAACCTTTAC
TAGCTTTATTCATCACTGTAC
AGGTTATTGATACCAATAC
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Tm
54
62
61
68
62
64
61
59
56
57
62
62
54
52
63
59
61
56
52
59
52
58
57
49
62
58
62
58
58
60
58
62
56
52

Ta
55
55
62
62
63
63
60
60
57
57
63
63
53
53
60
60
57
57
53
53
53
53
50
50
59
59
59
59
59
59
59
59
53
53

Notes
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK

Standard Reaction Conditions:
10 μL 5X Q5 Reaction Buffer
1 μL 10 mM dNTPs
1 μL 20 μM Forward Primer
1 μL 20 μM Reverse Primer
1 μL Template DNA (1-10 ng)
0.5 μL Q5 High-Fidelity DNA Polymerase
35.5 μL Nuclease-Free Water
50 μL Total Reaction Volume

As the site-directed mutagenesis primers were only partially aligned for the first cycle,
the annealing temperature was calculated using only the sequence up to the mutation.
Therefore, the PCR program involves the first cycle with a lower temperature, and all
subsequent cycles involve temperature calculated from the whole sequence. For all other PCR
programs, the first cycle was not included.

Standard Reaction Program:
98 oC for 30 seconds (Initial Denaturation)
98 oC for 10 seconds (First Cycle Denaturation)
52-63 oC for 30 seconds (First Cycle Primer Annealing)
72 oC for 3 minutes (First Cycle Extension)
98 oC for 10 seconds (Subsequent Cycle Denaturation)
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63-72 oC for 30 seconds (Subsequent Cycle Primer Annealing)
72 oC for 3 minutes (Subsequent Cycle Extension)
GOTO Step 5, 18 Times (20 Total Cycles)
72 oC for 6 minutes (Final Extension)
6 oC for 5 minutes (Hold)

Initially, the plan was to directly mutate the PAZ5/pTX-GFP expression vector directly
rather than individually mutate PAZ5 and ligate it into pTX-GFP each time. However, the D.
discoideum genome - and by extension, the Ddp1 derived backbone of the pTX-GFP expression
vector - is very AT-rich, with content approaching 80% (Glöckner et al., 2002). The AT content
may have prevented even Ultra-High-Fidelity polymerases, such as Q5, from remaining
attached to the DNA strand (Charette & Cosson, 2004; Larsson et al., 2008).

2.3. Restriction Enzyme Digestion
After the PCR reaction designed to elicit site-directed mutagenesis, enzyme digests
using DpnI (New England Biolabs) were performed on the entire PCR product to hydrolyze the
parental DNA before transformation into chemically competent E. coli DH5α cells. 5 μL
CutSmart Buffer (New England Biolabs) and 0.5 μL DpnI were added to 50 μL PCR product and
incubated at 37 oC for 15 minutes, then heat-inactivated at 80 oC for 20 minutes. 2.5 μL of DpnIdigested PCR product was then run on a gel to validate the size of the PAZ5/pGEM plasmid (5.5
kb), to determine the degree of unwanted primer dimerization (Chou et al., 1992), and to
determine the concentration of DNA based on brightness relative to the ladder. 2.5 μL of DpnI43

digested PCR product would then be used to transform into chemically competent E. coli DH5α
cells.
After the cloning, recovery, and KpnI linker process, a second restriction enzyme
digestion was performed. Firstly, the PCR product was purified of its polymerase using a
Monarch PCR and DNA Cleanup Kit (New England Biolabs) and eluted in 50 μL of elution buffer.
An enzyme digest was then performed on the total volume using 5 μL CutSmart 10X Buffer, 0.5
μL DpnI and 0.5 μL KpnI-HF and incubated at 37 oC for 15 minutes. After that, it was purified
again using a Monarch PCR and DNA Cleanup Kit as KpnI-HF is resistant to heat-inactivation and
eluted in 20 μL. A gel was then run again to determine the ratio required for a T4 ligation (Kuhn
& Frank‐Kamenetskii, 2005).
A phenol-chloroform extraction could also be performed in place of the Monarch
Cleanup Kit (Sambrook & Russell, 2006). This step was the original method for purifying nucleic
acids in the experiments, but it was superseded due to the time it takes to process large
quantities of samples. It can also leave traces of chloroform in the final sample that makes use
of the NanoDrop untenable.
Lastly, before ligating the prepped DNA from the earlier step into the pTX-GFP
expression vector, the vector had to be digested with KpnI-HF and Antarctic Phosphatase (New
England Biolabs). These were used to cut and dephosphorylate the ends of the DNA to prevent
religation of the newly linearized plasmid DNA, respectively. The reaction involves 2 μg of
purified pTX-GFP immersed in 1 μL CutSmart, 2 μL KpnI-HF and nuclease-free water up to 10 μL,
incubated at 37 oC for 15 minutes. Immediately after, 2 μL of Antarctic Phosphatase buffer, 4 μL
Antarctic Phosphatase, and 4 μL nuclease-free water were added, then incubated at 37 oC for a
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further 30 minutes. After, the DNA was again purified using a Monarch PCR and DNA Cleanup
Kit and examined via NanoDrop for concentration (Desjardins & Conklin, 2010).

2.4. Gel Electrophoresis
Gel electrophoresis was performed with a 1% agarose gel and 1X TPE (Tris-PhosphateEDTA) buffer. The 1kb DNA ladder (NEB) (Figure A.4) was used as a marker at 0.5 μg/lane. Gel
Loading Dye, Purple (6X), no SDS Ladder (New England Biolabs) was added to each sample,
including the ladder. After the gels had been run, they were soaked in ethidium bromide (1
μg/mL) (Sutherland et al., 1984) and scanned at 600 dpi using an Azure Biosystems c300
Imaging System.

2.5. High-Efficiency Transformation and Cloning into E. coli
Cloning into E. coli was utilized at two stages of the experimental process. Firstly, for the
treated PCR product from the site-directed mutagenesis of the PAZ5/pGEM plasmid. Secondly,
cloning was used after ligating the KpnI-linker mutated PAZ5/pGEM plasmid and pTX-GFP
expression vector via the T4 ligation.
The DH5α cell line of E. coli (New England Biolabs) was used for the transformation and
cloning procedures. 2.5 μL (10-20 ng) of the digested PCR product was mixed into a tube of NEB
5-alpha Competent E. coli cells that had been thawed on ice; the mixture was then flicked 5
times to mix cells and DNA. The mixture was then placed on ice for 30 minutes before being
heat-shocked at 42 oC for 30 seconds. After being placed on ice for a further 5 minutes, 950 μL
of SOC Outgrowth Medium (2% bacto tryptone, 0.5% bacto yeast extract, 8.56 mM NaCl, 2.5
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mM KC1, 10 mM MgCl2, and 20 mM glucose) was added, and the tubes were incubated on a
shaker at 37 oC for one hour at 250 rpm. Cells were then mixed thoroughly by flicking the tube.
Finally, 125-200 μL (depending on plate size) of transformed cells were spread onto an LB (1%
tryptone peptone, 0.5% yeast extract, and 0.17 M NaCl, 1.5% agar) plate that had been spread
with 40 μL ampicillin (500X stock) 30 minutes prior. The plates were then incubated at 37 oC
overnight (16-20 hours) (Biolabs, n.d.-a; Inoue et al., 1990). The remaining vial of cells was
stored at -20 oC for up to 14 days.
After incubation, 2-4 individual colonies were picked and incubated overnight (16-20
hours) in 5 mL LB+AMP solution (ampicillin at 100 μg/mL) in a 50 mL conical tube. After this, a 1
mL fraction of the incubated solution was stored and frozen at -80 oC by suspending it in
glycerol at a 680:320 μL ratio (Lovelock, 1953). The remaining solution was then processed
using the QIAprep Spin Miniprep Kit (Qiagen) to extract the sample's plasmid DNA (QIAprep
Spin Miniprep Kit - QIAGEN Online Shop, n.d.; Sauer et al., 1998). This process involves lysing the
bacterial cultures by centrifuging the cells at 5000 rpm for 5 minutes, then immediately
removing the supernatant and adding a series of buffers provided in the kit, labeled in order:
‘P1, P2, N3, PB and PE’. This procedure acts to bind, wash and elute the lysate such that the
DNA binds to a silica membrane until all the impurities are washed away, before being eluted in
a small volume of elution buffer.
Depending on the application, the eluted DNA could then be further precipitated via the
ethanol precipitation protocol. Wherein 1/10 of the volume of 3M NaCH3COO and 3 volumes of
100% ethanol are mixed into the DNA solution and allowed to freeze overnight at -20 oC. After
this, the tube was spun at full speed (14,000 rpm) in a desktop microcentrifuge for 30 minutes
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before being decanted, washed with 300 μL of 70% ethanol, and dried in a vacuum
concentrator (Green & Sambrook, 2016). Thereupon it was eluted in 20 μL of elution buffer and
examined for concentration via a NanoDrop.

2.6. Ligation and Verification of Fusion Protein Expression Vectors
The PAZ5 gene had earlier given one of a series of mutations, then had a KpnI linker
cassette added on both ends via PCR, then been digested using DpnI and KpnI to cut the PAZ5
gene from the PAZ5/pGEM plasmid, confirmed via gel electrophoresis. The pTX-GFP expression
vector had been cut with KpnI and dephosphorylated with Antarctic Phosphatase to prevent
the linearized plasmid DNA from re-ligating on its own. The amount of pTX-GFP recovered was
also confirmed via gel electrophoresis.
Based on the gel electrophoresis results, a T4 ligation reaction was set up using a molar
ratio of 1:3 vector: insert. The required mass of 37 ng Insert DNA was calculated using the Insert
DNA length (2.2 kb for PAZ5), the Vector DNA length (11.2 kb for pTX-GFP), and the Vector DNA
mass (64 ng); calculated using the NEBioCalculator (Biolabs, 2018; NEBioCalculator, n.d.). The
T4 ligation reaction involved mixing the components and incubating at room temperature for
20 minutes, then chilling on ice and transforming 2.5 μL into 25 μL NEB DH5α competent cells
using the protocol stated earlier (Biolabs, n.d.-b; Tabor, 1989).

Standard T4 Ligation Reaction:
2 μL T4 DNA Ligase Buffer (10X)
1 μL Vector DNA (pTX-GFP at 0.020 pmol)
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1 μL Insert (PAZ5 Mutant at 0.060 pmol)
1 μL T4 DNA Ligase
15 μL Nuclease-Free Water

The resulting colonies were then screened for the correct ligation outcome via the
Boiling Miniprep method for rapid small-scale plasmid DNA preparation. This step is necessary
due to the often-low ligation efficiency provided by the T4 ligation; moreover, there is a 50/50
chance that the PAZ5 gene will be inserted in the wrong direction in the pTX-GFP plasmid. The
boiling miniprep process involves partially lysing the cells to allow plasmid molecules to escape
into the supernatant while leaving genomic DNA within the cell lysate; this was performed by
centrifuging the cells at 6000 rpm for 5 minutes. Any remaining genomic DNA is removed
during a lysozyme (10mg) and STET (8g sucrose, 5 mL Triton X-100, 10 mL 0.5 M EDTA, 5 mL 1M
Tris-Cl at pH 8.0, water) digestion. Then a high-temperature denaturation step was immediately
followed by rapid annealing via isopropanol. During subsequent ethanol precipitation, any
remaining genomic DNA is lost while the plasmid DNA reassociates (Harwood, 1996), and the
plasmid DNA is left in a concentrated form.
The plasmid DNA was then ready to be examined on a gel, but first, some had to be
digested using KpnI to cut open the ligated portions of the PAZ5/pTX-GFP vector. The DNA must
then be treated with ribonuclease to degrade leftover RNA from the sample. If successful
ligation has occurred, the gel will have two bands, a 2.2 kb band corresponding to PAZ5 and an
11.2 kb band corresponding to the pTX-GFP plasmid. Upon confirmation of successful ligation
strains, a second digestion had to be performed on the remaining portion of plasmid DNA, this
48

time using EcoRI. This step was to confirm that the PAZ5 gene had been ligated into the pTXGFP vector in the correct orientation (Dooley et al., 1993). Both PAZ5 (Figure A.1) and pTX-GFP
(Figure A.2) have EcoRI sites such that, if PAZ5 is ligated in the correct orientation, it will have a
band dropout with a 2.1 kb size; if it is in the wrong orientation, the band will instead be 1.4 kb
in size. Only sequences with the correct EcoRI band dropout will be transformed into D.
discoideum.

Standard Boiling Miniprep Digestion Reaction:
1 μL CutSmart Buffer
2 μL Plasmid DNA
1 μL Enzyme (EcoRI or KpnI, diluted 2:8 Enzyme: Buffer)
6 μL Nuclease-Free Water

Upon confirmation of successful ligation via KpnI and EcoRI digestions, the original
colony can be grown up overnight using the E. coli cloning method. The strain could then be
frozen for further use and processed using a Qiagen Spin Miniprep kit in anticipation of
sequencing and transformation into D. discoideum.

2.7. Sequencing PAZ5 for Mutation and KpnI Linker Cassette
Sequencing was performed at three points. Firstly, to confirm the presence of the base
substitution that mutated the KpnI site in the wild-type strain of the PAZ5/pGEM from a GTA
Valine to a GTT valine. Secondly, sequencing was used to confirm the specific base mutations
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made via the mismatched primer PCRs in the PAZ5/pGEM plasmid. The final use of sequencing
was after the PAZ5 gene had the KpnI linker cassette placed at either end, then been ligated
into the PAZ5/pTX-GFP expression vector. This was to confirm both that the KpnI linkers were
there (also confirmed by cutting PAZ5/pTX-GFP with KpnI and looking for the two dropout
bands at 2.2 kb and 11.2 kb) and that the 5’ and 3’ ends of PAZ5 were in-frame with the pTXGFP plasmid.
Sequencing was performed via the Thermo Fisher 3730 DNA Analyzer with the XL
upgrade (Fisher, 2002). The Sanger sequencer was capable of yielding between 800-1000 bases
of sequence per primer; hence a total of three primers were used to sequence the 2.2 kb PAZ5
gene. Outputted sequences were run through the Auto PeakTrace RP Basecaller suite
(PeakTrace White Paper, n.d.) to improve basecalling reads. They were then formatted in the 5’
to 3’ direction, as needed (Reverse Complement, 2020). The formatted sequences were
manually merged to produce a complete sequence of the PAZ5 gene and provide a sequence
for the bases up- and down-stream of the PAZ5 insert in the pTX-GFP plasmid. The sequences
were translated using the online ExPASy tool (ExPASy - Translate Tool, 2020) to determine the
reading frame they were in and place them in a FASTA format. Finally, the translated read was
exported to MUSCLE, a multiple sequence alignment tool (MUSCLE < Multiple Sequence
Alignment, 2020), and compared to the standard PAZ5/pTX-GFP sequence for verification of
correct mutagenesis and ligation.
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2.8. Transformation of Expression Vector into D. discoideum via Electroporation
Transformation of the PAZ5/pTX-GFP expression vector into D. discoideum was
accomplished using Electroporation (Fey et al., 2007; Knecht & Pang, 1995). The cells to be
transformed were the PAZ5-KO line, which contained a knockout PAZ5 gene; created by
inserting a 1.4 kb Blasticidin S (BLS) resistance cassette into the ClaI site of PAZ5. The mutant
PAZ5/pTX-GFP plasmid would act as a rescue of the PAZ5-KO. The PAZ5-KO cells for
transformation were grown over 2-3 days in the presence of BLS such that they were still
growing in the log phase. They were grown to 1-2 x 106 cells/mL (cultures over 4 x 106 cells/mL
secrete factors that trigger entry into development). Cell counts were performed manually
using a Metallized Hemacytometer (Metallized Hemacytometer Reichert Bright-Line, n.d.). Each
transformation required 1 x 107 cells/mL and 5-10 μg of plasmid DNA at a minimum
concentration of 500 ng/μL. According to the number of transformations, the appropriate
number of cells were harvested and pelleted at 500 x g for 4 minutes at 4 oC. The pelleted cells
were then gently washed with 5 mL of ice-cold Electroporation buffer (E buffer) (1 mM NaPO4
pH 6.3 and 250 mM sucrose) and pelleted again. The pellet was then resuspended in E buffer at
2 x 107 cells/mL, with each 500 μL corresponding to the number of transformations to be
performed.
Then 5-10 μg of Plasmid DNA in a maximum of 10 μL elution buffer were placed into a
cold Eppendorf tube with the 500 μL of E buffer mixed cells, then flicked four times and allowed
to incubate on ice for 5 minutes. 450 μL of the sample mixture was then transferred to a 0.2 cm
electroporation cuvette and gently pipetted up and down. Electroporation was performed using
a Bio-Rad Gene Pulser I system; the settings used were 1.2 kV, 3 μF capacitance, 200 ohms
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resistance, and 125 μF extended capacitance. A time constant of 0.5-0.6 ms was ideal. The
samples were then incubated on ice for 10 minutes. The sample was then transferred to a cell
culture plate with 2 μL of healing solution (100mM CaCl2 and 100 mM MgCl2), swirled gently,
and incubated at 22 oC for 15 minutes. Then 13 mL of HL-5 media was added. The plate was
then incubated for 24 hours at 22 oC, thereupon 13 μL of the antibiotic G418 (20 μg/mL in 10
μM Hepes pH 7.2; 13 μL G418 in 13 mL HL-5) was added for drug selection of the expression
vector (Pang et al., 1999). 50 μL of heat-killed Klebsiella aerogenes (made from overnight
culture and killed by heating to 70 oC for 20 minutes) was also added to the sample to promote
initial growth (Joly et al., 1993). The media was then changed (13 mL HL-5 and 13 μL G418)
every 72 hours for 14 days, then every week after that, to remove dead cells and encourage
growth. For the first 14 days, the media is changed with care not to disturb cells adhering to the
plate itself; after 14 days, the plate is instead rinsed such that the adhered cells are mixed into
the media to be removed.

2.9. Storing D. discoideum Cell Lines
Between 14 and 21 days after the electroporation, freezer stocks were made for longterm storage. 2 x 107 cells/mL (1 mL per freezer stock vial) were pelleted at 500 x g for 4
minutes at 4 oC. The pellets were then resuspended in HL-5 containing 25% fetal bovine serum,
corresponding to half the final total volume. Then HL-5 containing 25% fetal bovine serum and
40% DMSO were added to bring the cells up to the final volume. Then 1 mL of the cell mixture
was pipetted into screw cap Eppendorf tubes; these were encased in a Styrofoam block and
placed in a -20 oC freezer for 2 hours. The Styrofoam block was then moved into a -80 oC
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freezer. After 24 hours, the cultures were removed from the Styrofoam block and stored
indefinitely at -80 oC.

2.10. Photography of D. discoideum Development
The D. discoideum cells needed to undergo starvation in order to trigger their fruiting
body lifecycle. Cell lines to be examined were grown up to a suitable concentration by rinsing
the media from a plate undergoing log phase and depositing the HL-5 mixed with live-cells into
a shaking flask containing 100 mL HL-5 and 100 μL G418. After 48-72 hours, the cells would
have reached a concentration of 1-3 x 106 cells/mL, indicating they are still in their log-phase. 5
x 107 cells per plate were harvested and pelleted at 500 x g for 4 minutes. They were then
washed with an equal volume of sterile development buffer (DB) (10 mM NaPO4 pH 6.3, 2 mM
MgSO4, and 0.2 mM CaCl2). The cells were then re-pelleted and re-suspended in 5 mL of DB (5
mL per plate). The cells were then added to a sterile DB plate (DB with 1.5% agar) and allowed
to sit for 5 minutes. The excess DB was then carefully aspirated off, and the plates were allowed
to dry for 1 minute at room temperature.
The plates were then incubated at 22 oC for 48 hours post-starvation (hps). Time-lapse
studies involved images being taken at 4X magnification every 6 minutes for 48 hours (480
total). Images began being taken within 15 minutes post-starvation, using an Olympus
microscope and a SPOT Idea 1.3-megapixel digital microscope camera (SPOTTM Idea 1.3 Mp,
n.d.). Imaging of the plates took place at 48 hours using an iPhone 8 attached to a Gosky Cell
Phone Adapter Mount. All images were processed using Fiji ImageJ (Hartig, 2013; Rasband,
1997). Studies were performed on multiple clones a minimum of three times.
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2.11. Confocal Imaging of Fluorescent D. discoideum Cells
The D. discoideum cells should have a fluorescent GFP tag thanks to the GFPmut2 coding
region in the pTX-GFP plasmid. The cells for imaging were collected by rinsing the growth plates
during their log-phase and placing 1mL of the cell-suspended HL-5 into the wells of a sterile 24well black microcavity plate with clear glass bottom and lid. The cells were left to adhere to the
bottom of the microcavity plate for 15 minutes at 22 oC; then, the media was removed using a
Pasteur pipette. 1 mL of DB was then gently added to the cells for a minimum of 2 hours; this
allowed the cells to extrude stores of material that provide low-level autofluorescence during
confocal imaging (Engel et al., 2006). After a minimum of 2 hours, the DB was gently removed
and replaced with an equal volume of fresh DB. The microcavity lid had to cover the cells at all
times of the process to prevent evaporation of the media.
Sequential scanning was performed using the Olympus FluoView FV1000 with an
Olympus IX-81 inverted microscope, and a 30 milliwatt multi-argon laser was used to collect
images. Either a 20X, 40X, or 100X oil immersion objective lens was used in conjunction with
Alexa Fluor 488 nm excitation. A negative control cell line was used each time in the form of the
PAZ5-KO as this lacked the GFP tag; autofluorescence was observed in the PAZ5-KO line and
adjusted for accordingly. A positive control cell line was also used to calibrate settings for the
excitation laser, in the form of a PAZ8-GFP line kindly created by Joel Amburg (Amburg, 2010).
The settings used were:
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Confocal Settings on Olympus FluoView FV1000
Alexa Fluor 488 Laser: 488nm, 5%, 500 HV, 1 Gain, 0% Offset
TD1 Laser: 488nm, 5%, 128 HV, 1 Gain, 0% Offset
Exposure: 8 μs/pixel
C.A.: 105 μm
Lamp: 7.5v

2.12. Statistical Analysis of Mutant Phenotypes versus Wild-Type
A minimum of ten random images was taken for each plate at 48 hps. A grid of ten
squares was superimposed onto the images, and each square was counted for fruiting bodies.
The fruiting bodies were divided into three categories: Those that had developed growing
normally (upright) (Labeled ‘1’ in Figure 2.1); those that developed along the agar, including
those that formed a standard spore head slightly above the surface of the agar (along agar)
(Labeled ‘2’ in Figure 2.1); and those that had fallen over and contacted the surface of the plate
breaking open the spore head (fallen) (Labeled ‘3’ in Figure 2.1). These counts were then
computer into percentages, and standard deviations were calculated.
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Figure 2.1. Analysis of D. discoideum Fruiting Body Development. Pictured is an example of
fruiting body analysis. Cells were developed for 48 hours post-starvation. Pictured are the
lower and upper focal planes (A-1 and A-2). The upright fruiting bodies are labeled ‘1’ in picture
A-2; the fruiting bodies that have developed along the agar and formed a spore head without
breaking are labeled ‘2’ in picture A-1; the fallen fruiting bodies with intact spore heads are
labeled ‘3’ in picture A-1. Captured using a 4X objective on an Olympus light microscope with a
camera attachment.
2.13. Rescue of Knockout
The wildtype PAZ5/pTX-GFP fusion expression vector would be used to confirm the
rescue of the knockout. The wild type still contains the KpnI mutation that allowed for ligation
into the KpnI site of the pTX-GFP plasmid; however, this mutation was designed to interrupt the
KpnI recognition site without disrupting the in-frame valine. Instead, the wild-type does not
contain any other mutations in its sequence, such as the substitutions of conserved residues
typical of the mutant strains. This wild-type PAZ5/pTX-GFP strain would be transformed into
the KO line and, if all goes to plan, provide a statistical count of fruiting body phenotypes similar
to the D. discoideum AX2 strain, the original strain lacking a knockout.
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2.14. Development on Bacterial Lawn
Cells for cloning can also be obtained using a bacterial lawn of Klebsiella aerogenes. The
K. aerogenes culture is grown overnight at 37 oC, then 200 μL was spread on SM/5 (0.2%
dextrose, 0.2% bacto-peptone, 0.02% yeast extract, 0.231% KH2PO4, 0.1% K2HPO4, 2% agar)
plates and incubated overnight at 37 oC (M. Sussman, 1987). D. discoideum cells are then grown
into the log growth phase at around 1-2 x 106 cells/mL at 22 oC. A 10 μL drop of the cell culture
was added to the bacterial lawn and grown for 48-72 hours at 22 oC.
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CHAPTER 3
RESULTS

3.1. Creation of PAZ5-KO and PAZ5 Mutant Cell Lines
A variety of mutants were created to determine the significance of the conserved amino
acids in the PAZ5 protein. In addition, a knockout line of the pazE gene (PAZ5-KO) was
regenerated. Each amino acid change involved a substitution point mutation that changed an
individual amino acid without altering other amino acids in its vicinity. The mutations were
introduced using PCR via site-directed mutagenesis. For each mutation, a pair of
oligonucleotides (primers) were designed to resemble a portion of the pazE sequence, albeit
with an error in its sequence, the error allowing for a different codon sequence. The primers
would introduce this mutation into the PAZ5/pGEM plasmid, and PCR would amplify its
presence relative to the parent plasmid. The parent template would then be removed using
DpnI, methylation-dependent endonuclease, then transformed into E. coli. The PCR product to
be transformed into bacteria was also run on a gel to confirm that the PAZ/pGEM plasmid was
still of the same size and to evaluate the efficiency of the PCR by looking for evidence of primerdimer (Figure 3.1). A total of seventeen mutations were created in this manner (Table 3.1,
Appendix B). Of these seventeen, two were created in the DPG and TTYE motifs, four were
made to the CHHC zinc-fingers directly flanking the DHHC motif, and nine were made to
conserved non-cysteine amino acids in the DHHC-CRD (Table 3.1). The type of mutation
introduced varied depending on their purpose. Some were designed to elicit a substantial
change, and others to elicit a smaller change
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Name
G477Y (1)
C506A (2)
C509G (3)
D475A(4)
T628A (5)
C523G (6)
E631A (7)
P514A (8)
R516P (9)
W536L (10)
N538I (11)
G542S (12)
F549V (13)
F549S (14)
H519L (15)
F530S (16)
Q546L (17)

Original Amino Acid
Glycine (GGC)
Cysteine (TGT)
Cysteine (TGT)
Aspartic acid (GAT)
Threonine (ACT)
Cysteine (TGT)
Glutamic acid (GAA)
Proline (CCA)
Arginine (CGT)
Tryptophan (TGG)
Asparagine (AAT)
Glycine (GGT)
Phenylalanine (TTC)
Phenylalanine (TTC)
Histidine (CAT)
Phenylalanine (TTT)
Glutamine (CAA)

New Amino Acid
Tyrosine (TAC)
Alanine (GCT)
Glycine (GGT)
Alanine (GCT)
Alanine (GCT)
Glycine (GGT)
Alanine (GCA)
Alanine (GCA)
Proline (CCT)
Leucine (TTG)
Isoleucine (ATT)
Serine (AGT)
Valine (GTC)
Serine (TCC)
Leucine (CTT)
Serine (TCT)
Leucine (CTA)

PAZ5 Region
DPG Motif
1st Zinc Finger
1st Zinc Finger
DPG Motif
TTYE Motif
2nd Zinc Finger
TTYE Motif
DHHC-CRD
DHHC-CRD
DHHC-CRD
DHHC-CRD
DHHC-CRD
DHHC-CRD
DHHC-CRD
1st Zinc Finger
DHHC-CRD
DHHC-CRD

MW Change (g/mol)
75 to 181
121 to 89
121 to 75
133 to 89
119 to 89
121 to 75
147 to 89
115 to 89
174 to 115
204 to 131
132 to 131
75 to 105
165 to 117
165 to 105
155 to 131
165 to 105
146 to 131

Chemistry Change
Non-Polar+Aliphatic --> Polar+Aromatic
Non-Polar+Sulfur-Containing --> Non-Polar+Aliphatic
Non-Polar+Sulfur-Containing --> Non-Polar+Aliphatic
Negatively-Charged+Acidic --> Non-Polar+Aliphatic
Polar+Hydroxylic --> Non-Polar+Aliphatic
Non-Polar+Sulfur-Containing --> Non-Polar+Aliphatic
Negatively-Charged+Acidic --> Non-Polar+Aliphatic
Non-Polar+Aliphatic --> Non-Polar+Aliphatic
Positively-Charged+Basic --> Non-Polar+Aliphatic
Non-Polar+Aromatic --> Non-Polar+Aliphatic
Polar+Amidic --> Non-Polar+Aliphatic
Non-Polar+Aliphatic --> Polar+Hydroxylic
Non-Polar+Aromatic --> Non-Polar+Aliphatic
Non-Polar+Aromatic --> Polar+Hydroxylic
Positively-Charged+Basic --> Non-Polar+Aliphatic
Non-Polar+Aromatic --> Polar+Hydroxylic
Polar+Amidic --> Non-Polar+Aliphatic

Table 3.1. Amino Acid Substitutions for All Mutants. The amino acid substitutions for all
mutations are outlined in this table. The type of amino acid change is specified, as is the region
in PAZ5 (DPG, TTYE, zinc fingers, or DHHC-CRD); the change in molecular weight; and the
changes to the side chain (polarity and group). Red indicates a mutation to a conserved amino
acid; purple are members of the first CCHC zinc-finger; blue corresponds to the second CCHC
zinc finger; and teal are members of the TTYE motif.

Figure 3.1. Mutation Creation in PAZ5/pGEM using PCR. Mutations were made on the
PAZ5/pGEM (5.2 kb) vector (1-2). The efficiency of the PCR was evaluated by examining the
formation of primer dimers. These mutations could later be excised and inserted into the pTXGFP vector for expression in D. discoideum. A 1kb ladder (NEB) provides a reference (A).
Confirmation that the mutation had been created and that no errant mutations had
accidentally been created was performed using Sanger sequencing. Plasmid DNA was obtained
by lysing and prepping plasmid DNA from an E. coli clone. Sanger sequencing produced reads
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between 800-1000 bp, so three primers were designed at intervals of 800 bp for the reads to
start at. The three reads were then compiled into a single string. The string was examined for
reading frame consistency and compared to a wildtype sequence to confirm that only the
intended mutation was created. An example of this comparison is pictured for the G477Y PAZ5
mutant (Figure 3.2). Upon confirmation of success, mutations would then be ligated into a pTXGFP plasmid expression vector using a KpnI (GGTACC) site.

Figure 3.2. Example of Wildtype and Mutant Sequence Comparison. Example of sequence
comparison between the original wildtype sequence (ACT) (figure A) and the PAZ5 mutant
C523G (GCT) (figure B). 5’-3’ direction, sense strand, location at 1569 bp on PAZ5, in the TTYE
domain.
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Before ligating into pTX-GFP could happen, a naturally present KpnI site within PAZ5 first
had to be removed. So that digesting PAZ5/pGEM with KpnI would only cleave PAZ5 from
pGEM, rather than cleaving PAZ5 itself. Two primers were created to mutate the KpnI site
without changing the amino acid composition of what was essentially the wildtype. The original
valine (GTA) was changed to an alternate valine (GTT); hence the KpnI site (GGTACC) naturally
present within PAZ5 was changed to GGTTCC and was no longer digestible with the KpnI
restriction enzyme. This was confirmed via digestion of PAZ5 with the KpnI restriction enzyme
(Figure 3.3).

Figure 3.3. PAZ5 Before and After Removal of KpnI Site. The PAZ5 protein already contained a
KpnI restriction site, in addition to the KpnI cassette added to the ends to be used for ligation.
The existing KpnI site (rows 3 & 4), when digested with a KpnI restriction enzyme, produces two
fragments, at 1 kb and 1.25 kb, corresponding to the total length of PAZ5, at 2256 bp. PAZ5 was
then mutated via PCR to remove the KpnI site (rows 1 & 2). The original valine (GTA) was
changed to a new valine (GTT); hence the KpnI site (GGTACC) naturally present within PAZ5 was
no longer digestible with the KpnI restriction enzyme. A 1kb ladder (NEB) provides a reference
(A & B).
The PAZ5-KO line was created by inserting a 1.4 kb Blasticidin S (BLS) resistance cassette
into the ClaI site (ATCGAT) of PAZ5, located at 1040 bp. The addition of the BLS cassette served
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two purposes, to disrupt the coding sequence of PAZ5 and provide BLS resistance for antibiotic
selection. Several clones were picked from the resulting transformation. The presence of the
BLS cassette within the PAZ5-KO lines was confirmed via PCR of genomic DNA. The wildtype
PAZ5 was 2.2 kb, and the BLS cassette was 1.4 kb in size. Using a combination of primers, it was
possible to examine the fragments of PAZ5-KO to determine whether both sequences were
present (Figure 3.4). The point mutations of PAZ5 contained within the pTX-GFP expression
vector were later transformed into cells of the PAZ5-KO D. discoideum strain to act as a mutant
rescue.

Figure 3.4. Confirmation of PAZ5-KO BLS Insertion. The PAZ5-KO strain contains a 1.4 kb BLS
cassette inserted at the ClaI (ATCGAT) site of the PAZ5 sequence. PAZ5-KO is 3.6 kb as PAZ5 is
originally 2.2 kb in length. Two clones were analyzed for correct BLS insertion; these were
labeled PAZ5-KO (1) and (2). A PCR of the genomic DNA for PAZ5-KO was used to confirm the
presence of the BLS insertion. PCR from both ends of PAZ5-KO (ATG to STOP codons) should
present a 3.6 kb band. PAZ5-KO (1) (row 1) produced a 3.6 kb band indicating the BLS cassette
presence. PAZ5-KO (2) (row 2) produced a 2.2 kb band, indicating it possessed a wild type
sequence and did not contain the BLS cassette. A 1kb ladder (NEB) provides a reference (A & B).
Gels were performed on different days, accounting for the change in ladder spread.
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3.2. Creation of PAZ5/pTX-GFP Fusion Expression Vector
Successful PAZ5 protein mutants in the PAZ5/pGEM vector were ligated into the pTXGFP plasmid. The pTX-GFP plasmid expression vector was used due to its potential to provide
uniform cell-to-cell expression and because it encodes a green fluorescent protein (GFP) on the
C-termini of a KpnI multi cloning site for sequence ligations. The plasmid contains several useful
domains conducive to the expression of the mutated PAZ5 protein in D. discoideum. The Ddp1
backbone, allowing the plasmid to replicate autonomously in D. discoideum (Levi et al., 2000;
Noegel et al., 1985). The GFP fusion cassette was derived from pGFPmut2, a 20-30 times
brighter variant than the wildtype GFP. Lastly, pTX-GFP has a Geneticin (G418)-resistance
cassette, an antibiotic used to inhibit prokaryotes and eukaryotes, allowing for antibiotic
selection of the successful transformants.
After sequencing the individual mutations, the PAZ/pGEM plasmid DNA was then
modified by adding a KpnI linker cassette (GGTACC) to the ends of the PAZ5 protein. This
cassette allowed for the PAZ5 to be excised from the pGEM plasmid and make it able to be
inserted into the KpnI site in pTX-GFP (Figure 3.5). Insertion was accomplished using PCR and
two primers designed to add the small insertions. DpnI was used to remove the parental
template DNA, after which the plasmid was immediately cleaved using the KpnI restriction
enzyme. The presence of the newly introduced KpnI site was confirmed by running a gel of the
PCR product and looking for the PAZ5 band at 2.2 kb.
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Figure 3.5. Successful Ligation of PAZ5 into pTX/GFP Expression Vector. PAZ5/pazE was ligated
into pTX-GFP using the KpnI restriction site (GGTACC). The 5’ end of PAZ5 and the 3’ end of the pTX-GFP
construct are shown (figure A). The 3’ end of PAZ5 and the 5’ end of the pTX-GFP construct are also
shown (figure B); the TAG/STOP codon of PAZ5 has been removed. The first and last nucleobases
represented in the image make up the KpnI site (GGTACC).
The T4 ligase catalyzes the insertion of PAZ5 mutants into pTX-GFP; however, the
direction that the strands will align in is up to chance. The resulting ligated material was then
transformed into E. coli and clones were picked from the resulting colonies. A Boiling Mini-Prep
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method was used to rapidly prepare the plasmid DNA for digestion with either the KpnI or
EcoRI restriction enzymes. The purpose of KpnI digestion was to determine whether the ligation
had successfully taken place. If it had, the 11.2 kb pTX-GFP and 2.2 kb PAZ5 protein would be
cleaved from one another with the KpnI enzyme, resulting in two distinct bands indicating the
respective protein (Figure 3.6). The purpose of the EcoRI digestion was to determine the
orientation of the PAZ5 protein ligated into pTX-GFP. There are a total of three EcoRI sites in
the PAZ5/pTX-GFP fusion plasmid, of which one is located 719 bp into PAZ5 from the 5’ end. It
was determined that if the PAZ5 had ligated in the correct direction, it would form an EcoRI RE
band of ~2100 bp and, if it were in the wrong direction, would generate a ~1400 bp EcoRI RE
product (Figure 3.7).
Clones confirmed with this method were then sequenced to confirm that the ligation
between PAZ5 and pTX-GFP was in-frame and to doubly confirm that the correct mutation was
present for each (Appendix C). This was confirmed for 16 of the 17 clones, with the exception of
F549S, which was not remade as a different mutation to the same phenylalanine was used
instead (F549V) (Appendix C). The plasmid DNA was then ready to be transformed into D.
discoideum.
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Figure 3.6. Clonal Selection via KpnI Digestion for Two PAZ5/pTX-GFP Ligations. Two PAZ5
mutants were cut out from PAZ5/pGEM, and T4 ligated into pTX-GFP. Eight clones of each
mutant were then processed using the boiling miniprep method and were digested with the
KpnI restriction enzyme (1a-h & 2a-h). Successful ligations have bands at 2.2 kb and 11.2 kb,
respectively, corresponding to PAZ5 and pTX-GFP. Successful ligations were 1adfg & 2abcefgh.
A 1kb ladder (NEB) provides a reference (A).

Figure 3.7. Clonal Orientation Test via EcoRI Digestion for Two PAZ5/pTX-GFP Ligations. The
previous ligations from Figure 3. They were further digested with EcoRI to determine the
orientation of PAZ5 as it ligated into pTX-GFP. Regardless of correct orientation, both would
have bands at 6 kb and 4 kb. Ligations in the correct orientation will have bands at 2.1 kb; those
with the incorrect orientation will have bands at 1.4 kb. Those with correct orientations include
1adg & 2ag. A 1kb ladder (NEB) provides a reference (A).
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Upon confirmation of successful PAZ5/pTX-GFP ligation, the plasmid was then moved
into the D. discoideum PAZ5-KO cell line. The plasmid DNA was transformed using the process
of electroporation. Electroporation allowed for the introduction of macromolecules, such as
plasmid DNA, directly into live cells by discharging an electric field into the cell media. The cell
membrane pores are briefly forced open, permitting the molecules to transit through the
plasma membrane into the cell to recombine with the cell line. The cells were then be selected
for and challenged with the antibiotic G418, as the PAZ5/pTX-GFP fusion protein has a G418resistance cassette. Growth in the presence of G418, in tandem with the presence of
fluorescence, was one of the methods of confirming that successful transformation of the PAZ5
/pTX-GFP mutants had occurred. The process from electroporation to cloning and usage of the
mutant cell lines took up to 21 days. However, due to several difficulties with transformation
efficiency, only six of the seventeen mutations were successfully ligated into the D. discoideum.
Of these six, only four were able to grow in shaking culture. However, all mutants successfully
transformed into D. discoideum were able to grow in HL-5 media enriched with the G418
antibiotic.

3.3. Localization of Fluorescence for GFP-Tagged Cells
The resultant PAZ5/pTX-GFP transformations were then analyzed for fluorescence, both
to confirm that the GFP cassette in the pTX-GFP plasmid was functional; and to study where the
mutated PAZ5 protein would localize. This work was attempted with all successful
transformants. In addition, as negative fluorescence controls, the PAZ5-KO and wildtype (AX2)
lines, which lacked the GFP cassette, were also studied for fluorescence. Later, two clone lines
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that had previously shown fluorescence in previous years were also used as positive
fluorescence controls; these were PAZ8-GFP (PAZ8/pTX-GFP) and pCV5-YFP. PAZ8-GFP was
grown from a frozen D. discoideum stock; PAZ8 had been ligated into the pTX-GFP plasmid in
2009 (Amburg, 2010). PAZ8-GFP was to determine if the fluorescence settings used for
examining the mutant strains would produce a fluorescent signal. pCV5-YFP was created in
2018 for viewing localization and function of the Gα2 subunit of the G protein (S. A. Alamer,
2018). pCV5 used an eYFP construct cloned into the CV5 vector. It was grown from an E. coli
stock and electroporated into the PAZ5-KO strain. This was to determine if the electroporation
process was causing the loss of fluorescence.
None of the successful PAZ5/pTX-GFP transformants showed any signs of fluorescence
above background- or cell-autofluorescence. The cells of D. discoideum will autofluoresce if
immediately examined after growth in the axenic HL-5 growth media. However, placing them in
development buffer (DB) helps to reduce their autofluorescence. This is most obvious with
epifluorescence imaging (Figure 3.8).
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Figure 3.8. Epifluorescence Imaging of PAZ5-KO Cells. Confocal epifluorescence imaging of the
PAZ5-KO cell line, which lacks the GFP cassette present in the PAZ5/pTX-GFP fusion vector,
indicating autofluorescence. Using the 40x objective and SAP-GFP mirror on the Olympus
FluoView FV1000. The image was captured by pointing a camera at the microscope lens itself.
Imaging of the PAZ5/pTX-GFP cells was accomplished using confocal imaging. The laser
intensity threshold had to be set relatively low, not to bleach the cell and avoid viewing the
background or cell autofluorescence (settings in Chapter 2.13). When initially viewing the cells,
a confusing aspect was the occasional presence of bright ‘fuzzy’ cells, which did not have the
kind of fluorescent signal expected. The fluorescence was not localizing anywhere, but neither
did it have mislocalized cytoplasmic fluorescence typical of a construct error. Instead, the
artifacts have a ‘fuzzy’ kind of fluorescent signal; moreover, these artifacts always appeared in
clusters. These artifacts only appear at higher laser powers, and they appear across multiple cell
lines, including PAZ5-KO, which lacks any GFP insertions (Figure 3.9).
The artifacts ceased to appear after sufficiently lowering the laser voltage; this was
confirmed by viewing both negative controls, the PAZ5-KO and wildtype (AX2) wildtype cells, at
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adjusted settings with lower voltages and noting no fluorescence (Figure 3.10). However, at
these settings, no fluorescence was seen for any of the PAZ5/pTX-GFP cell lines either (Figure
3.11). This was after the PAZ5/pTX-GFP cell lines had been grown up in G418 antibiotic enriched
media, which suggested that the G418 resistance marker in pTX-GFP had worked. Hence, the
use of two cell lines that had previously shown fluorescence, PAZ8-GFP (Figure 3.12) and pCV5YFP (Figure 3.13), were used as positive controls. Both positive controls exhibited notable
fluorescence at the useful settings. PAZ8-GFP localized to the endoplasmic reticulum, and pCV5YFP localized to the endoplasmic reticulum and plasma membrane. This observation also
suggests that Gα2 (product of pCV5-YFP) is not palmitoylated by PAZ5 as it still appears bound to
the plasma membrane (Figure 3.13). In combination, the results suggest that the settings are
not to blame for lack of fluorescence, nor is the transformation process. As the loss of
fluorescence only appears in the PAZ5/pTX-GFP constructs, it may be that the pTX-GFP plasmid
or the GFP cassette has had a loss of function.
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Figure 3.9. Fluorescent Artifacts Appear with Higher Laser Voltage Regardless of Cell Line.
Fluorescent artifacts appear across multiple cell lines if the laser voltage is too high. The
fluorescence does not localize to any specific area in the cell; instead, it appears ‘fuzzy.’ These
fuzzy cells always appeared in clusters and were more likely to be found nearer the edge of the
wells on the 24-well plate. Pictured in order (A-D) are PAZ5-KO, T628A (5), R516P (9), and
Q546L (17). Captured using a 20x objective and Alexafluor 488 on the Olympus FluoView
FV1000.
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Figure 3.10. Fluorescent Negative Controls. Pictured here are the two negative fluorescent
controls, PAZ5-KO and wildtype (AX2), corresponding to A and B. These were viewed under the
same fluorescent laser conditions that elicited fluorescence in the positive controls. The
transmitted detector laser setting was adjusted between image sets, accounting for the change
in grey color. Captured using a 40x objective and Alexafluor 488 on the Olympus FluoView
FV1000.

Figure 3.11. Example of PAZ5/pTX-GFP Mutants Lacking Fluorescence. Pictured here are two
mutant PAZ5 proteins ligated into pTX-GFP; neither fluoresce when exposed to laser light at the
correct voltage to avoid artifact formation. Pictured in order (A & B) are T628A (5) and Q546L
(17). Captured using a 40x objective and Alexafluor 488 on the Olympus FluoView FV1000.
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Figure 3.12. Fluorescent Localization for Positive Control PAZ8-GFP (PAZ8/pTX-GFP). Pictured
is the positive control PAZ8-GFP, which was designed a decade ago to determine PAZ8
localization in D. discoideum. It was ligated into the same plasmid, pTX-GFP, as PAZ5/pTX-GFP.
Fluorescence was seen to localize to the endoplasmic reticulum, though this was not confirmed
with an ER stain. Captured using 40x (A) and 100x (B-E) objectives and Alexafluor 488 on the
Olympus FluoView FV1000.
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Figure 3.13. Fluorescent Localization for Positive Control pCV5-YFP. Pictured is the positive
control pCV5-YFP, which was designed to localize the Gα2 subunit in D. discoideum (S. A. Alamer,
2018). This plasmid was grown from an E. coli stock and transformed into PAZ5-KO in the same
way as the mutants were with PAZ5/pTX-GFP. Fluorescence was seen to localize to the
endoplasmic reticulum and plasma membrane. Captured using the 100x objective and
Alexafluor 488 on the Olympus FluoView FV1000.
3.4. Characterizing the Developmental Phenotypes of D. discoideum Strains
Analysis of developing cells was performed 48 hours post-starvation (hps). D.
discoideum cells were starved on a development buffer (DB) plate after having been subjected
to a DB wash (Chapter 2.12). The process causes the cells to begin the starvation phase of the
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developmental cycle. Images were captured using a light microscope with camera attachment
at 48 hps. For movies, images were taken every 6 minutes for 48 hours.
Figures 3.14-3.19 show the six strains that were able to grow in shaking culture after
induction into the starvation phase. Figures 3.20-3.24 show developmental time-lapses for five
of the six strains (AX2, PAZ5-KO, T628A, C523G, H519L). Fifty million cells were spread on each
plate for 48 hours-post-starvation (hps). Photographs labeled (A-1, A-2, B-1, etc.) show two
planes of focus for an individual plate so that the ‘upright’ fruiting bodies can be differentiated
from the ‘fallen’ or ‘along agar.’ This is because the fruiting bodies can reach up to 2 mm in
height, those that are out of focus are standing tall, and those on the same plane of focus are
lying down. Photographs labeled (A, B, C, D, etc.) do not have any visible fruiting bodies that are
upright; hence the second plane of focus is not provided.
The wildtype strain, AX2, was used as a control as it had an intact PAZ5 sequence
(Figures 3.14 and 3.20). In contrast, the PAZ5-KO strain had an interrupted PAZ5 sequence,
thanks to the BLS insert at an internal ClaI site of PAZ5 (Figures 3.15 and 3.21). The four
mutants that grew in shaking culture had an individual mutation of a conserved amino acid in
the PAZ5 protein (Figures 3.16-3.19 and 3.22-3.24). All observations were made under the same
conditions (Chapter 2.12). At around 5 hps, both the wildtype and PAZ5-KO strains began to
form streams of cells as they aggregated together. Aggregation for PAZ5-KO finished by 7 hps,
forming small to medium aggregates and leaving few cells on their own. Wildtype aggregation
was finished by 9 hps, with mounds combining to form more massive mounds; the aggregate
colonies tended to be medium to large. Moreover, the wildtype had far more individual cells
that had not aggregated into mounds than the PAZ5-KO strain.
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As slugs, the PAZ5-KO strain did not move after aggregation was completed; the cells
stayed in place until 17 hours post-starvation (hps), after which they began the process of
culmination. In contrast, some wildtype aggregates formed into motile slugs at 13 hps and
began moving around, whereas other aggregates immediately began the culmination process
(Figures 3.20 and 3.21). By 24 hps, a few wildtype mounds had formed fruiting bodies; more
aggregates continued to form fruiting bodies up to 35 hps. This was because some slugs kept
moving until 30 hps, or they collided with a smaller aggregate and immediately began
culmination. The medium to smaller-sized mounds for the wildtype did not begin culminating,
but by 40 hps, they had begun moving around, though not to the extent of more massive motile
slugs, however by 48 hps, they still had not begun culminating. Some fruiting bodies collapsed
between 36 to 48 hps, though the majority stayed upright. For PAZ5-KO, culmination did not
take place until 24 hps; only the largest mounds culminated. As mentioned earlier, the vast
majority of PAZ5-KO mounds were small to medium in size. After 24 hps, no further mounds
culminated, and PAZ5-KO also produced fewer fruiting bodies than the wildtype (Figures 3.20
and 3.21).
As the mutant strains in the PAZ5/pTX-GFP fusion vector failed to exhibit fluorescence
associated with the GFP cassette, the plasmid has likely had a function loss. However, it is
unknown what this loss of function has affected. Hence, any results I interpret from the
developmental cycle cannot be confirmed as a direct result of the mutations introduced:
For the mutant T628A (5), a conserved threonine located in the TTYE motif at 628 aa
was substituted for an alanine (Figures 3.16 and 3.22). After the start of starvation, it took 9
hours post-starvation (hps) for streams to begin to form. Sparse small aggregates appeared at
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10.5 hps, but then the aggregates broke apart again at 16 hps. At 24 hps, the cells began to
form streams once again, forming a larger number of medium-sized aggregates. However, by 28
hps, these medium-sized aggregates broke apart and began moving around the agar surface.
Occasionally some would collide with each other, but the cells did not start the developmental
stage no matter how much time passed or how large the aggregates became. A few cells were
left outside of mounds; these tended to be either cells that never aggregated, cells that were
left behind when the aggregates broke apart at 16 hps, or cells that were not encroached upon
by aggregates moving around. By 48 hps, no cells had passed beyond the tight aggregate
(mound) phase.
For the mutant C253G (6), a conserved cysteine in the DHHC-CRD at 253 aa was
substituted for a glycine (Figures 3.17 and 3.23). After the start of starvation, it took 7 hours
post-starvation (hps) for the cells to begin aggregating. By 9 hps, the cells had formed several
small aggregates; however, at 14 hps, all the aggregates on the plate broke apart again and
formed into loose streams of cells mimicking their appearance before 7 hps. The cells then
remained spread out like they were at the very start of starvation until 24 hps when the cells
began forming streams of cells once more. Nevertheless, by 29 hps, the cells had once more
broken apart from the aggregate; from then until 48 hps, a few intermittent streams of cells
were observed, with the occasional mound-forming, but by and large, it was mostly individual
cells spread out.
For the mutant R516P (9), a conserved arginine in the DHHC-CRD at 516 aa was
substituted for a proline (Figure 3.18). By 48 hours post-starvation (hps), the cells were mostly
in the mound phase; however, some fruiting bodies had formed. These fruiting bodies were
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very diminutive in size, but they were upright for the most part. A video was not taken for
R516P due to time constraints.
For the mutant H519L (15), a conserved histidine in the first CCHC zinc finger in the
DHHC-CRD at 519 aa was substituted for a leucine (Figures 3.19 and 3.24). After the start of
starvation, it took 6 hours post-starvation (hps) for the cells to begin aggregating. By 8 hps,
several medium-sized aggregates had formed; however, there were quite a few cells that did
not aggregate. The mounds did not move after 8 hps, but by 21 hps, the mounds had begun to
shrink in size, perhaps forming Mexican hats as they culminated; a minimal number of these
formed into small fruiting bodies, much smaller than the typical height. At 29 hps, a few
aggregates broke apart, then reformed by 31 hps. This phenomenon happened again at 37 hps,
where they again reformed at 39 hps. By 48 hps, a slim number of tiny fruiting bodies were
standing upright; however, the vast majority of mounds were small and had not culminated.
These results suggest that, barring R516P, the PAZ5 mutants produced phenotypes dissimilar to
both the knockout and wildtype strains. Moreover, the knockout strain produced a phenotype
with more fallen fruiting bodies than the wildtype, suggesting that the knockout produced the
same effect seen before (Amburg, 2010).Taken together three of the four lines examined
(T628A, C523G, H519L) showed radical departures from both the wildtype and knockout
strains; whereas the R516P strain was very similar to the wildtype, albeit producing very small
fruiting bodies.
Statistical analysis of the different fruiting body phenotypes is presented in Tables 3.1
and 3.2. The fruiting bodies were divided into three categories: Those that had developed
growing normally (upright); those that had fallen over and contacted the surface of the plate,
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breaking open the spore head (fallen); and those that developed along the agar, including those
that formed a normal spore head slightly above the surface of the agar (along agar). Counts
were performed at 48 hps across all plates and displayed as a percentage figure. As some plates
exclusively produced mounds and others produced an overwhelming number of mounds
compared to the other phenotypes, the two types of data were split into different tables. Table
3.2 shows the total count of phenotypes, including mounds. Table 3.3 shows the previous
phenotype count, with mounds subtracted.
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Cell Line

% Upright

% Fallen

% Along Agar

% Mound

Wildtype

35 (+/- 3)

12 (+/- 2)

7 (+/- 1)

44 (+/- 4)

PAZ5-KO

11 (+/- 4)

9 (+/- 3)

11 (+/- 4)

66. (+/- 14)

T628A (5)

0 (+/- 0)

0 (+/- 0)

0 (+/- 0)

100 (+/- 0)

C523G (6)

0 (+/- 0)

0 (+/- 0)

0 (+/- 0)

100 (+/- 0)

R516P (9)

33 (+/- 3)

8 (+/- 1)

9 (+/- 1)

49 (+/- 4)

H519L (15)

9 (+/- 2)

1 (+/- 0)

0 (+/- 0)

87 (+/- 9)

Table 3.2. Statistical Analysis of PAZ5 Phenotypes with Mounds Included. Plates were
developed and counted as described. Clones of different cell lines were counted and compared
to each other. The clones presented are wildtype (AX2), PAZ5-KO (knockout), and the four
mutants that were able to grow in shaking culture (T628A, C523G, R516P, H519L). Red indicates
a mutation to a conserved amino acid; purple are members of the first CCHC zinc finger; blue
corresponds to the second CCHC zinc finger; and teal are members of the TTYE motif.

Cell Line

% Upright

% Fallen

% Along Agar

Wildtype

64 (+/- 3)

22 (+/- 2)

13 (+/- 1)

PAZ5-KO

34 (+/- 4)

30 (+/- 3)

35 (+/- 4)

T628A (5)

0 (+/- 0)

0 (+/- 0)

0 (+/- 0)

C523G (6)

0 (+/- 0)

0 (+/- 0)

0 (+/- 0)

R516P (9)

65 (+/- 3)

16 (+/- 1)

17 (+/- 1)

H519L (15)

81 (+/- 2)

13 (+/- 0)

5 (+/- 0)

Table 3.3. Statistical Analysis of PAZ5 Phenotypes with Mounds Excluded. Plates were
developed and counted as described. Clones of different cell lines were counted and compared
to each other. The clones presented are wildtype (AX2), PAZ5-KO (knockout), and the four
mutants that were able to grow in shaking culture (T628A, C523G, R516P, H519L). Red indicates
a mutation to a conserved amino acid; purple are members of the first CCHC zinc finger; blue
corresponds to the second CCHC zinc finger; and teal are members of the TTYE motif.
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Figure 3.14. Development of Wildtype (AX2) Cells at 48 HPS Across Two Focal Planes. Cells
were developed for 48 hours post-starvation. Each letter corresponds to an individual plate.
Images ending in a number (-1, -2) correspond to two focal planes of the same plate to visualize
whether cells are upright or have fallen to the agar surface. The wildtype cells mostly form
upright fruiting bodies, though some fall over, and some mounds fail to differentiate. Captured
using a 4X objective on an Olympus light microscope with a camera attachment.
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Figure 3.15. Development of PAZ5-KO (Knockout) Cells at 48 HPS Across Two Focal Planes.
Cells were developed for 48 hours post-starvation and imaged as described. Each letter
corresponds to an individual plate. Images ending in a number (-1, -2) correspond to two focal
planes of the same plate to visualize whether cells are upright or have fallen to the agar
surface. The PAZ5-KO cells tend not to differentiate from the mound stage. Those that do are
more likely to collapse and grow along the agar; however, some grow upright, similar to the
wildtype. Captured using a 4X objective on an Olympus light microscope with a camera
attachment.
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Figure 3.16. Development of T628A (5) Cells at 48 HPS Across One Focal Plane. Cells were
developed for 48 hours post-starvation and imaged as described. Each letter corresponds to an
individual plate. For T628A, a conserved threonine located in the TTYE motif was substituted for
an alanine. These cells were unable to differentiate past the mound stage; none could form
fruiting or motile slugs. Captured using a 4X objective on an Olympus light microscope with a
camera attachment.
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Figure 3.17. Development of C523G (6) Cells at 48 HPS Across One Focal Plane. Cells were
developed for 48 hours post-starvation and imaged as described. Each letter corresponds to an
individual plate. For C523G, a conserved cysteine located in the second CCHC zinc finger was
substituted for a glycine. These cells showed different morphologies on different days;
however, the cells could not differentiate past the mound stage in general. Sometimes the cells
would not aggregate at all, resulting in fewer mounds than for other strains. Captured using a
4X objective on an Olympus light microscope with a camera attachment.
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Figure 3.18. Development of R516P (9) Cells at 48 HPS Across Two Focal Planes. Cells were
developed for 48 hours post-starvation and imaged as described. Each letter corresponds to an
individual plate. Images ending in a number (-1, -2) correspond to two focal planes of the same
plate to visualize whether cells are upright or have fallen to the agar surface. For R516P, a
conserved arginine in the DHHC-CRD was substituted for a proline. The cells tended to produce
upright fruiting bodies; however, they were much smaller than those of the wild-type or PAZ5KO strains. The focal plane adjustment is needed to visualize them far finer than on other
plates, except for H519L. Captured using a 4X objective on an Olympus light microscope with a
camera attachment.
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Figure 3.19. Development of H519L (15) Cells at 48 HPS Across Two Focal Planes. Cells were
developed for 48 hours post-starvation and imaged as described. Each letter corresponds to an
individual plate. Images ending in a number (-1, -2) correspond to two focal planes of the same
plate to visualize whether cells are upright or have fallen to the agar surface. For H519L, a
conserved histidine in the first CCHC zinc finger in the DHHC-CRD was substituted for a leucine.
Very few of the mounds differentiated into fruiting bodies; however, those that did were
mostly upright. Like R5196P, the fruiting bodies were very diminutive in size compared to AX2
and PAZ5KO. Captured using a 4X objective on an Olympus light microscope with a camera
attachment.
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Figure 3.20. Development of Wildtype (AX2) Strain from 0 to 36 HPS. Cells were developed for
36 HPS. Images were captured using a 4X objective on an Olympus light microscope with a SPOT
camera attachment. Color differences between this and other strains were due to varying bulb
brightness on different days when using the light microscope.
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Figure 3.21. Development of the PAZ5-KO (Knockout) Strain from 0 to 36 HPS. Cells were
developed for 36 HPS. Images were captured using a 4X objective on an Olympus light
microscope with a SPOT camera attachment. Color differences between this and other strains
were due to varying bulb brightness on different days when using the light microscope.
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Figure 3.22. Development of T628A (5) PAZ5 Mutant Strain from 0 to 36 HPS. Cells were
developed for 36 HPS. Images were captured using a 4X objective on an Olympus light
microscope with a SPOT camera attachment. Color differences between this and other strains
were due to varying bulb brightness on different days when using the light microscope.
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Figure 3.23. Development of C523G (6) PAZ5 Mutant Strain from 0 to 36 HPS. Cells were
developed for 36 HPS. Images were captured using a 4X objective on an Olympus light
microscope with a SPOT camera attachment. Color differences between this and other strains
were due to varying bulb brightness on different days when using the light microscope.
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Figure 3.24. Development of H519L (15) PAZ5 Mutant Strain from 0 to 36 HPS. Cells were
developed for 36 HPS. Captured using a 4X objective on an Olympus light microscope with a
SPOT camera attachment. Color differences between this and other strains were due to varying
bulb brightness on different days when using the light microscope.
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CHAPTER 4
DISCUSSION

This study's focus was to determine if mutations to conserved amino acids in the DHHCCRD, DPG, and TTYE regions of PAZ5 would elicit a similar fruiting body malformation to those
seen in the PAZ5-KO and DHHC-mutant strains. Moreover, as the mutations to the cysteines in
the CRD have been shown to affect palmitoylation in an enzymatic model, it may be possible to
show that cysteine disruption in PAZ5 elicits an observable change using an in vivo model,
namely using D. discoideum. Correlation of the mutations to the known phenotype may allow
for increased characterization of the PAZ family of proteins, and by extension, the DHHC family
of palmitoyltransferases.

4.1. Low Transformation Efficiency of PAZ5/pTX-GFP into D. discoideum
The process of transforming the 17 mutant PAZ5/pTX-GFP constructs into D. discoideum
was mostly unsuccessful. Until recently, transformation using electroporation has been a very
successful technique in the Gundersen lab. Electroporation is a mature technology for plasmid
integration into the organism; iteratively explored parameters used to optimize the number of
successful colonies has been known for decades (Pang et al., 1999). It is typical to obtain a
single successful transformant per 1 x 105 cells; with a mean of 5 x 106 cells per transformation,
50 successful colonies is the norm. However, of the seventeen mutations made to PAZ5, then
integrated into the pTX-GFP vector, only six were transformed successfully over eight months.
Five of these were transformed in a single electroporation in March of 2020, wherein all plates
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electroporated had successful colonies. Of these six transformants, four were unable to grow in
shaking culture. All successful colonies were able to be grown in G418 selection media (20
μg/mL, 13 μL per 13 mL HL-5), suggesting that the transformation had been a success. For some
unsuccessful transformants, the cells that initially seemed to survive electroporation were killed
by the G418 selection media before they could produce viable colonies. There have also been
issues relating to fungal and bacterial contamination of the plates; though these have been
solved, electroporation efficiency has still not improved.
Attempts have been made to investigate what aspect of the procedure has been
interfering with the efficiency. This issue has still not been rectified, though various methods
have been attempted. Initially, it was thought that efficiency was being impacted by the
distilled water used for buffers, so all buffers were remade using new water. Then issues with
contamination of the plates appeared around 14 days after electroporation. The contamination
was traced to the heat-killed bacteria, added to the initial transformants to aid in growth, not
being entirely heat-killed, allowing for slow but sizeable growth to overwhelm the amoeboid
cells. The antibiotic concentration was also lowered, which did initially help growth. However,
this was deemed unviable because it allowed for the possibility of lower plasmid expression,
and antibiotic concentration had never before been an issue with this plasmid before. Another
plasmid, pCV5-YFP, was used to determine if the pTX-GFP plasmid was somehow responsible
for the change in electroporation efficiency. However, pCV5 also had significantly lowered
transformation efficiency. Only two colonies appeared on a single plate out of 16 total plates
made over two weeks; moreover, these two colonies grew much more slowly than they did
years prior. Methods for rectifying electroporation that have not yet been tried including
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remaking all buffers using entirely new components or using a different gene pulser machine
for the electroporation itself. There are also more modern methods of electroporation for D.
discoideum using oscillating electric fields instead of the classic exponential decay
electroporation technique that is currently the standard for D. discoideum transformation
(Alibaud et al., 2003).

4.2. Absence of Fluorescent Signal for PAZ5/pTX-GFP Strains
Before characterizing the PAZ5 protein using phenotypic analysis of the developmental
lifecycle, fluorescence microscopy was to be used to study the localization of the expressed
PAZ5-GFP in D. discoideum cells. Fluorescence, together with sustained growth in the G418
selection media, would also be used to confirm that the pTX-GFP fusion expression vector was
functioning correctly. All mutations in the PAZ5/pTX-GFP fusion expression vector failed to
exhibit any fluorescence over the background. This lack of fluorescence was confirmed for all
mutants, suggesting that the fault was due to a problem with the pTX-GFP vector itself rather
than the transformation process.
Initially, it was thought that some cells were fluorescing. However, it was determined
that the laser intensity settings were too high, creating ‘fuzzy’ artifacts that looked as though
they were constitutively expressing a GFP signal in the entire cell (Figure 3.9). This was doubtful
as the fluorescence resolution was inferior, and the fluorescence did not localize anywhere, nor
did it appear to have mislocalized to the cytoplasm either. These artifacts also appeared in the
PAZ5-KO strain, which lacks a GFP cassette entirely.
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D. discoideum cells also exhibit autofluorescence. Resuspension in DB (Chapter 2.13)
triggers their starvation response and reduces autofluorescence. However, this process still
leaves a degree of autofluorescence within the cell. However, the GFP cassette in pTX-GFP
should provide a far higher signal than background or autofluorescence; it should not be
difficult to view. A previously successful pTX-GFP transformant from 2009 was thawed and
grown from D. discoideum stock; this plasmid contained an unmutated PAZ8 protein ligated
into pTX-GFP, PAZ8-GFP. This provided a positive control to vet the PAZ5/pTX-GFP line against.
The PAZ8-GFP clonal line showed successful fluorescence and localized to the endoplasmic
reticulum of the cell (Figure 3.12) as it had over a decade prior, though this had not been
confirmed with an ER stain (Amburg, 2010).
It is still not known where the PAZ5 protein localizes to when it is expressed in D.
discoideum. It is thought that the PAZ protein, like other DHHC proteins, would localize to the
Golgi and ER. Previous attempts to examine PAZ5 fluorescence localization were hampered
because the natural KpnI site within PAZ5 was not accounted for (Amburg, 2010).
Consequently, the PAZ5-GFP construct that was created would mislocalize to the cytoplasm.
This issue was corrected by mutating the KpnI site from GGTACC to GGTTCC, thereby keeping
the valine intact but interrupting the ability of the KpnI enzyme to cleave the site.
The pCV5-YFP strain was chosen as a second positive control; it was used to determine
whether the loss of fluorescence was related to the electroporation itself rather than an issue
with the pTX-GFP plasmid directly. However, the pCV5-YFP, despite having very low
electroporation efficiency as was the case with all the transformations in the recent past, was
still able to fluorescence when examined (Figure 3.13). pCV5 was a fluorescence tag of the Gα2
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subunit of the G protein. As expected, it localized to the plasma membrane, Golgi, and ER of the
cell (S. A. Alamer, 2018). It did so at the same settings used for capturing the PAZ8-GFP
fluorescence; using a low enough laser voltage to avoid the background and autofluorescence
of cells that lacked the GFP cassette. At these settings, it was confirmed again that the mutant
PAZ5 strains in the PAZ5/pTX-GFP constructs were not expressing any fluorescence.
As a result, it is surmised that the pTX-GFP plasmid may have had a loss of function,
though precisely how or in what way is not known and requires further investigation and
testing. It may be that the GFP cassette alone has ceased to function correctly. However, it is
also possible that a promoter region is malfunctioning or that another part of the plasmid is the
cause of the error. As mentioned in Chapter 3.2, all PAZ5/pTX-GFP ligations that were
successful, insofar as PAZ5 ligated in the corrected orientation, were subsequently sequenced.
Sequencing determined that the PAZ5 mutation was successful and that the ligation into the
pTX-GFP vector was in-frame. As a side effect of Sanger sequencing, sequence reads up to 160
bp upstream of the PAZ5 insertion and 450 bp downstream of the PAZ5 sequence was
achieved. The problem was that as the read reaches its end, it degrades and drops bases, but in
each case, the pTX-GFP sequence did not move out of frame, suggesting that there were no
mutations in the area it reads up to. However, the pTX-GFP plasmid is 11.2 kb (Figure A.2 and
Table A.2) in size, and only a maximum of 1 kb has been sequenced for all mutations outside of
the 2.2 kb PAZ5 protein. What precisely was the cause of pTX-GFP losing fluorescence cannot
be confirmed without designing a set of at least eight new primers in order to perform an entire
sequence read of the vector. Or, instead of sequencing the entire plasmid, a Western Blot could
be performed by attaching an antibody to the Poly-His tag in pTX-GFP on the N-terminus of the
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PAZ5 insert. For the moment, without knowing what has changed, the validity of the
phenotypic analyses of the developmental stage of D. discoideum has been called into question.

4.3. Characterization of Knockout and Mutant Phenotypes
Previous work in the Gundersen lab has discovered that the DHHC domain of the PAZ5
protein is essential for proper function in D. discoideum (Amburg, 2010). The first histidine in
DHHC was converted to alanine, and separately the cysteine in DHHC was converted to serine.
A PAZ5-KO mutant was also created by disrupting the PAZ5 protein with a 1.4 kb BLS resistance
cassette midway through the sequence. It was found that both mutations elicited the same
phenotypic change in fruiting body formation as the PAZ5-KO mutant. The change manifested
as a reduced number of cellulose-producing stalk cells nearer the stalk base, leading to a
collapse in the structure during spore migration up the stalk and growth along the agar surface
instead of directly into the air. Moreover, the cells could be rescued with an intact PAZ5
sequence, resulting in a phenotype indistinguishable from the wildtype. Taken together, this
suggested that an intact DHHC domain was essential to PAZ5 function (Amburg, 2010).
The notion that a DHHC site is essential to proper protein function, in this case,
mediation of palmitoylation via the catalytic ping-pong mechanism, has more recently been
confirmed via an enzymatic study of the DHHC catalytic domain of the human DHHC3 protein
(Gottlieb et al., 2015). The authors note that a DHHC cysteine mutation to a serine rendered the
protein catalytically inactive, with serine mutations to conserved cysteines in the DHHC-CRD
either halting or reducing enzyme activity (Gottlieb et al., 2015). The authors also determined
that mutations to the conserved cysteines in and around the DHHC disrupt the tertiary
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structure of the DHHC3 protein. Disruption was primarily linked to the loss of the intact CCHC
zinc-fingers, as the conserved cysteines were unable to coordinate zinc; furthermore, the zincbinding function of the cysteines was found to exist solely as a structural role, rather than a
catalytic or regulatory role (González Montoro et al., 2013; Gottlieb et al., 2015).
Despite studies into the DHHC motif and the conserved cysteines in the DHHC-CRD,
there has been little work examining the function of other conserved residues in the DHHC-CRD
or the conserved residues that make up the DPG and TTYE motifs that flank the DHHC-CRD.
Thus, the work's basis was to further characterize the structure and function of the PAZ5 DHHC
protein by performing multiple developmental studies with various mutations to these
conserved residues in and around the DHHC-CRD.
A total of seventeen mutations were created for the study of PAZ5. Of these seventeen,
two were created in the DPG and TTYE motifs, four were made to the CHHC zinc-fingers directly
flanking the DHHC motif, and nine were made to conserved non-cysteine amino acids in the
DHHC-CRD (Table 3.1). Mutations were created using site-directed mutagenesis to change
either one or two nucleotides in the PAZ5 sequence. The type of mutation introduced varied
depending on their purpose. Some were designed to elicit a substantial change, and others to
elicit a smaller change. For example, some introduced large size differences (e.g., G477Y,
C509G, etc.), others involved changing side-chain polarity (C506A, T628A, etc.) or side-chain
group type (N538I, G542S, etc.) (Table 3.1).
Of the seventeen mutations created in PAZ5, then ligated into the PAZ5/pTX-GFP fusion
expression vector, only six were successfully transformed into D. discoideum using
electroporation. Of these six, only four could be grown up in an antibiotic enriched shaking
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culture and examined via developmental study. The mutant T628A (5) involved a single base
substitution that changed the first conserved threonine of the TTYE motif to an alanine. This
mutation was a conserved substitution than a radical one. Threonine is generally considered a
slightly polar amino acid; it is of medium size with a fairly reactive hydroxyl group and forms
hydrogen bonds with many polar substrates (Betts & Russell, 2003). By comparison, alanine is
non-polar, has low hydrophobicity, and is relatively small compared to other amino acids. The
mutant C523G (6) used a single base substitution to change a conserved cysteine residue to a
glycine, in the second CCHC zinc finger in the DHHC-CRD, a more radical substitution. Cysteines
are small and non-polar; they tend not to show a preference for substitution with any other
amino acid (Betts & Russell, 2003). As this cysteine has been implicated in binding zinc, a glycine
was chosen to elicit a radical substitution. Though glycine is non-polar, it is disfavored for
cysteine substitutions (Betts & Russell, 2003).
The mutant R516P (9) involved an arginine to proline substitution, a radical substitution,
as proline is disfavored as an arginine substitution. Arginine is a large, polar, basic, and
positively charged amino acid that favors substitution to similar profiled amino acids. On the
other hand, proline is much smaller, non-polar, and cyclic (Betts & Russell, 2003). The final
mutation that was developmentally examined was H519L (15), a histidine to leucine
substitution. The histidine was involved in the first CCHC zinc finger in the DHHC-CRD. The
leucine substitution was considered a radical substitution. Histidine is generally polar, basic,
positively charged, and does not commonly substitute with other amino acids. On the other
hand, leucine is a bit smaller, non-polar, hydrophobic, and aliphatic (Betts & Russell, 2003).
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As previously stated, fluorescence localization of these PAZ5/pTX-GFP mutants could
not be identified. Taken together, this suggests that the plasmid has experienced a loss of
function, though precisely what has gone wrong is currently unknown. Despite the loss of
fluorescence and low transformation efficiencies, phenotypes for successful transformants
were characterized, though it is unknown if they were expressing the mutant PAZ5/pTX-GFP
expression vectors. However, it is important to keep in mind that since the extent of the
plasmid dysfunction is still unknown, the phenotypes observed may not be entirely a result of
the intended mutations or intended expression level. The fruiting bodies were divided into
three categories: Those that had developed growing normally (upright); those that had fallen
over and contacted the surface of the plate, breaking open the spore head (fallen); and those
that developed along the agar, including those that formed a normal spore head slightly above
the surface of the agar (along agar).
The experiments suggest that the PAZ5-KO line produces significantly fewer fruiting
bodies than the AX2 wild type, and the fruiting bodies produced for PAZ5-KO tended to collapse
much more readily than the mainly upright fruiting bodies of the wildtype. In previous
examinations of fruiting body development in PAZ5, the phenotypes' counts did not include
analysis of the tight aggregate (mound) stage (Amburg, 2010). A clear difference between the
AX2 wildtype and the other cell lines, excluding R516P, was an increase in the number of
mounds relative to fruiting bodies. Two mutants did not move past the mound stage at all
(T628A and C523G); in both cases, no fruiting bodies were present on any plates. However, it is
odd that the PAZ5-KO phenotype, with a wholly disrupted PAZ5 protein, still produced fruiting
bodies compared to these two mutants that only had disruptions to the conserved residues
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flanking the DHHC domain. The R516P mutation was most similar to the wildtype with similar to
the AX2 wildtype, rather than the PAZ5-KO phenotype, suggesting that despite the radical
substitution, the conserved residue may not be integral to DHHC function. However, the
fruiting bodies were small compared to fruiting bodies in the wildtype and PAZ5-KO strains. This
is a phenotype that has not been observed in the Gundersen lab before. The final mutation,
H519L, formed far more mounds than the PAZ5-KO strain, but unlike the T628A and C523G, this
strain produced fruiting bodies. Like the R516P strain, these fruiting bodies were significantly
smaller in size than the wildtype or PAZ5-KO, though most of them were still upright. However,
it is important to keep in mind that very few fruiting bodies were observed as on some plates,
almost all phenotypes were solely mounds.
Besides the final phenotype count, movies of each strain were produced (except for
R516P). The AX2 wildtype and PAZ5-KO lines showed similar initial growth until the aggregation
stage. After initial mound differentiation, the wildtype cells that did not culminate continued to
wander around until they accumulated more cells, wherein they began the second round of
culmination. In comparison, PAZ5-KO showed much-delayed development in the mound stage
and only produced a single round of culmination, as the mounds did not move around the agar
surface after forming the tight aggregate. All the observed mutants were either delayed in
aggregation or de-aggregated at least once before forming a mound. In all cases, mound
culmination took much longer than even the PAZ5-KO strain, and many mounds tended not to
differentiate at all.
Calcofluor staining involves the binding of a fluorescent dye to polysaccharide polymers
present in chitin and cellulose in the cell walls of different organisms (Hageage & Harrington,
101

1984) (Table D.1). Using calcofluor-white staining, it is also possible to diagnose whether the
fruiting bodies that have fallen over in the mutant strains share a similar root cause as the
PAZ5-KO strain. This is because the PAZ5-KO strain was previously reported to have fewer
cellulose-producing cells in the lower stalk region, which resulted in the fruiting body collapsing
during spore movement up the stalk (Amburg, 2010). This difference in cell sorting also
provides another means of comparing the change in cellular sorting and differentiation
between the AX2 wildtype and the PAZ5-KO strains.
The positive fluorescent control plasmid pCV5-YFP was created in 2018 for viewing
localization and function of the Gα2 subunit of the G protein (S. A. Alamer, 2018). pCV5-YFP was
transformed into the PAZ5-KO strain to determine if the loss of fluorescence seen in mutant
strains of PAZ5 was tied to electroporation. As seen in Figure 3.13, the tagged Gα2 localized to
the plasma membrane without rescuing the disabled PAZ5 protein. Suggesting that Gα2 was not
palmitoylated by PAZ5, as it still appears bound to the plasma membrane without a functioning
PAZ5 protein. As PATs with the DHHC-CRD are the only proteins that mediate S-palmitoylation,
and the only DHHC PATs in D. discoideum are the 14 PAZ proteins, it stands to reason that a
different PAZ protein must be responsible for Gα2 palmitoylation in D. discoideum.
It was hypothesized that the PAZ5 mutants would produce developmental phenotypes
that statistically fell between the wildtype and PAZ5-KO strains. This was because the AX2
wildtype had a fully functional PAZ5 domain, whereas the PAZ5-KO strain had a BLS cassette
inserted halfway through the sequence, functionally disrupting the entire protein. However, of
the four mutants that were able to grow, only the R516P mutation fell in this domain. The other
mutations produced phenotypes that were far outside the range of both wildtype and PAZ5-KO.
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For this reason, the results observed are likely a product of the faulty pTX-GFP construct rather
than as a direct result of the substitution mutations introduced. Without knowing the precise
nature of what has changed in the construct, it is impossible to definitively say what effect it is
having on the mutant PAZ5 protein expression during development.

4.4. Potential Remedies for the Malfunctioning PAZ5/pTX-GFP Plasmid
Based primarily on the lack of fluorescence localization seen in any of the mutant
PAZ5/pTX-GFP strains, and to a lesser extent on the unusual phenotypic development of the
strains compared to both the wildtype and knockout, the pTX-GFP construct has likely had a
loss of function. If this were the case, the most rapid way to diagnose what has gone wrong in
the construct would be to sequence the entire 11.4 kb plasmid. The PAZ5 portion of the fusion
expression vector has already been sequenced, as has the area around the ligation, confirming
that the pTX-GFP vector is intact here. Hence, a set of at least eight new primers would need to
be created in order to perform an entire sequence read of the vector. An indirect method of
confirming the transformations would be to check for the direct presence of the pTX-GFP
plasmid construct by using an antibody for the Poly-His tag present at the N-terminal end of
PAZ5 in the fusion protein. These antibodies are widely available and a Western Blot test to
confirm the antibody binding would be comparatively simple. However, performing these
procedures may not be necessary as it does not resolve the issue directly. Fixing the root cause
of the issue would be faster and likely more cost-efficient.
Instead, it may be wise to either order a fresh stock of the pTX-GFP vector and re-do all
the PAZ5 ligations again; or to ligate the mutant PAZ5-GFP fusion protein into a different D.
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discoideum expression vector. The Gundersen lab has a pJK1 vector on hand that has been
successfully used for development studies. The GFP could also be replaced with a YFP tag ready
for insertion (Little, 2013). Before usage, the YFP tag would need to be inserted into the pJK1
vector. One issue with pJK1 is that it uses a BglII (AGATCT) site instead of KpnI (GGTACC). This
would necessitate adding either a BamHI (GGATCC) or BglII cassette to the end of the PAZ5
protein, as these cohesive ends are compatible with one another (Vanamee et al., 2004).
It may also be the case that the lack of fluorescence is due to a problem with the
attachment of the GFP to the PAZ5 protein. Fluorescent tagging of GFP to the PAZ5 protein has,
in the past, suffered from poor characterization due to mis-localization (Amburg, 2010).
However, this was later attributed to improper insertion of PAZ5 into the pTX-GFP construct, as
the KpnI site naturally present in the PAZ5 sequence was not removed, likely cleaving PAZ5 as it
was inserted into the expression plasmid. Yet, it is possible that the fluorescent protein is
altering the function, localization, and detection, of the PAZ5 protein. It may be that the GFP is,
for example, pH-sensitive and is failing to fluoresce in organelles that have different pH
differences. This adds to the notion of using a different plasmid besides pTX-GFP for examining
expression of PAZ5, as it may be that GFP is not the appropriate fluorescent tag to use for its
developmental study. However, other PAZ proteins have successfully been studies using pTXGFP, such as PAZ8 and PAZ10 (Amburg, 2010). It was also previously observed that YFPattachments to the Gα2 subunit were rapidly lost if clonal lines were left to grow over weeks;
instead, cells were grown from stocks that were frozen as soon as log-phase growth was
observed in D. discoideum (S. Alamer et al., 2018). However, the PAZ5/pTX-GFP constructs were
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similarly observed for fluorescence in the same way and still did not fluorescence, suggesting
that the loss was not due to this phenomenon.

4.5. Conclusions and Future Directions
This study was designed to further characterize the PAZ5 protein in D. discoideum as it
relates to protein acyltransferase mediation by the DHHC domain. PAZ5 is the first of the
fourteen DHHC-containing PAZ proteins identified by the Gundersen lab to have its DHHC
domain characterized. Mutagenesis to the conserved DHHC motif had previously shown that an
intact DHHC was essential to PAZ5 protein function. The study aimed to determine if other
conserved residues flanking the DHHC motif were also essential to PAZ5 protein function,
especially those that made up the two CCHC zinc fingers and the conserved DPG and TTYE
domains outside the DHHC-CRD.
Of the seventeen mutations designed to modify the PAZ5 protein function, only four
were eventually studied due to D. discoideum electroporation efficiency issues.
Characterization was further hampered due to a still as-of-yet unknown fault in the PAZ5/pTXGFP fusion expression vector. This fault has prevented the study of PAZ5 fluorescent
localization in live cells. It has likely also disrupted the mutants' expression and distorted the
statistical analysis of the fruiting body phenotype in developing cells.
The immediate focus should be to remedy what has gone wrong in the pTX-GFP
plasmid; this can be accomplished by first confirming the presence of pTX-GFP in D. discoideum
cells, then sequencing the vector to determine what may have changed. Following on, a new
pTX-GFP plasmid may be used, or a different vector may be used for fluorescence and
105

developmental study, such as pJK1-YFP. Successful fluorescence localization of PAZ5, when
combined with qRT-PCR data from previous studies (Bodwell, 2007), may provide a powerful
means of categorizing which substrates might be mediated by PAZ5 palmitoylation. This is
especially relevant for the Gα2 subunit, which is known to be palmitoylated for localization to
the plasma membrane (S. Alamer et al., 2018). D. discoideum provides a powerful in vivo
approach to a field typically isolated to purely enzymatic study. Further analysis of fruiting body
phenotypes that are correctly expressing the PAZ5 mutations may also lead to an increased
understanding of palmitoylation domains not only in PAZ5 but for DHHC PATs as a whole.
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APPENDIX A
PAZ5 AND PTX-GFP RESTRICTION SITES AND SEQUENCES

Figure A.1. Restriction Sites of PAZ5 with Mutated KpnI Site. Restriction sites for commonly
available restriction enzymes are seen here, together with the relevant location within the
protein sequence. The calculator and enzymes are all provided by NEB.
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Figure A.2. Diagram of the pTX-GFP Plasmid Vector. The pTX-GFP expression vector is shown,
with mention to its restriction sites (KpnI in particular), ampicillin resistance (Amp), GFP coding
region (GFP), G418 resistance (G418), and Ddp1 backbone (Levi et al., 2000).
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Table A.1. PAZ5 Sequence (2,256 bp) with Mutant KpnI Site Highlighted (GGTTCC).
ATGATACCAACACAAACACCCCCAAGACAACAAATGATGAATCATAATCATCAACCACAACAAA
TACAACAACCACAACAAATACAACCACATCAACCACAACAACAACAACCACATCAATTTAGACC
ATTGGATGAAAATGCAGAAATTCCATTTTTACAAATTGTAACACCAAATCAAATGATTAAATTA
CCACCAATGTTTCAAGAACAATATAAACAATTATTAAATAGATGGTCAAATCAATGTATTAAAA
AATCTGGATTATTATATACTCAAGCAGTACCATATAATCAAGTTTTGGTATTATTAGAAATTGC
TAAAAATGGTGATATTCAAGAATATAGAGATTTCATTCAAGTAATTATTGAGTCAAATCAAAAT
AAAGATGGTGATGAAAATGAAGAATCAATTCAACAACAACAACAACAACAACAATTAACATTAA
AATCAATAATAAATTTAATAGATTTAGAAGGTAATACATCAATTCATTATGCAATTATGAGAAA
GAATAAAGCAATGGTTAGTTATTTAATTGATTGTGGTGCAAATTTAGATATTCAAAATTTAGAG
GAAGGTCATACACCATTACATTGGGCATGTATTAAAGCAGATTCATCATTTGTGTTACAATTGG
TTGAAAATGGTGCAGATATTCATTTGACTGATAAGAGGGGTTACAATGCATTACTTCATGCTGC
ACAATATAATGAAGTGAATTCAGTGCGTTATTTAATTGAGAAAGGATTGGACCCAGTGCAATGC
AAAGACATTCAATTACATACTGCAGTGCATTGGACCTCGTTTCAAGGTCATGCAAATATGGCAC
GTTATTTCATAAGTTTAGGCGTTGACCCAAATGCACAAGACATTCAAGGCAGAACGGCATTCCA
TTGGGGTTGTATCAAAGGTCACAAACAAGTGGTCAGCATGTTATGTTCATTCGAAGGTCAAGAT
AGTATAGATAAAACCATTCGTGATAATGATGGTAAGACAGCCTACCAATTGGCAGAATCAAAGG
AACATTATGAAATCATCGATTATTTAGACACAAAGCTTAAAGATGATAAATTATTTGGCGGCAA
TGAGAGACTCTATCATAGATTTTGGACAGTGATGGGTGTGTTGACAGTATTGGTGCCAACCTGG
ATTCTATGCTATGTGCCAGTGATATTTGGGTTACCATTGTTGGCTGTCGGTGGCTACTTTTTAA
AGAATTATTTACACTTAAATTATTGGGTTCCAGAGAGAAACAATTGGTTATTACCCTCGATTTT
ATATTCTTCAGTATCTATTTGGTATTTGATTTATTTACTTAGAATTGCACCATTGGTAATGGCA
ATTAACATTTTCCCAAATTTAATAATTAATGCAACCTCGTGGTACTTTTTCTACTTTTTCATTC
GTTTAACAAAGGAAGATCCAGGCACAATTTCTAAACATATCTCTAAAGAGAAATCAAATGAAAA
CTTTATGAATGCTCTCTCAAGTGGTCGTCAAATCCCTTTGATTTGTCCAACCTGTTTAATTAAT
CGTCCAATTCGTTCAAAACATTGTCCATCTTGTAAAGGTTGTTTTGCACGTTTTGATCATCATT
GTGTTTGGATTAATAAATGTATTGGTATCAATAACCAAGCTTTATTCATCACTGTACTCTTCTC
ATATGTTATCTTGGTAATTTCTGGTTTCATTGTAACTTGGGATTACTTTAAATCTGATTCAAAT
GCTCCAATACTATCTGAAAGTTATATTCAATCATTTTTATTCTACTATACCAATTACCCCTTTA
TTTTATTATTCTCAATCTATGGTATTGGTATGGCTATTTGGATTGGTAAATTAGCAATCTCACA
AGTTTTAACAATTTTATTCAATAAAACTACTTATGAACAAATTCAACAAATTAGAGAATTTGAA
AGTAGACAAGGTCATGGTCATAGTCACGGTGGTGATCAACAATGTAATCATAGTCATGGTAGTG
GTGGTGGTGATCATGGTCATAGCCATGGTGGTAGTTCTGGTAGTGGTAGTGGTAGTGGTAGTGG
TGATCATGGTCATAGTCATGGTGGTCAACCTTCACTTCCATCTTCAAGTGGTGGAAGTAAAAAA
GATTCTGATAAATCATTCCATAATCAACAAACTAATTTTGATATGTATCATCGTGGTGTTGTAA
ATAATGTTAAAGAATTTTTATTCGATTCTCAAAAATTCTATTTCCAAACTGAAAATATTTATGC
TGATTCAAGAGTTTAG
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Table A.2. pTX-GFP Sequence (11,116 bp) with KpnI Ligation Site Highlighted (GGTACC).
AGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTC
CTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAA
AGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC
CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT
TGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCG
GCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCA
GGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGG
CGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTG
GCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCT
CCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC
TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTG
TGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCC
AACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA
GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGAC
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGA
TCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCA
GAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA
AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTA
AATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACC
AATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTG
ACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATG
ATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGG
CCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA
AGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC
GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAG
TTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAG
AAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTC
ATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGT
GTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAG
AACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCG
CTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTT
TCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGC
GACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGC
GCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTA
AATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAA
GAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAA
CCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAG
GGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAA
AGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACA
CCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTT
GGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGC
AAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGT
GAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGAGCTGGTCGACTAGATAAAAAAAATTT
TTATTTATTTTTATTATTTTGAATTAAATAGATTACAAATGATTACAAATTAATTAATCCCATC
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AAATCTTTAAAAAAAAAAATGGTTTAAAAAAACTTGGGTTGGTTAATTATTATTTGAAAATTTT
AAAACCCAAATTAAAAAAAAAAAATGGGATTCAAAAATTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTCAGATTGCATAAAAAGATTTTTTTTTTTTTTTTTTCTTATTTCTT
AAAACAAATAAATTAAATTAAATAAAAAATAAAAATCAGATCCAAGCTTAAAAAATGCATCATC
ATCATCATCATCATCATGATATCGGTACCAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCC
AATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAA
GGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCGCGTATGGTCTTCAATGCTTTGCGAGATACCCAGATCA
TATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATA
TTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTG
TTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAATT
GGAATACAACTATAACTCACACAATGTATACATCATGGCAGACAAACAAAAGAATGGAATCAAA
GTTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAAC
AAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACAATC
TGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCT
GCTGGGATTACACATGGCATGGATGAACTATACAAAGAGAATTCAGAGCTCGGATCCACTCGAG
ATGCATTAGAACAAAAATTATTATCAGAAGAAGATTTAAATTAATCTAGACGATCCCCCGGGCT
GCAGGAATTCAGAGGTTTATTTTTAAAAATTACAAAAACTAAAAAGAAAAATAAAAAGGAAAAA
TCTTATTAATCTGAAAATTACAGATTTGCCCCAATTTAAAGAAAAATTATCCAAAATAATCAAT
CAACAACGATATCTTTTTGATAGATATTTATAAAAACTTTATCTTTTTTATTTTTTCAAAGTTG
CGCAAAATAATAAAATTAAAATAAATATAAAAACTGTAAAAAGAAAAAAAAAAGTGTAAAGGGT
TATTAATTATTTAATTATTATTCACTTTTTGTAATTATTTTTTTATTTTGAAGAATAATGATGG
ATATTTTATATAAAAAAAAAAGAGATATGAAAAAATAATAATTaTAAAAAAAAAAAAAAAAATA
GAATTTTAAAGTTTTTGTACAAATGGATGATTTTTTTTTTTTTTTTTTTCCTAAATAATTCAAG
TAATAAACAAAGAATTGATATTCTGATGCCTAATTAAAAAAGAAATTTTTAAATAAAAAATGGG
TTTTTTTTAAGTAAAGTTATTTGAAATTGATTGAAATTTTCAAACCtaGGGTGGTTTTTCGCTT
TAAAATTGGGATTTTATTTTTATTTTTTTATATTTTTTATTTTTTATTTTTTTTTTTTTTGAGG
TTTCTGAGATTATAAAATGAAATTTTTTTTTTTTTTTTAATTAATTCAAAAAATAATCAAATAA
ATAAATATAATATAAAATGGATGGTGAAGATGTTCAAGCTGGATCGTTTCGCATGATTGAACAA
GATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCAC
AACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCT
TTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCG
TGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGG
ACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGA
GAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCA
TTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCG
ATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAA
GGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACtCATGGCGATGCCTGCTTGCCGAATATC
ATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCT
ATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCG
CTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTT
GACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCC
ATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGG
GACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCGGGC
TCGATCCCCTCGCGAGTTGGTTCAGCTGCTGCCTGAGGCTGGACGACCTCGCGGAGTTCTACCG
GCAGTGCAAATCCGTCGGCATCCAGGAAACCAGCAGCGGCTATCCGCGCATCCATGCCCCCGAA
CTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCCCGGATCAGCTTTATCTTTTTGATTTTC
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ATACTCTTTGGCTGTTTTACATCTAATGCATATATTTATCTTCACCATTCAAAATGTATCTGTA
AATAATAAATTTTTTAAATATATTTGATTTTTTTGATAGAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAATTAAAATACCTTAATAATTATTAAGATTTAAAAAAAAAAAATTAAAAAAAAA
AGAAAATATTAGATTATTACAACAATTTGTTTTTTTATTATTTATTAAATAATTTAAAAACATT
TTCTGTGAACAATTGATGGACCCTCAGGAAGATCGCACTCCAGCCAGCTTTCCGGCACCGCTTC
TGGTGCCGGAAACAGGCAAAGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGAT
CGGTGCGGGGATCTCGAAGAAAAATCGAGCATAATATCGTCAAGCTTGATGTCAGAATTAATAT
AACCAAAAACATCACCAACAAACGAAGTTTGGTGAGAAATTTGAATAAAGATACCTTTTAAAAA
ATTATTATCAATGAGATATGAGTAATTATCAATAAACCGTTGGAGTGAAATTTTACCAGCTGAT
AGTGAACAAAAATATGGAAACTCTTTAAGTGAATCAATATTTGGAAATGGTGGATCAGAAGAGT
CGATATAGATTTGGGTTATGGTATTGGAAATGTATTGATTTAAAGATTTCAAAAGGTTGGCTTC
AGAAATTTCATTTGAGGATGTCCTTTCTGTTACAGCTTCAGTATAAACTTTAACATAAATTGAT
TTTAATAGATTGGGATACTGGGATGATTCTTTTTTTTTTTTATCTGCATTTGAAATCATCATGG
TGAGGTTTGAAAGGACACCTTCAAGTTGATCGCTTACCTGTTGAACTTGATTTGTTTTAAATAG
TTCACCATCAACAGGGACAGGCTTTTTAACAAATTTGAGAGCATTAACAACGTGATATTGAACT
TGTGAAACAAGGTTATAAGTAGAGCTGTTAGCTAAATCAAGACGAAAAATTTTCCCCAATTTGT
TTTTAAATTCTTCGCTTGCGCCAATTAAAACTCCAGCTAATGAATATGAATTGTGAATGTTTTG
AACTCCTAAAATTTCAACATTTTGTTTTTTTGGTGTGTTGTTCGATGGAGGAGCAATTTTCCTT
TTGTTTGTTGTTGTTGTTGTTGTTGACATTTGAAATTACAATGAATGTTTTTCGGTTTTTATTT
TTTACTTTTTATTTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAAATTTTTTTTTT
TTTTTTTTCAAATTTTTTTTTTTTTAAAAAAAAAAAAATTCATTTTTGTATTTAAATTATTTTA
TAAATAAAAAATGATAGTAGTAGAAATTGTTTTTTGGACAAGAATCGTAAAGTCAAAATATTCA
GTTGATGATGAAATCTTTAAATATTTGGTTAATAGAGCAAAAGTTGTGTATAACAATTCAGATT
ATAAAACACTATCTCAAACTGATTTAGAGAAATGGGCGATTCAAAACACTCACAGAACAATAAC
TTCAATTAAAAATCGTTTTTCAGTCAAAAAGATTGGAGATGAAGAAAAGTTATTTAGAATTTCA
AAAAATGGTAAAATCCATCTTTATACATGTTCATTTTAATTTATTTTAACTAATTTTTTAAATT
AGGGGAGCTTATTGTTCTTAATGAATTAGAATTCGATAATTTTCATATTAAAGAAGGAAAGCAT
TTAAGAAAATCAAAAATGTTTAATCATATCAAAGACAGTGGTTATTATGCAACAAACGAAGAAA
TTGAAATTTTTCTTGAAAGCTGCACTCTATGTAAGGAAATTACTGCACAAACCAAACGTAATTC
ATATAAAAAAAGAAATATAATTAATAAATTACCGGAAGAAGAAGAAGAAGAAGAAGAAGAAGAA
GAAGAAGAAGAAGAAGAAGAAGAACAAGAAGAAGAAGTAGAAAAACCGACAATATCGGAAGAAG
AAGAAGAAGAAACACCTGCAGTATCAGAAGAAGAAAAAGAAGAGGAAGAACAAGAAGAAGATAA
AGAAAAAGATAAAGAAAAAAAAATAGAAGAAGATACAGAAACAGGAAAAAAAAAAGATGAAGTT
ATGAATGAACGTCAAGATGGTATTGAAATTAGTGAAAAAACAAATGATAAACCAACAGAAAAAA
CAAAAGTTAAAAAGAATGTTTCACGAGTCAAAGATATTAATCTTCATAAAAAAGGAAATCCTAT
TACCCCAAAAAAAATAAAAAATTTCAGTCAACAACAATTACGTTTAGCTTCTGGTGTTTCAAAT
GAAAAAAGAGCAATAATTACTCTTAAAAAATAATAAAACTTTATTTAATTAAAAAAATAATTAA
AAAGAAAATTAAATATATATTAATTTTTAAATTATTTGAAATGTTTTTTTCTTGAGTTACTGAC
TTTTCCATACCGTTATTTGAGCCATCAAGCTTTGGATTGTAAATTGTTGATAAAAATTCAGAAT
CAGATGCACCATACTTTGGAGTACACTTTGTTGTTTTAAAATCAAGATTGTTTTGAATGTTTTC
ATTCTTACAATAGTGGCACAATGGATCTGTACATGTAAATCTATTGGATTTCTCTTGTGTAATG
TTTGTAATATGATATACATTTTCAAATTTTGAACAAATGTTGAATTTTTCAATAATTGTTTTAC
TATTTTTTGTACAATCCATTGAAAGAGAAGTAATTTCAACAAAGCTGTCTTCCACTCTAAACAA
ATAACCATCATCAGTTTCATTATATTCTTTATAAAGAATAGACTCTCCAAACTCGTCATTAATA
CATTCATTAAGCTTAATTAAGTTTGTTAAATTACGAAAATTGTTACATCTTGAATTATTTGTTT
CAATGTCATCATAAAAAAGCGCATGAGTACTATTTGTTTCAACTCTTCCATGAATATTACATTC
ATCATAAATTACGGCGCCTGTCATTGACTTTTCAACACAGTTTTCTTTTTGATACATAACAATA
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AGAAGTTGAAAATATTTTACTTCAATCTGATCATTTTGAAGAACAGAAGATTTTGATACAATAA
AAAAAAAAAGAAAAAATAATAACGTTGTTGAGTACATTATATACAATGAAAATAATAAATGAAC
AAAAAATAATTTTTTATTATAATATATTAAACCCCACCCCACAACCACACCTAAAAAAAAGTTA
ATACTTTTTTAAATATAATTTTTTTAATAGTTATTTTAATACGTTTTTAACATAAAATATATTT
TAATTTTTTTTTTAATTTTTTAGAAAATTTTTTTTTCATAATTATTTTAATACTTTTTTACAAA
AAATATTTTTAAAATTTTAAAAATTTTTTTTTTATAATTATTTTAATAGCTTAATTACAAAAAC
AATTTAATAATTTTTTTAATTTTTTTTTCATAATATTTTTAATAGCTTTTTTACAAATTATTTT
TACGAAAATTTTTGTTATATTTTTTTATAATTATTTTAATACATTTTTAACATTAAATAATTAT
ATAATTTTTTAATACAATAATTACAGTTATAAATTCATATTATTTAAATATTTTTAAATGAGTT
TATTTAGAAATTAAGTTTATATTTTATTTAATTAGTTTTGACTCTCAGAATGTATAGACACTTT
TTAGAACACTGTGCACAAAGATGAAGTTTACATTCTTGGTTCAAATTACATTTAGTTCCGTTCT
TACTACACATGGCACACTTCTTGTTGATTACCGAATCATTGAAACATGGAGGGCAAAGTTTAGA
ATTAATAACAACATTATATATGTTTATGTTTATTCCTAAACAATTATAGCAAATATTGTTTTGA
CATCCATCTCTTGTACATGAAATATATAAATTTTTTCCTTGACACAAAGAATGACAATTAATAC
ACTTTACTTCTAAGAGAGAATAATTTTCTGGATTTGAAAGGGCATCTGTTGAAGAAACTAAAAA
GAAATCAATTTTGGAAGAAGTTTTATTGACTTCTTCTTTAATAAACTTTTTTAAATCGGCAATT
TCATTGGAATTTATTTGGGTAGATTCGGATTGAATTTTGTAATAATTGCTATTTACTTTTTCGA
AGTTATTGAAAAAAGGTTTTAAATTAAATATATCTTGTGTTGAAAATTCTTTTAATGAAAGTAT
TTGTTTTAAAGCAGTACTTTGACTTTGAATATGAATTAAAAGATTTTTGGTTTCTTCATAATTA
ATTAGCGATGGAAAATATCTAAATACAAGAATGCTTGTTATATGAACAATTTTTCCTTGCGAAT
TAATTCTAATTGAGTAATGAATAAAGGAATCGCTAAAAGGTGTTGAGTCTACAAAAACAGAAGG
AGGTTTAATTAACAACGCCATATTATTCTGATCGTTTTCATTAAAAAAACAATATTTATCTACT
AATGAAAATCGATTAATAATATAATTATCTAAATTATTAAAAGTCTCTTTATCTTTTAAAAGAA
CAAGTGTATGACGAGAAACTTGATCAAGGCAGTAATGTGCAGACGCGATTGATTCTTTAAATGC
ATCAAATGATTCATCTAAAATTTGGTCACTGTATGCTTCCAATGTTTGTTTTTGATAAATTTGA
ATAGTTGCTTTTAAGAAATTCAAAAAATATTGAAATACATTAAAGTTAAAGTGATTATTTGAAA
CAACAAACTGGACATTATCTTGGTTTGAACAATTTGAGTTGGCAAACGAATAAACCATTGTTTG
AGTTGTATTTTCATTATTGTTTTTGCTATTTCTGTTATTTGTATTTATACTAGTTAAAAACTCA
ACTGAAGTGGAAATATATTTTTCATAAACTTTGGCACGTTCGTTTAATTTTGAAATCAATGAAT
CTCGTTTTAATATTTCATGTTTGTAAGAATATTCAAAAGCAGGTTGTGTGATTTGATTGGAAAC
TGTTGGTGTTGTTTCTAATTGAATAATTCGAGACCTTAAAGATTCAATTTCTTTTTCAAGGCTA
TAATTTTTTGTATTAAGATCATTTAATTGAGATTTATGTTCATTTGAAATCTTTAAAGAATTTA
AAAGGTTAAAGTCTTTAAAGTTATTTTTAAGAGTTTCTAATTCTGCATTGATTTGATCGTTTTT
ATCTTTTAAAACTCTACCAGCGGCATACGATACTTGTAATTCTTTTTCTTTTTCTGAAAAACAA
TTTTCATATTCATTTATATAATTTTGGTAG
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Table A.3. Complete PAZ5/pTX-GFP Fusion Sequence (13,434 bp) with KpnI Ligation Sites
Highlighted (GGTACC).
AGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTC
CTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAA
AGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTC
CAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT
TGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCG
GCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCA
GGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGG
CGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTG
GCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCT
CCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC
TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTG
TGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCC
AACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA
GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGAC
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGA
TCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCA
GAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA
AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTA
AATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACC
AATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTG
ACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATG
ATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGG
CCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA
AGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC
GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAG
TTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAG
AAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTC
ATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGT
GTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAG
AACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCG
CTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTT
TCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGC
GACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGC
GCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTA
AATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAA
GAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAA
CCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAG
GGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAA
AGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACA
CCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTT
GGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGC
AAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGT
GAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGAGCTGGTCGACTAGATAAAAAAAATTT
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TTATTTATTTTTATTATTTTGAATTAAATAGATTACAAATGATTACAAATTAATTAATCCCATC
AAATCTTTAAAAAAAAAAATGGTTTAAAAAAACTTGGGTTGGTTAATTATTATTTGAAAATTTT
AAAACCCAAATTAAAAAAAAAAAATGGGATTCAAAAATTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTCAGATTGCATAAAAAGATTTTTTTTTTTTTTTTTTCTTATTTCTT
AAAACAAATAAATTAAATTAAATAAAAAATAAAAATCAGATCCAAGCTTAAAAAATGCATCATC
ATCATCATCATCATCATGATATCGGTACCATGAAAAAAATGATACCAACACAAACACCCCCAAG
ACAACAAATGATGAATCATAATCATCAACCACAACAAATACAACAACCACAACAAATACAACCA
CATCAACCACAACAACAACAACCACATCAATTTAGACCATTGGATGAAAATGCAGAAATTCCAT
TTTTACAAATTGTAACACCAAATCAAATGATTAAATTACCACCAATGTTTCAAGAACAATATAA
ACAATTATTAAATAGATGGTCAAATCAATGTATTAAAAAATCTGGATTATTATATACTCAAGCA
GTACCATATAATCAAGTTTTGGTATTATTAGAAATTGCTAAAAATGGTGATATTCAAGAATATA
GAGATTTCATTCAAGTAATTATTGAGTCAAATCAAAATAAAGATGGTGATGAAAATGAAGAATC
AATTCAACAACAACAACAACAACAACAATTAACATTAAAATCAATAATAAATTTAATAGATTTA
GAAGGTAATACATCAATTCATTATGCAATTATGAGAAAGAATAAAGCAATGGTTAGTTATTTAA
TTGATTGTGGTGCAAATTTAGATATTCAAAATTTAGAGGAAGGTCATACACCATTACATTGGGC
ATGTATTAAAGCAGATTCATCATTTGTGTTACAATTGGTTGAAAATGGTGCAGATATTCATTTG
ACTGATAAGAGGGGTTACAATGCATTACTTCATGCTGCACAATATAATGAAGTGAATTCAGTGC
GTTATTTAATTGAGAAAGGATTGGACCCAGTGCAATGCAAAGACATTCAATTACATACTGCAGT
GCATTGGACCTCGTTTCAAGGTCATGCAAATATGGCACGTTATTTCATAAGTTTAGGCGTTGAC
CCAAATGCACAAGACATTCAAGGCAGAACGGCATTCCATTGGGGTTGTATCAAAGGTCACAAAC
AAGTGGTCAGCATGTTATGTTCATTCGAAGGTCAAGATAGTATAGATAAAACCATTCGTGATAA
TGATGGTAAGACAGCCTACCAATTGGCAGAATCAAAGGAACATTATGAAATCATCGATTATTTA
GACACAAAGCTTAAAGATGATAAATTATTTGGCGGCAATGAGAGACTCTATCATAGATTTTGGA
CAGTGATGGGTGTGTTGACAGTATTGGTGCCAACCTGGATTCTATGCTATGTGCCAGTGATATT
TGGGTTACCATTGTTGGCTGTCGGTGGCTACTTTTTAAAGAATTATTTACACTTAAATTATTGG
GTTCCAGAGAGAAACAATTGGTTATTACCCTCGATTTTATATTCTTCAGTATCTATTTGGTATT
TGATTTATTTACTTAGAATTGCACCATTGGTAATGGCAATTAACATTTTCCCAAATTTAATAAT
TAATGCAACCTCGTGGTACTTTTTCTACTTTTTCATTCGTTTAACAAAGGAAGATCCAGGCACA
ATTTCTAAACATATCTCTAAAGAGAAATCAAATGAAAACTTTATGAATGCTCTCTCAAGTGGTC
GTCAAATCCCTTTGATTTGTCCAACCTGTTTAATTAATCGTCCAATTCGTTCAAAACATTGTCC
ATCTTGTAAAGGTTGTTTTGCACGTTTTGATCATCATTGTGTTTGGATTAATAAATGTATTGGT
ATCAATAACCAAGCTTTATTCATCACTGTACTCTTCTCATATGTTATCTTGGTAATTTCTGGTT
TCATTGTAACTTGGGATTACTTTAAATCTGATTCAAATGCTCCAATACTATCTGAAAGTTATAT
TCAATCATTTTTATTCTACTATACCAATTACCCCTTTATTTTATTATTCTCAATCTATGGTATT
GGTATGGCTATTTGGATTGGTAAATTAGCAATCTCACAAGTTTTAACAATTTTATTCAATAAAA
CTACTTATGAACAAATTCAACAAATTAGAGAATTTGAAAGTAGACAAGGTCATGGTCATAGTCA
CGGTGGTGATCAACAATGTAATCATAGTCATGGTAGTGGTGGTGGTGATCATGGTCATAGCCAT
GGTGGTAGTTCTGGTAGTGGTAGTGGTAGTGGTAGTGGTGATCATGGTCATAGTCATGGTGGTC
AACCTTCACTTCCATCTTCAAGTGGTGGAAGTAAAAAAGATTCTGATAAATCATTCCATAATCA
ACAAACTAATTTTGATATGTATCATCGTGGTGTTGTAAATAATGTTAAAGAATTTTTATTCGAT
TCTCAAAAATTCTATTTCCAAACTGAAAATATTTATGCTGATTCAAGAGTTGGTACCAGTAAAG
GAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCA
CAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTT
ATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCGCGTATGGTC
TTCAATGCTTTGCGAGATACCCAGATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCC
CGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCT
GAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAG
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AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTATACATCAT
GGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTGAAGATGGA
AGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTAC
CAGACAACCATTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCA
CATGGTCCTTCTTGAGTTTGTAACAGCTGCTGGGATTACACATGGCATGGATGAACTATACAAA
GAGAATTCAGAGCTCGGATCCACTCGAGATGCATTAGAACAAAAATTATTATCAGAAGAAGATT
TAAATTAATCTAGACGATCCCCCGGGCTGCAGGAATTCAGAGGTTTATTTTTAAAAATTACAAA
AACTAAAAAGAAAAATAAAAAGGAAAAATCTTATTAATCTGAAAATTACAGATTTGCCCCAATT
TAAAGAAAAATTATCCAAAATAATCAATCAACAACGATATCTTTTTGATAGATATTTATAAAAA
CTTTATCTTTTTTATTTTTTCAAAGTTGCGCAAAATAATAAAATTAAAATAAATATAAAAACTG
TAAAAAGAAAAAAAAAAGTGTAAAGGGTTATTAATTATTTAATTATTATTCACTTTTTGTAATT
ATTTTTTTATTTTGAAGAATAATGATGGATATTTTATATAAAAAAAAAAGAGATATGAAAAAAT
AATAATTaTAAAAAAAAAAAAAAAAATAGAATTTTAAAGTTTTTGTACAAATGGATGATTTTTT
TTTTTTTTTTTTTCCTAAATAATTCAAGTAATAAACAAAGAATTGATATTCTGATGCCTAATTA
AAAAAGAAATTTTTAAATAAAAAATGGGTTTTTTTTAAGTAAAGTTATTTGAAATTGATTGAAA
TTTTCAAACCtaGGGTGGTTTTTCGCTTTAAAATTGGGATTTTATTTTTATTTTTTTATATTTT
TTATTTTTTATTTTTTTTTTTTTTGAGGTTTCTGAGATTATAAAATGAAATTTTTTTTTTTTTT
TTAATTAATTCAAAAAATAATCAAATAAATAAATATAATATAAAATGGATGGTGAAGATGTTCA
AGCTGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTG
GAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCC
GGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGA
ACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTG
CTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATC
TCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCT
GCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCA
CGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCG
CGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGAC
tCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGAC
TGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTG
AAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTC
GCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAA
TGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGA
AAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTC
ATGCTGGAGTTCTTCGCCCACCCCGGGCTCGATCCCCTCGCGAGTTGGTTCAGCTGCTGCCTGA
GGCTGGACGACCTCGCGGAGTTCTACCGGCAGTGCAAATCCGTCGGCATCCAGGAAACCAGCAG
CGGCTATCCGCGCATCCATGCCCCCGAACTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTC
CCGGATCAGCTTTATCTTTTTGATTTTCATACTCTTTGGCTGTTTTACATCTAATGCATATATT
TATCTTCACCATTCAAAATGTATCTGTAAATAATAAATTTTTTAAATATATTTGATTTTTTTGA
TAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTAAAATACCTTAATAATTATTAA
GATTTAAAAAAAAAAAATTAAAAAAAAAAGAAAATATTAGATTATTACAACAATTTGTTTTTTT
ATTATTTATTAAATAATTTAAAAACATTTTCTGTGAACAATTGATGGACCCTCAGGAAGATCGC
ACTCCAGCCAGCTTTCCGGCACCGCTTCTGGTGCCGGAAACAGGCAAAGCGCCATTCGCCATTC
AGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGGATCTCGAAGAAAAATCGAGCATAATA
TCGTCAAGCTTGATGTCAGAATTAATATAACCAAAAACATCACCAACAAACGAAGTTTGGTGAG
AAATTTGAATAAAGATACCTTTTAAAAAATTATTATCAATGAGATATGAGTAATTATCAATAAA
CCGTTGGAGTGAAATTTTACCAGCTGATAGTGAACAAAAATATGGAAACTCTTTAAGTGAATCA
ATATTTGGAAATGGTGGATCAGAAGAGTCGATATAGATTTGGGTTATGGTATTGGAAATGTATT
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GATTTAAAGATTTCAAAAGGTTGGCTTCAGAAATTTCATTTGAGGATGTCCTTTCTGTTACAGC
TTCAGTATAAACTTTAACATAAATTGATTTTAATAGATTGGGATACTGGGATGATTCTTTTTTT
TTTTTATCTGCATTTGAAATCATCATGGTGAGGTTTGAAAGGACACCTTCAAGTTGATCGCTTA
CCTGTTGAACTTGATTTGTTTTAAATAGTTCACCATCAACAGGGACAGGCTTTTTAACAAATTT
GAGAGCATTAACAACGTGATATTGAACTTGTGAAACAAGGTTATAAGTAGAGCTGTTAGCTAAA
TCAAGACGAAAAATTTTCCCCAATTTGTTTTTAAATTCTTCGCTTGCGCCAATTAAAACTCCAG
CTAATGAATATGAATTGTGAATGTTTTGAACTCCTAAAATTTCAACATTTTGTTTTTTTGGTGT
GTTGTTCGATGGAGGAGCAATTTTCCTTTTGTTTGTTGTTGTTGTTGTTGTTGACATTTGAAAT
TACAATGAATGTTTTTCGGTTTTTATTTTTTACTTTTTATTTGATTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTAAAATTTTTTTTTTTTTTTTTTCAAATTTTTTTTTTTTTAAAAAAAAAAA
AATTCATTTTTGTATTTAAATTATTTTATAAATAAAAAATGATAGTAGTAGAAATTGTTTTTTG
GACAAGAATCGTAAAGTCAAAATATTCAGTTGATGATGAAATCTTTAAATATTTGGTTAATAGA
GCAAAAGTTGTGTATAACAATTCAGATTATAAAACACTATCTCAAACTGATTTAGAGAAATGGG
CGATTCAAAACACTCACAGAACAATAACTTCAATTAAAAATCGTTTTTCAGTCAAAAAGATTGG
AGATGAAGAAAAGTTATTTAGAATTTCAAAAAATGGTAAAATCCATCTTTATACATGTTCATTT
TAATTTATTTTAACTAATTTTTTAAATTAGGGGAGCTTATTGTTCTTAATGAATTAGAATTCGA
TAATTTTCATATTAAAGAAGGAAAGCATTTAAGAAAATCAAAAATGTTTAATCATATCAAAGAC
AGTGGTTATTATGCAACAAACGAAGAAATTGAAATTTTTCTTGAAAGCTGCACTCTATGTAAGG
AAATTACTGCACAAACCAAACGTAATTCATATAAAAAAAGAAATATAATTAATAAATTACCGGA
AGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAACAAGAAGAAGAA
GTAGAAAAACCGACAATATCGGAAGAAGAAGAAGAAGAAACACCTGCAGTATCAGAAGAAGAAA
AAGAAGAGGAAGAACAAGAAGAAGATAAAGAAAAAGATAAAGAAAAAAAAATAGAAGAAGATAC
AGAAACAGGAAAAAAAAAAGATGAAGTTATGAATGAACGTCAAGATGGTATTGAAATTAGTGAA
AAAACAAATGATAAACCAACAGAAAAAACAAAAGTTAAAAAGAATGTTTCACGAGTCAAAGATA
TTAATCTTCATAAAAAAGGAAATCCTATTACCCCAAAAAAAATAAAAAATTTCAGTCAACAACA
ATTACGTTTAGCTTCTGGTGTTTCAAATGAAAAAAGAGCAATAATTACTCTTAAAAAATAATAA
AACTTTATTTAATTAAAAAAATAATTAAAAAGAAAATTAAATATATATTAATTTTTAAATTATT
TGAAATGTTTTTTTCTTGAGTTACTGACTTTTCCATACCGTTATTTGAGCCATCAAGCTTTGGA
TTGTAAATTGTTGATAAAAATTCAGAATCAGATGCACCATACTTTGGAGTACACTTTGTTGTTT
TAAAATCAAGATTGTTTTGAATGTTTTCATTCTTACAATAGTGGCACAATGGATCTGTACATGT
AAATCTATTGGATTTCTCTTGTGTAATGTTTGTAATATGATATACATTTTCAAATTTTGAACAA
ATGTTGAATTTTTCAATAATTGTTTTACTATTTTTTGTACAATCCATTGAAAGAGAAGTAATTT
CAACAAAGCTGTCTTCCACTCTAAACAAATAACCATCATCAGTTTCATTATATTCTTTATAAAG
AATAGACTCTCCAAACTCGTCATTAATACATTCATTAAGCTTAATTAAGTTTGTTAAATTACGA
AAATTGTTACATCTTGAATTATTTGTTTCAATGTCATCATAAAAAAGCGCATGAGTACTATTTG
TTTCAACTCTTCCATGAATATTACATTCATCATAAATTACGGCGCCTGTCATTGACTTTTCAAC
ACAGTTTTCTTTTTGATACATAACAATAAGAAGTTGAAAATATTTTACTTCAATCTGATCATTT
TGAAGAACAGAAGATTTTGATACAATAAAAAAAAAAAGAAAAAATAATAACGTTGTTGAGTACA
TTATATACAATGAAAATAATAAATGAACAAAAAATAATTTTTTATTATAATATATTAAACCCCA
CCCCACAACCACACCTAAAAAAAAGTTAATACTTTTTTAAATATAATTTTTTTAATAGTTATTT
TAATACGTTTTTAACATAAAATATATTTTAATTTTTTTTTTAATTTTTTAGAAAATTTTTTTTT
CATAATTATTTTAATACTTTTTTACAAAAAATATTTTTAAAATTTTAAAAATTTTTTTTTTATA
ATTATTTTAATAGCTTAATTACAAAAACAATTTAATAATTTTTTTAATTTTTTTTTCATAATAT
TTTTAATAGCTTTTTTACAAATTATTTTTACGAAAATTTTTGTTATATTTTTTTATAATTATTT
TAATACATTTTTAACATTAAATAATTATATAATTTTTTAATACAATAATTACAGTTATAAATTC
ATATTATTTAAATATTTTTAAATGAGTTTATTTAGAAATTAAGTTTATATTTTATTTAATTAGT
TTTGACTCTCAGAATGTATAGACACTTTTTAGAACACTGTGCACAAAGATGAAGTTTACATTCT
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TGGTTCAAATTACATTTAGTTCCGTTCTTACTACACATGGCACACTTCTTGTTGATTACCGAAT
CATTGAAACATGGAGGGCAAAGTTTAGAATTAATAACAACATTATATATGTTTATGTTTATTCC
TAAACAATTATAGCAAATATTGTTTTGACATCCATCTCTTGTACATGAAATATATAAATTTTTT
CCTTGACACAAAGAATGACAATTAATACACTTTACTTCTAAGAGAGAATAATTTTCTGGATTTG
AAAGGGCATCTGTTGAAGAAACTAAAAAGAAATCAATTTTGGAAGAAGTTTTATTGACTTCTTC
TTTAATAAACTTTTTTAAATCGGCAATTTCATTGGAATTTATTTGGGTAGATTCGGATTGAATT
TTGTAATAATTGCTATTTACTTTTTCGAAGTTATTGAAAAAAGGTTTTAAATTAAATATATCTT
GTGTTGAAAATTCTTTTAATGAAAGTATTTGTTTTAAAGCAGTACTTTGACTTTGAATATGAAT
TAAAAGATTTTTGGTTTCTTCATAATTAATTAGCGATGGAAAATATCTAAATACAAGAATGCTT
GTTATATGAACAATTTTTCCTTGCGAATTAATTCTAATTGAGTAATGAATAAAGGAATCGCTAA
AAGGTGTTGAGTCTACAAAAACAGAAGGAGGTTTAATTAACAACGCCATATTATTCTGATCGTT
TTCATTAAAAAAACAATATTTATCTACTAATGAAAATCGATTAATAATATAATTATCTAAATTA
TTAAAAGTCTCTTTATCTTTTAAAAGAACAAGTGTATGACGAGAAACTTGATCAAGGCAGTAAT
GTGCAGACGCGATTGATTCTTTAAATGCATCAAATGATTCATCTAAAATTTGGTCACTGTATGC
TTCCAATGTTTGTTTTTGATAAATTTGAATAGTTGCTTTTAAGAAATTCAAAAAATATTGAAAT
ACATTAAAGTTAAAGTGATTATTTGAAACAACAAACTGGACATTATCTTGGTTTGAACAATTTG
AGTTGGCAAACGAATAAACCATTGTTTGAGTTGTATTTTCATTATTGTTTTTGCTATTTCTGTT
ATTTGTATTTATACTAGTTAAAAACTCAACTGAAGTGGAAATATATTTTTCATAAACTTTGGCA
CGTTCGTTTAATTTTGAAATCAATGAATCTCGTTTTAATATTTCATGTTTGTAAGAATATTCAA
AAGCAGGTTGTGTGATTTGATTGGAAACTGTTGGTGTTGTTTCTAATTGAATAATTCGAGACCT
TAAAGATTCAATTTCTTTTTCAAGGCTATAATTTTTTGTATTAAGATCATTTAATTGAGATTTA
TGTTCATTTGAAATCTTTAAAGAATTTAAAAGGTTAAAGTCTTTAAAGTTATTTTTAAGAGTTT
CTAATTCTGCATTGATTTGATCGTTTTTATCTTTTAAAACTCTACCAGCGGCATACGATACTTG
TAATTCTTTTTCTTTTTCTGAAAAACAATTTTCATATTCATTTATATAATTTTGGTAG
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Table A.4. Amino Acid Composition of the PAZ5 Protein.
Amino Acid Composition
Ala[A]

30

4.0 %

Arg[R]

23

3.1 %

Asn[N]
Asp[D]

47
35

6.3 %
4.7 %

Cys[C]

15

2.0 %

Gln[Q]
Glu[E]

62
30

8.3 %
4.0 %

Gly[G]
His[H]

52
34

6.9 %
4.5 %

Ile[I]

67

8.9 %

Leu[L]
Lys[K]

66
37

8.8 %
4.9 %

Met[M]
Phe[F]

14
37

1.9 %
4.9 %

Pro[P]
Ser[S]

33
58

4.4 %
7.7 %

Thr[T]
Trp[W]

29
13

3.9 %
1.7 %

Tyr[Y]
Val[V]

34
35

4.5 %
4.7 %
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APPENDIX B
PAZ5 MUTANT SEQUENCE ALIGNMENTS

Table B.1. Sequence Alignment for Mutant G477Y (1).

G477Y
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

G477Y
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

G477Y
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

G477Y
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

G477Y
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

G477Y
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

G477Y
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

G477Y
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPYTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
******************************************************** ***

G477Y
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************************************************

G477Y
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

G477Y
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

G477Y
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

G477Y
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.2. Sequence Alignment for Mutant C506A (2). The mutation created was a C506R
instead of C506A, the primers were correct, and the cause of this change is unknown.
C506A
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

C506A
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

C506A
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

C506A
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

C506A
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

C506A
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

C506A
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

C506A
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

C506A
PAZ5

KHISKEKSNENFMNALSSGRQIPLIRPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************* **********************************

C506A
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

C506A
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

C506A
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

C506A
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.3. Sequence Alignment for Mutant C509G (3).
C509G
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

C509G
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

C509G
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

C509G
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

C509G
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

C509G
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

C509G
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

C509G
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

C509G
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTGLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
**************************** *******************************

C509G
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

C509G
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

C509G
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

C509G
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.4. Sequence Alignment for Mutant D475A (4).
D475A
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

D475A
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

D475A
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

D475A
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

D475A
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

D475A
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

D475A
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

D475A
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEAPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
****************************************************** *****

D475A
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************************************************

D475A
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

D475A
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

D475A
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

D475A
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.5. Sequence Alignment for Mutant T628A (5).
T628A
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

T628A
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

T628A
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

T628A
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

T628A
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

T628A
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

T628A
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

T628A
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

T628A
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************************************************

T628A
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

T628A
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKATYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
***************************:********************************

T628A
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

T628A
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.6. Sequence Alignment for Mutant C523G (6).
C523G
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

C523G
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

C523G
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

C523G
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

C523G
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

C523G
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

C523G
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

C523G
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

C523G
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSGKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
****************************************** *****************

C523G
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

C523G
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

C523G
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

C523G
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.7. Sequence Alignment for Mutant E631A (7).
E631A
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

E631A
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

E631A
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

E631A
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

E631A
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

E631A
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

E631A
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

E631A
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

E631A
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHHCVWINK
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFD-HHCVWINK
*************************************************** ********

E631A
PAZ5

CIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFIL
CIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFIL
************************************************************

E631A
PAZ5

LFSIYGIGMAIWIGKLAISQVLTILFNKTTYAQIQQIREFESRQGHGHSHGGDQQCNHSH
LFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSH
******************************* ****************************

E631A
PAZ5

GSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDM
GSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDM
************************************************************

E631A
PAZ5

YHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
YHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
********************************
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Table B.8. Sequence Alignment for Mutant P514A (8).
P514A
PAZ5

------PPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
******************************************************

P514A
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

P514A
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

P514A
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

P514A
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

P514A
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

P514A
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

P514A
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

P514A
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRAIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
*********************************.**************************

P514A
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

P514A
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

P514A
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

P514A
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.9. Sequence Alignment for Mutant R516P (9). The read error in the lower-middle was
due to the sequencing machine.
R516P
PAZ5

MIPTPNPPQG---NQNDEFIIIKPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQN
MIPTQTPPRQQMMNHNHQ-----PQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQI
**** .**.
*:* :
************************************

R516P
PAZ5

CNTKSNDLNYPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQE
V-TPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQE
* .: :: **************************************************

R516P
PAZ5

YRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKA
YRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKA
************************************************************

R516P
PAZ5

MVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHA
MVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHA
************************************************************

R516P
PAZ5

AQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQG
AQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQG
************************************************************

R516P
PAZ5

RTAFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKL
RTAFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKL
************************************************************

R516P
PAZ5

KDDKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYW
KDDKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYW
************************************************************

R516P
PAZ5

VPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLMQPRGTFSTFSFVQR---VPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKE
*****************************************:
:: * *. *

R516P
PAZ5

---KIQAQFLNISLKRNQMKTL----MLSQVVVKSLFVQPVLIVQFLQNIVHLVKVVLHV
DPGTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHC
.*. :: : . : * *::*
:. : ..*: .*:
: .
:... *

R516P
PAZ5

LIIIVFGYKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLF
VWI----NKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLF
: *
****************************************************

R516P
PAZ5

YYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHG
YYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHG
************************************************************

R516P
PAZ5

GDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSF
GDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSF
************************************************************

R516P
PAZ5

HNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTEIFMLIQEF
HNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
********************************* :
. .

143

Table B.10. Sequence Alignment for Mutant W536L (10).
W536L
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

W536L
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

W536L
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

W536L
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

W536L
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

W536L
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

W536L
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

W536L
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

W536L
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVLINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
******************************************************* ****

W536L
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

W536L
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

W536L
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

W536L
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.11. Sequence Alignment for Mutant N538I (11).
N538I
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

N538I
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

N538I
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

N538I
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

N538I
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

N538I
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

N538I
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

N538I
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

N538I
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWIIKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
********************************************************* **

N538I
PAZ5

IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
************************************************************

N538I
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

N538I
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

N538I
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.12. Sequence Alignment for Mutant G542S (12).
G542S
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

G542S
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

G542S
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

G542S
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

G542S
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

G542S
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

G542S
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

G542S
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

G542S
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************************************************

G542S
PAZ5

ISINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
*.**********************************************************

G542S
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

G542S
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

G542S
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.13. Sequence Alignment for Mutant F549V (13).
F549V
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

F549V
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

F549V
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

F549V
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

F549V
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

F549V
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

F549V
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

F549V
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

F549V
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************************************************

F549V
PAZ5

IGINNQALVITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
********.***************************************************

F549V
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

F549V
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

F549V
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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Table B.14. Sequence Alignment for Mutant F549S (14). Incomplete read at 5’ end, believed to
be a machine read error.
F549S
PAZ5

DTNTNTPKTTNDESSSTTTNTTTTTNTTTSTTTTTTTSITIGKCRNSIFTNCNTKSNDIT
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQF----RPLDENAEIPFLQIV
*:**
: . . .:
.:
. .
. :
..: *.:
:*.

F549S
PAZ5

TNVSRTITIIKMVKSMYKIWIIIYSSSTISSFGIIRNCKWYSRIRFHSSNYVKSKRWKRI
TP-NQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLL---------------YTQAVPYNQV
* .. *.: *.:. ** : :*.. *.. *::
*.:: ::.:

F549S
PAZ5

NSTTTTTTTINIKINNKFNRFRRYINSLCNYEKESNG--------------LFNLWCKFR
------LVLLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIIN
. ::* *..:: :* :*: : : :::.:*
:.*.. :.

F549S
PAZ5

YSKFRGRS---YTI---TLGMYSRFIIC------------VTIGKWCRYSFDEG--LQCI
LIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLV
.: *.:
*:*
. .* * :* *
* :*. . *.. ** :

F549S
PAZ5

TSCCTIS-----EFSALFNERIGPQCNAKTF----------SKDIQLHTAVHWTSFQGHA
ENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHA
. . *
:.**::
: *: :
.******************

F549S
PAZ5

NMARYFISLGVDPNAQDIQGRTAFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTA
NMARYFISLGVDPNAQDIQGRTAFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTA
************************************************************

F549S
PAZ5

YQLAESKEHYEIIDYLDTKLKDDKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFG
YQLAESKEHYEIIDYLDTKLKDDKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFG
************************************************************

F549S
PAZ5

LPLLAVGGYFLKNYLHLNYWVPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPN
LPLLAVGGYFLKNYLHLNYWVPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPN
************************************************************

F549S
PAZ5

LIINATSWYFFYFFIRLTKEDPGTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRP
LIINATSWYFFYFFIRLTKEDPGTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRP
************************************************************

F549S
PAZ5

IRSKHCPSCKGCFARFDHHCVWINKCIGINNQALSITVLFSYVILVISGFIVTWDYFKSD
IRSKHCPSCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSD
********************************** *************************

F549S
PAZ5

SNAPILSESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQ
SNAPILSESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQ
************************************************************

F549S
PAZ5

QIREFESRQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPS
QIREFESRQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPS
************************************************************

F549S
PAZ5

LPSSSGGSKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
LPSSSGGSKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*********************************************************
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Table B.15. Sequence Alignment for Mutant H519L (15).
H519L
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

H519L
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

H519L
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

H519L
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

H519L
PAZ5

NSVRYLIEKGLDPVQCKDIQFTYCQCIGPWFSXV-HANMARYFHKVGVDPKCTKTFQGRT
NSVRYLIEKGLDPVQCKDIQL---HTAVHWTSFQGHANMARYFISLGVDPNA-QDIQGRT
********************:
:
* *
******** .:****:. : :****

H519L
PAZ5

AFPLGVVSKVTNKWSACYVHSKVKIVIKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKD
AFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKD
** * :. .: *
.. . : *********************************

H519L
PAZ5

DKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVP
DKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVP
************************************************************

H519L
PAZ5

ERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDP
ERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDP
************************************************************

H519L
PAZ5

GTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKLCPSCKGCFARFDHHCVW
GTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVW
****************************************** *****************

H519L
PAZ5

INKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYP
INKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYP
************************************************************

H519L
PAZ5

FILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCN
FILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCN
************************************************************

H519L
PAZ5

HSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTN
HSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTN
************************************************************

H519L
PAZ5

FDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
FDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
***********************************
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Table B.16. Sequence Alignment for Mutant F530S (16). Incomplete read at 5’ end, believed to
be a machine read error.
F530S
PAZ5

-NKYNNHNKYNHINHNNN-------NHINLDHWMKMQKFHFYKLHQ-IKLNYHQCFKNNI
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPN:. . : :***::
::*: : : * .:* * : :: : * .. *

F530S
PAZ5

NNYIDGQINVLKNLDYYILKQYHIIKFWYYKLLK--------MVIFKNIEISFKLLSQIK
--------QMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGD
:::*
: : :::: * : :*
* :::: : ::: .: .

F530S
PAZ5

IKMVMKMKNQFNNNNNNNNHNQIIKVIHQFIMQLERIKQWLVILIVVQ-------IIFKI
IQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRK
*:
.: : : :.*:*:: :: : *:*
* :
: :: ** ::
*:.

F530S
PAZ5

RKVIHHYI--------------GHVLKQIHHLCYNWLKMVQIFILIRGVTMHYF-----NKAMVSYLIDCGANLDIQNLEEGHT--PLHWACIKADSSFVLQLVENGADIHLTDKRGYN
.*.: *:
**.
:*. * : . . : :: .*. :*

F530S
PAZ5

-MLHNIM--KIQCV--ILRKDWTPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNA
ALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNA
:**
:::.* :: *. *************************************

F530S
PAZ5

QDIQGRTAFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDY
QDIQGRTAFHWGCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDY
************************************************************

F530S
PAZ5

LDTKLKDDKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYL
LDTKLKDDKLFGGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYL
************************************************************

F530S
PAZ5

HLNYWVPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFI
HLNYWVPERNNWLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFI
************************************************************

F530S
PAZ5

RLTKEDPGTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFAR
RLTKEDPGTISKHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFAR
************************************************************

F530S
PAZ5

FDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFL
FDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFL
************************************************************

F530S
PAZ5

FYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSH
FYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSH
************************************************************

F530S
PAZ5

GGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKS
GGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKS
************************************************************

F530S
PAZ5

FHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
FHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRV
******************************************
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Table B.17. Sequence Alignment for Mutant Q546L (17).
Q546L
PAZ5

MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
MIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQ
************************************************************

Q546L
PAZ5

MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
MIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQ
************************************************************

Q546L
PAZ5

VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
VIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLI
************************************************************

Q546L
PAZ5

DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
DCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEV
************************************************************

Q546L
PAZ5

NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
NSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHW
************************************************************

Q546L
PAZ5

GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
GCIKGHKQVVSMLCSFEGQDSIDKTIRDNDGKTAYQLAESKEHYEIIDYLDTKLKDDKLF
************************************************************

Q546L
PAZ5

GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
GGNERLYHRFWTVMGVLTVLVPTWILCYVPVIFGLPLLAVGGYFLKNYLHLNYWVPERNN
************************************************************

Q546L
PAZ5

WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
WLLPSILYSSVSIWYLIYLLRIAPLVMAINIFPNLIINATSWYFFYFFIRLTKEDPGTIS
************************************************************

Q546L
PAZ5

KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
KHISKEKSNENFMNALSSGRQIPLICPTCLINRPIRSKHCPSCKGCFARFDHHCVWINKC
************************************************************

Q546L
PAZ5

IGINNLALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
IGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILSESYIQSFLFYYTNYPFILL
***** ******************************************************

Q546L
PAZ5

FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
FSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFESRQGHGHSHGGDQQCNHSHG
************************************************************

Q546L
PAZ5

SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
SGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGGSKKDSDKSFHNQQTNFDMY
************************************************************

Q546L
PAZ5

HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
HRGVVNNVKEFLFDSQKFYFQTENIYADSRV
*******************************
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APPENDIX C
MUTANT PAZ5/PTX-GFP FUSION SEQUENCE ALIGNMENTS

Table C.1. PAZ5/PTX-GFP Sequence Alignment for Mutant G477Y (1).
G477Y-5'
PAZ5/PTX-GFP-5'

KMHHHHHHHHDIGTWKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRP
KMHHHHHHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRP
************** *********************************************

G477Y-5'
PAZ5/PTX-GFP-5'

LDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVL
LDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVL
************************************************************

G477Y-5'
PAZ5/PTX-GFP-5'

LEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTS
LEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTS
************************************************************

G477Y-5'
PAZ5/PTX-GFP-5'

IHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLT
IHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLT
************************************************************

G477Y-5'
PAZ5/PTX-GFP-5'

DKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDI-----------------------DKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISL
************************************

G477Y-3'
PAZ5/PTX-GFP-3'

---------------------------------------ISGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
*********************

G477Y-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

G477Y-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

G477Y-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

G477Y-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFFCQWRGRCNI---RKTYPFICHYWKTTLFHGPTLGHYFRVWV
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPW-PTLVTTF-AYG
****************** . * :
. * ***
* .: . ***
* .:

G477Y-3'
PAZ5/PTX-GFP-3'

FNALAKIL-RSKQHDLFQEWPCRKVMYRKELIFF
LQCFARYPDHMKQHDFFK--SAMPEGY------::.:*.
. ****:*: ..
*
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Table C.2. PAZ5/PTX-GFP Sequence Alignment for Mutant C506A (2).
C506A-5'
PAZ5/PTX-GFP-5'

IPNKKKMDSKIVFSFSSCFQMHKKIFFFSINKIKIKIKSDPKLKNASSSSSSSYRYHKKY
-----KMH-------------HHHHHHHDIGTMKKMIPT--------------------**
*:: ....*..:* * :

C506A-5'
PAZ5/PTX-GFP-5'

QHKHPQDNKLMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMI
--QTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMI
: * :::**************************************************

C506A-5'
PAZ5/PTX-GFP-5'

KLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVI
KLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVI
************************************************************

C506A-5'
PAZ5/PTX-GFP-5'

IESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDC
IESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDC
************************************************************

C506A-5'
PAZ5/PTX-GFP-5'

GANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNS
GANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNS
************************************************************

C506A-5'
PAZ5/PTX-GFP-5'

VRYLIEKGLDPVQCK--------------------------------------------VRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGC
***************

C506A-3'
PAZ5/PTX-GFP-3'

------------------------------------------FIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
******************

C506A-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

C506A-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

C506A-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

C506A-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGAQIFCQWRGRCNIRKTY-PIYLHYWKTTCSMANTCHYFRVWSSML
GVVPILVELDGDVNGHKFSVSGEGEGD--ATYGKLTLKFICTTGKLPVP------W---*************** :: . * :
** : *:: ** .:. .
*

C506A-3'
PAZ5/PTX-GFP-3'

CEIPQIINSMTFSRVPCLEGYVQERLLF-FQRRELQDTCSQLKVITLVIDRVKVLIRR
---PTLVTTFAYG-LQCFARYPDHMKQHDFFKSAMPEGY------------------* ::.::::. : *: * :
. * . : :
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Table C.3. PAZ5/PTX-GFP Sequence Alignment for Mutant C509G (3).
C509G-5'
PAZ5/PTX-GFP-5'

KMHHHHHHHHDIGTLKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRP
KMHHHHHHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRP
**************:*********************************************

C509G-5'
PAZ5/PTX-GFP-5'

LDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVL
LDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVL
************************************************************

C509G-5'
PAZ5/PTX-GFP-5'

LEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTS
LEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTS
************************************************************

C509G-5'
PAZ5/PTX-GFP-5'

IHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLT
IHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLT
************************************************************

C509G-5'
PAZ5/PTX-GFP-5'

DKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCK-------------------------DKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISL
**********************************

C509G-3'
PAZ5/PTX-GFP-3'

------------------------------------------FIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
******************

C509G-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

C509G-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

C509G-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

C509G-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTPIYFALLENYLFHGQHLSLLSRMVFN
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGK--LPVPWPTLVTTFAYG
********************************** ::.
: :
. :*:: :.:.

C509G-3'
PAZ5/PTX-GFP-3'

ALRRILRSYETALFQSACSRLLYREKNLYFSKM---L--QCFARYPDHM----------KQHDFFKSAMPEGY
. : *
:
.::::: * *
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Table C.4. PAZ5/PTX-GFP Sequence Alignment for Mutant D475A (4).
D475A-5'
PAZ5/PTX-GFP-5'

AEKKLLKLVVLLNLIQKKNGSNFCILLSLCFRCIKKDFFFFLFLNKINKKSDPKLKNASS
---KMHH--------HHHHHHDIGTMKKM-----------------IPTQTPPR-----*: :
:::: :: : .:
* .:: *.

D475A-5'
PAZ5/PTX-GFP-5'

SSSSSYRYHKKYQHKHPQDNKIIIIKPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPF
--------QQMMNHNH---------QPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPF
:: :*:*
:**********************************

D475A-5'
PAZ5/PTX-GFP-5'

LQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDI
LQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDI
************************************************************

D475A-5'
PAZ5/PTX-GFP-5'

QEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKN
QEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKN
************************************************************

D475A-5'
PAZ5/PTX-GFP-5'

KAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALL
KAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALL
************************************************************

D475A-5'
PAZ5/PTX-GFP-5'

HAAQYNEVNSVRYLIEKGLDPVQCKDI--------------------------------HAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDI
***************************

D475A-3'
PAZ5/PTX-GFP-3'

--------------------------------------VISGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
**********************

D475A-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

D475A-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

D475A-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

D475A-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKIYLHYWENYLFPWPTLVTTFRVWS
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK-FICTTGKLPVPWPTLVTTF---************************************ ::
: .*********
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Table C.5. PAZ5/PTX-GFP Sequence Alignment for Mutant T628A (5).
T628A-5'
PAZ5/PTX-GFP-5'

STNLVNINNQDPKLKNGIIIIIIIMISVPMEKYQHKHPPGQQMMNHNHQTQQIQQPQQIQ
KMHHHHHHHHD--------------IGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQ
. : : :::*
*.. :
: ** *********.**********

T628A-5'
PAZ5/PTX-GFP-5'

PHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGL
PHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGL
************************************************************

T628A-5'
PAZ5/PTX-GFP-5'

LYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTL
LYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTL
************************************************************

T628A-5'
PAZ5/PTX-GFP-5'

KSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSF
KSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSF
************************************************************

T628A-5'
PAZ5/PTX-GFP-5'

VLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCK-----------VLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTS
************************************************

T628A-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

T628A-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKATYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
**********************************************:*************

T628A-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

T628A-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

T628A-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPNTCHYFRVWSS
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
*************************************************.
*
.

T628A-3'
PAZ5/PTX-GFP-3'

MLCEIPRIIKQHDFFQEWPCPRVMYRKRPIIFPK-CFARYPDHMKQHDFFKS-------------AMPEGY
:. * :******:.
:*:
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Table C.6. PAZ5/PTX-GFP Sequence Alignment for Mutant C523G (6).
C523G-5'
PAZ5/PTX-GFP-5'

KKSTGFSCHVFFQMHKRIFFFLFTIIINKNKIRSQAKNASSSSSSSYRYMKKMIPTQTPP
------KMHHHHHHHHDI-----------------------------GTMKKMIPTQTPP
. * ..: *: *
***********

C523G-5'
PAZ5/PTX-GFP-5'

RQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKLPPMF
RQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKLPPMF
************************************************************

C523G-5'
PAZ5/PTX-GFP-5'

QEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQN
QEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQN
************************************************************

C523G-5'
PAZ5/PTX-GFP-5'

KDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDI
KDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDI
************************************************************

C523G-5'
PAZ5/PTX-GFP-5'

QNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIE
QNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIE
************************************************************

C523G-5'
PAZ5/PTX-GFP-5'

KGLDPVQCK--------------------------------------------------KGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGCIKGHKQ
*********

C523G-3'
PAZ5/PTX-GFP-3'

------------------------------------------FIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
******************

C523G-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

C523G-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

C523G-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

C523G-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
************************************************************

C523G-3'
PAZ5/PTX-GFP-3'

CFARYPDHMKQHDFFKSAMPEGYVQEKTIFFQRRGTTRHVLKSRLRIPLYRSSLKVFDFK
CFARYPDHMKQHDFFKSAMPEGY------------------------------------***********************
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Table C.7. PAZ5/PTX-GFP Sequence Alignment for Mutant E631A (7).
E631A-5'
PAZ5/PTX-GFP-5'

KKMVSKLVYQFYLYFSDAKDFFFFYSLKRYLLKNSIPKPNASSSSSSSSVPLKKYQHQTP
K------MHHHHHHHHDIG------TMKKMIPTQTPPRQ-------------QMMNHNHQ
*
:::.: :. *
::*. : .:: *.
: :*:

E631A-5'
PAZ5/PTX-GFP-5'

PKTTKIIIINTTIHSTQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKLPPMFQE
PQQIQ--------QPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKLPPMFQE
*: :
:. ********************************************

E631A-5'
PAZ5/PTX-GFP-5'

QYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQNKD
QYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIESNQNKD
************************************************************

E631A-5'
PAZ5/PTX-GFP-5'

GDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDIQN
GDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGANLDIQN
************************************************************

E631A-5'
PAZ5/PTX-GFP-5'

LEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIEKG
LEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVRYLIEKG
************************************************************

E631A-5'
PAZ5/PTX-GFP-5'

LDPVQCKDI--------------------------------------------------LDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGCIKGHKQVV
*********

E631A-3'
PAZ5/PTX-GFP-3'

---------------------------------------ISGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
*********************

E631A-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYAQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************* **********

E631A-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

E631A-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

E631A-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
************************************************************

E631A-3'
PAZ5/PTX-GFP-3'

CFARIPRSY-ETALFRSAMPRLCTGKNLIIFQDDGY
CFARYPDHMKQHDFFKSAMP-------------EGY
**** *
: :*.****
:**
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Table C.8. PAZ5/PTX-GFP Sequence Alignment for Mutant P514A (8).
P514A-5'
PAZ5/PTX-GFP-5'

KNGKNLGWLIYLEFTKKKKMDSKLFFLLFFFRMHKKDFFFSILNKINKKNQIPSKMHHHH
------------------------------------------------------KMHHHH
******

P514A-5'
PAZ5/PTX-GFP-5'

HHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAE
HHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAE
************************************************************

P514A-5'
PAZ5/PTX-GFP-5'

IPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKN
IPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKN
************************************************************

P514A-5'
PAZ5/PTX-GFP-5'

GDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIM
GDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIM
************************************************************

P514A-5'
PAZ5/PTX-GFP-5'

RKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYN
RKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYN
************************************************************

P514A-5'
PAZ5/PTX-GFP-5'

ALLHAAQYNEVNSVRYLIEKGLDPVQCKDI-----------------------------ALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNA
******************************

P514A-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

P514A-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

P514A-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

P514A-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

P514A-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
************************************************************

P514A-3'
PAZ5/PTX-GFP-3'

CFARYPDHMKQHDFFRVPCPKVMYRKELYFSKMTGTTRTRAEVKFEGDNSFVIRIRSRLL
CFARYPDHMKQHDFFKSAMPEGY------------------------------------***************. . *:
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Table C.9. PAZ5/PTX-GFP Sequence Alignment for Mutant R516P (9).
R516P-5'
PAZ5/PTX-GFP-5'

ILKKCKTGGIYEINHKKKMDSNSLFFVFSCQMHKKIFFFFFYSKTNKIKKNQIPSKMHHH
-------------------------------------------------------KMHHH
*****

R516P-5'
PAZ5/PTX-GFP-5'

HHHHHDIGTLKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENA
HHHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENA
*********:**************************************************

R516P-5'
PAZ5/PTX-GFP-5'

EIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAK
EIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAK
************************************************************

R516P-5'
PAZ5/PTX-GFP-5'

NGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAI
NGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAI
************************************************************

R516P-5'
PAZ5/PTX-GFP-5'

MRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGY
MRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGY
************************************************************

R516P-5'
PAZ5/PTX-GFP-5'

NALLHAAQYNEVNSVRYLIEKGLDPVQCKD-----------------------------NALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPN
******************************

R516P-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

R516P-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

R516P-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

R516P-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

R516P-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFFCQWRGRCNIR-KNLPLNLFALLGKLPVPWPTLVTTFAYGLQ
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
****************** . * :
:*.*:::. *******************

R516P-3'
PAZ5/PTX-GFP-3'

CFGEIPRSYETALFSRSGHARRVMYRKRTNIFKRRGTTKTRGS
CFARYPD-----------------HMKQHDFFK---SAMPEGY
**. *
: *. ::**
:: . *
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Table C.10. PAZ5/PTX-GFP Sequence Alignment for Mutant W536L (10).
W536L-5'
PAZ5/PTX-GFP-5'

KKKWIPKSCFFVYVSSDAKRFFFFFLFNNKIIKNKIRSQAKNASSSSSSSYRYMKKMIPT
----------------------------------KMHHHHHHHHDIGT-----MKKMIPT
*:. : :: . .:
*******

W536L-5'
PAZ5/PTX-GFP-5'

QTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKL
QTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMIKL
************************************************************

W536L-5'
PAZ5/PTX-GFP-5'

PPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIE
PPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVIIE
************************************************************

W536L-5'
PAZ5/PTX-GFP-5'

SNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGA
SNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDCGA
************************************************************

W536L-5'
PAZ5/PTX-GFP-5'

NLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVR
NLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNSVR
************************************************************

W536L-5'
PAZ5/PTX-GFP-5'

YLIEKGLDPVQCKDI--------------------------------------------YLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGCIK
***************

W536L-3'
PAZ5/PTX-GFP-3'

--------------------------------------VISGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
**********************

W536L-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

W536L-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

W536L-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

W536L-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
************************************************************

W536L-3'
PAZ5/PTX-GFP-3'

CFARYPDHMKQHDFFKSAMARRLCYRKELYFSKMTELQEHVLKSSLKVIPLLIDRVKRLL
CFARYPDHMKQHDFFKSAMPEGY------------------------------------*******************.
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Table C.11. PAZ5/PTX-GFP Sequence Alignment for Mutant N538I (11).
N538I-5'
PAZ5/PTX-GFP-5'

AKMHHHHHHHHDIGTLKKMIPTQTPPKTQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFR
-KMHHHHHHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFR
**************:**********. ********************************

N538I-5'
PAZ5/PTX-GFP-5'

PLDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLV
PLDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLV
************************************************************

N538I-5'
PAZ5/PTX-GFP-5'

LLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNT
LLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNT
************************************************************

N538I-5'
PAZ5/PTX-GFP-5'

SIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHL
SIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHL
************************************************************

N538I-5'
PAZ5/PTX-GFP-5'

TDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDI----------------------TDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFIS
*************************************

N538I-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

N538I-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

N538I-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

N538I-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

N538I-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGRCNIR--KTYPIYLHYWENYLFHGQHLSLLFAYGLQ
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFAYGLQ
************************ :
*
::
: .
*
******

N538I-3'
PAZ5/PTX-GFP-3'

CFARYPDHMKQHGLFQGVPWPKVMYRKELIFFQDDGTTDTCSQVWKVILLLDRVKR
CFARYPDHMKQHDFFKSA--------------MPEGY------------------************.:*:..
:*
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Table C.12. PAZ5/PTX-GFP Sequence Alignment for Mutant G542S (12).
G542S-5'
PAZ5/PTX-GFP-5'

PSLKMHHHHHHHHDIGTIEKNDTNTNTPKTT-NDESSSTQQIQQPQQIQPHQPQQQQPHQ
---KMHHHHHHHHDIGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQ
**************::* .. ..*.
: . ..*********************

G542S-5'
PAZ5/PTX-GFP-5'

FRPLDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQV
FRPLDENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQV
************************************************************

G542S-5'
PAZ5/PTX-GFP-5'

LVLLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEG
LVLLEIAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEG
************************************************************

G542S-5'
PAZ5/PTX-GFP-5'

NTSIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADI
NTSIHYAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADI
************************************************************

G542S-5'
PAZ5/PTX-GFP-5'

HLTDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCK----------------------HLTDKRGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYF
*************************************

G542S-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

G542S-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

G542S-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

G542S-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

G542S-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFFC--QWRGRCNIRKTPFKFICTTGKLPVSMANTLSLLFAYGL
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWP-TLVTTFAYGL
******************
: * .. * .:***********. . **
*****

G542S-3'
PAZ5/PTX-GFP-3'

QCFAKIPRIINSMTFFKSAMPEGLCNRKELLFFQKNGRGTNKTRAESQ
QCFARYPDHMKQHDFFKSAMPEGY-----------------------****. * ::. *********
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Table C.13. PAZ5/PTX-GFP Sequence Alignment for Mutant F549V (13).
F549V-5'
PAZ5/PTX-GFP-5'

KNVKTCVILNTIKNGQTSVFFSVIRCIKDFFFFFYSKTNNKIKIKSDPSKMHHHHHHHHD
-------------------------------------------------KMHHHHHHHHD
***********

F549V-5'
PAZ5/PTX-GFP-5'

IGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQ
IGTMKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQ
************************************************************

F549V-5'
PAZ5/PTX-GFP-5'

IVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQE
IVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQE
************************************************************

F549V-5'
PAZ5/PTX-GFP-5'

YRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKA
YRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKA
************************************************************

F549V-5'
PAZ5/PTX-GFP-5'

MVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHA
MVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHA
************************************************************

F549V-5'
PAZ5/PTX-GFP-5'

AQYNEVNSVRYLIEKGLDPVQCKDI----------------------------------AQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQG
*************************

F549V-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

F549V-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

F549V-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

F549V-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

F549V-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSCQWRRVKVMQHTGKLTLKFIWHYKTTLFHGPTLVTNFRVWV
GVVPILVELDGDVNGHKFSVSGEGEGDATY-GKLTLKFICTTGKLPVPWPTLVTTFAY-******************* .
: ********
. . *****.*
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Table C.14. PAZ5/PTX-GFP Sequence Alignment for Mutant H516L (15).
H516L-5'
PAZ5/PTX-GFP-5'

QHKHPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMI
--QTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMI
: ********************************************************

H516L-5'
PAZ5/PTX-GFP-5'

KLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVI
KLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVI
************************************************************

H516L-5'
PAZ5/PTX-GFP-5'

IESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDC
IESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDC
************************************************************

H516L-5'
PAZ5/PTX-GFP-5'

GANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNS
GANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNS
************************************************************

H516L-5'
PAZ5/PTX-GFP-5'

VRYLIEKGLDPVQCKD-------------------------------------------VRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGC
****************

H516L-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

H516L-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

H516L-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

H516L-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFLFPNKYFMLIQELVPVKEKNFSL
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************* * .: :
. : . * :::

H516L-3'
PAZ5/PTX-GFP-3'

ELSQFLLNMV-MLMGTNFSVQWRGVKVMHHTENLPFKFYFALLENLVSLVNTLSLTFRVW
GVVPILVELDGDVNGHKFSVSGEGEGDATYGK-LTLKF-ICTTGKLPVPWPTLVTTFAYG
: :*:::
: * :***. *
: : *.:** :.
:*
** **

H516L-3'
PAZ5/PTX-GFP-3'

SSCFCEIPRIIMKQHDFFKELPMPEGLCPEGLYFFK
LQCFARYPD-HMKQHDFFKS-AMPEGY--------.**. *
********. .****
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Table C.15. PAZ5/PTX-GFP Sequence Alignment for Mutant F530S (16).
F530S-5'
PAZ5/PTX-GFP-5'

SKKWLKTWWYLFDFKPIKKKWIPKFFLCVFFFRMHKKIFFFFFYFNKINKNKIRSQAKKC
------------------------------------KMHHHHHHHHDIGT---------*:.....:.:.*..

F530S-5'
PAZ5/PTX-GFP-5'

IIIIIIIMISVPLKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLD
------------MKKMIPTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLD
:***********************************************

F530S-5'
PAZ5/PTX-GFP-5'

ENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLE
ENAEIPFLQIVTPNQMIKLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLE
************************************************************

F530S-5'
PAZ5/PTX-GFP-5'

IAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIH
IAKNGDIQEYRDFIQVIIESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIH
************************************************************

F530S-5'
PAZ5/PTX-GFP-5'

YAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDK
YAIMRKNKAMVSYLIDCGANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDK
************************************************************

F530S-5'
PAZ5/PTX-GFP-5'

RGYNALLHAAQYNEVNSVRYLIEKGLDPVQCK---------------------------RGYNALLHAAQYNEVNSVRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGV
********************************

F530S-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

F530S-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

F530S-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

F530S-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

F530S-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPNTCHYFRVWSS
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTF----*************************************************.
*

F530S-3'
PAZ5/PTX-GFP-3'

MLCEIPRSYETALFQECHARRLCTGKNYIFQRRELQTRAEVKFEGDTPCNRVKRYFRRWN
-----------AYGLQCFARYPDHMKQHDF-----------------------------*
:*.**
*:: *
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Table C.16. PAZ5/PTX-GFP Sequence Alignment for Mutant Q546L (17).
Q546L-5'
PAZ5/PTX-GFP-5'

KKNGFQSSSFCFLLFFQMHKRFIFFSISNKINLNKKNQIPSKMHHHHHHHHDIGTMKKMI
-----------------------------------------KMHHHHHHHHDIGTMKKMI
*******************

Q546L-5'
PAZ5/PTX-GFP-5'

PTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMI
PTQTPPRQQMMNHNHQPQQIQQPQQIQPHQPQQQQPHQFRPLDENAEIPFLQIVTPNQMI
************************************************************

Q546L-5'
PAZ5/PTX-GFP-5'

KLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVI
KLPPMFQEQYKQLLNRWSNQCIKKSGLLYTQAVPYNQVLVLLEIAKNGDIQEYRDFIQVI
************************************************************

Q546L-5'
PAZ5/PTX-GFP-5'

IESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDC
IESNQNKDGDENEESIQQQQQQQQLTLKSIINLIDLEGNTSIHYAIMRKNKAMVSYLIDC
************************************************************

Q546L-5'
PAZ5/PTX-GFP-5'

GANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNS
GANLDIQNLEEGHTPLHWACIKADSSFVLQLVENGADIHLTDKRGYNALLHAAQYNEVNS
************************************************************

Q546L-5'
PAZ5/PTX-GFP-5'

VRYLIEKGLDPVQCKDI------------------------------------------VRYLIEKGLDPVQCKDIQLHTAVHWTSFQGHANMARYFISLGVDPNAQDIQGRTAFHWGC
*****************

Q546L-3'
PAZ5/PTX-GFP-3'

----------------------------------------SGFIVTWDYFKSDSNAPILS
SCKGCFARFDHHCVWINKCIGINNQALFITVLFSYVILVISGFIVTWDYFKSDSNAPILS
********************

Q546L-3'
PAZ5/PTX-GFP-3'

ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
ESYIQSFLFYYTNYPFILLFSIYGIGMAIWIGKLAISQVLTILFNKTTYEQIQQIREFES
************************************************************

Q546L-3'
PAZ5/PTX-GFP-3'

RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
RQGHGHSHGGDQQCNHSHGSGGGDHGHSHGGSSGSGSGSGSGDHGHSHGGQPSLPSSSGG
************************************************************

Q546L-3'
PAZ5/PTX-GFP-3'

SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
SKKDSDKSFHNQQTNFDMYHRGVVNNVKEFLFDSQKFYFQTENIYADSRVGTSKGEELFT
************************************************************

Q546L-3'
PAZ5/PTX-GFP-3'

GVVPILVELDGDVNGHKFFCQWRGRCNIRKTY-PIYLHYWKTTCSMA------NTCHYFS
GVVPILVELDGDVNGHKFSVSGEGEGD--ATYGKLTLKFICTTGKLPVPWPTLVTTFAYG
****************** . * :
** : *:: ** .:.
* . :.

Q546L-3'
PAZ5/PTX-GFP-3'

RMVFNALRDTRSLKQHDFFKSAMPRRLWYRKDLYFFKDDGNYRTRCSQGSDYPLNPRRLL
LQCFARYPD--HMKQHDFFKSAMPEGY--------------------------------*
*
:***********
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APPENDIX D
MISCELLANEOUS

Figure D.1. 1 kb DNA Ladder. An annotated figure of the 1 kb DNA Ladder from NEB (NEB,
2020).

Table D.1. Method for Staining Cellulose-Producing Stalk Cells with Calcofluor White.
After development on a DB plate, the fruiting bodies can be stained with calcofluor
white to visualize cellulose, and by extension, to visualize the individual cells that make up the
structure of the stalk assembly. A 1cm circle of agar was carefully excised from the DB plate
containing fruiting bodies. The agar was then placed upside down on a coverslip that contained
1 drop of calcofluor white stain (0.1% calcofluor white and 0.05% Evans blue) and 1 drop of 10%
KOH. After 10 seconds, excess solution was aspirated, and the coverslip was examined using
confocal fluorescence microscopy with the Alexafluor 405 filter.
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